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1.1 Introduction to Haemoglobinopathies 
 
1.1.1 The Haemoglobin molecule 
 
Haemoglobin is an iron-containing oxygen transport protein responsible for 
the delivery of oxygen into the cells. As Figure 1.1 illustrates, haemoglobin is a 
tetramer protein complex formed of two types of globin sub-units each bound to a 
haeme group - two -globin chains (HBB) and two -globin chains (HBA) in adult 





Figure 1.1 - Structure of human haemoglobin molecule. The α and β subunits, and 
the iron-containing haeme groups in blue are shown. Each erythrocyte contains 
approximately 270 million haemoglobin molecules (image from 
http://gassama.myweb.uga.edu/). 
 
The name haemoglobin comes from haeme and globin, since each subunit of 
haemoglobin is a globular protein with an embedded haeme (or haem) group. Each 
haeme group contains an iron atom responsible for the binding of oxygen. 
 
 
The haemoglobinopathies are a group of blood disorders characterised by the 
dysfunction of haemoglobin. Dysfunctions of the haemoglobin protein are caused by 
the imbalance of the  and  polypeptide ratio (as in the thalassaemias) or due to 
abnormalities in the function of the HBB haemoglobin chain caused by mutations 




resulting in structural variants that impair haemoglobin  normal mechanism of action 
(as in sickle cell anaemia). 
 
 and halassaemias 
 
 
The thalassaemias are mostly autosomal recessive diseases, being the most 
common monogenic disorders in the world. Studies estimate 270 million carriers 
worldwide, of which 80 million are of -thalassaemia trait carrier status. Depending 
on the chain imbalance in the haemoglobin tetramer molecule, several types of  and 





Alpha-thalassaemia is the generic term that encompasses all of those 
conditions in which there is a deficit in the production of HBA chains, and typically 
results from deletions involving HBA1 and HBA2 at their chromosome 16 loci. 
Underproduction of HBA gives rise to excess HBB-type chains which form HBG 




Carriers are normally unaffected and/or show minimal anaemia.  
There are two types of α thalassaemia that can cause serious health problems. 
The first is HbH disease, which can vary in severity depending on whether the patient 
has 3, 2 or 1 remaining functional HGA. Affected individuals are mainly compound 
heterozygotes (with some homozygous patients having been reported) for α-
thalassaemia and have a moderately severe anaemia characterised by the presence of 
excess HBB in the peripheral red blood cells. Severe post-natal -thalassaemia major 
or HbH disease is characterised by severe anaemia, heart ailments, 
hepatosplenomegaly or enlargement of liver and spleen, and urinary or genital 
abnormally, jaundice, bone deformities particularly in the upper jaw and forehead and 
constant exhaustion. Recent medical advances have allowed survival through in 




utero-blood transfusion. However, lifelong blood transfusions and constant medical 
care are necessary to sustain the child‟s life (http://www.alphathalassemia.net).  
The second most severe type of -thalassaemia is known as haemoglobin Bart 
hydrops fetalis syndrome or Hb Barts syndrome. Affected individuals synthesise very 
little or no α globin chains and have a very severe form of anaemia which causes 
death in utero or neonatally (Harteveld &
 
Higgs, 2010). In the presence of little or no 
HGA chains excess HGG chains during foetal development form HGG tetramers, 
which bind oxygen with very high affinity and do not readily release this to tissues. 
The resulting severe hypoxia gives rise to hydrops fetalis; that is, death before birth.  
-thalassaemia 
 
Beta-thalassaemia in the majority of cases is inherited as a recessive disorder. 
However, dominant mutations have also been reported. The genetic defect of -
thalassaemia arises from the absence or low levels of HBB chains resulting in the 
precipitation of un-tetramerised -chains, causing ineffective erythropoiesis (Sadelain 
et al., 2005) and consequent damage to red blood cells, which become vulnerable to 
mechanical injury and lyse easily. The resulting anemia and ineffective erythropoiesis 
that is associated with -thalassaemia may be severe and is accompanied by bone 
marrow expansion and extramedullary haematopoiesis in the liver, spleen and other 
sites such as paravertebral masses (Rund & Rachmilewitz, 2005). In the most severe 
forms, found in homozygote or compound heterozygote individuals, the anaemia is 
lethal within the first few years of life in the absence of any treatment (Sadelain et al., 
2005). 
The -thalassaemias are grouped into 3 categories: thalassaemia major, 
thalassaemia intermedia and thalassaemia minor. Most heterozygotes (carriers) are 
clinically normal and largely unaware of their genetic condition. Patients with 
thalassaemia intermedia are mostly homozygotes or compound heterozygotes. 
Inheritance of two copies of -thalassaemia causing genes, however, results in life-
threatening anemia and transfusion dependence for survival.  
 




Although deletions of HBB are uncommon, more than 200 mutations have 
been reported to date that give rise to -thalassaemia; the large majority are point 
mutations in functionally important regions of HBB (Galanello & Origa, 2010). Many 
mutations leading to β-thalassaemia have been informative with regard to the 
sequences and molecular mechanisms that control globin gene switching (see section 
1.2.3 of this report). 
A list of common mutations according to severity and ethnic distribution is 
listed in Table 1.1. 
 
Population -gene mutation Severity 
Indian -619 del 0 
Mediterranean -101 C→T 0 
Black -88 C→T 0 
Mediterranean; African -87 C→G 0 
Japanese -31 A→G ++ 
African -29 A→G ++ 
Southeast Asian -28 A→C ++ 
Mediterranean; Asian Indian IVS1-nt1 G→A 0 
East Asian; Asian Indian IVS1-nt5 G→C 0 
Mediterranean IVS1-nt6 T→C +/++ 
Mediterranean IVS1-nt110 G→A + 
Chinese IVS2-nt654 C→T + 
Mediterranean IVS2-nt745 C→G + 
Mediterranean codon 39 C→T 0 
Mediterranean codon 5 –CT 0 
Mediterranean; African-American codon 6 -A 0 
Southeast Asian codon 41/42 -TTCT 0 
African-American AATAAA to AACAAA ++ 
Mediterranean AATAAA to AATGAA ++ 
Mediterranean codon 27 G→T Hb (Hb Knossos) ++ 
Southeast Asian codon 79 G>A (Hb E) ++ 
Malaysia Codon 19 G>A (Hb Malay) ++ 
_____________________________________________________________________ 
Table 1.1 – Most common types of -thalassaemia - ethnic distribution and severity 









1.1.3 Current therapeutic options 
 
1.1.3.1 Regular blood transfusions 
 
The treatment for severe forms of thalassaemia (major and some intermedia) 
consists of regular packed red blood cell (RBC) transfusion therapy every 2-4 weeks. 
Transfusions are life-saving and aim to correct the anaemia, suppress the massive 
erythropoiesis, and inhibit increased gastrointestinal absorption of iron (Sadelain et 
al., 2005). Nevertheless, transfusion therapy invariably causes iron accumulation, and 
because humans naturally have no physiological excretory mechanism to deal with 
iron overload, patients maintained on a regular transfusion regime progressively 
develop clinical manifestations of iron accumulation: hypogonadism (35-55% of the 
patients), hypothyroidism (9-11%), hypoparathyroidism (4%), diabetes (6-10%), liver 
fibrosis, and heart dysfunction (33%) (Cunningham et al., 2004). 
The complications of iron overload, together with the sequelae of the anaemia, 
the ineffective erythropoiesis, and the chelation therapy itself, are the major causes of 
morbidity and mortality leading to an increased toxicity in the endocrine system and 
liver, pancrease damage and cardiomyopathy in transfusion dependent -
thalassaemias (Quek & Thein, 2007). It is therefore imperative to conduct a parallel 
treatment of iron chelation and management of secondary complications of iron 
overload. Iron chelators form a complex with the excess iron in the tissues, and 
facilitate its excretion from the body. Chelation therapies reduce tissue iron stores, 
prevent iron-induced organ damage, and reduce morbidity and mortality.  Regular 
treatment consists of slow subcutaneous injection of desferrioxamine, which must be 
administered for 12h per day, 6-days per week; a treatment that is time consuming, 
expensive, and also very painful for the patient. Patients also risk acquiring viral 
infections transmitted with blood transfusions (Cunningham et al., 2004). 
Scientific advances in recent years saw the introduction of two orally 
administered iron chelators, namely deferiprone (Feriprox) and deferasivox (Exjade) 
have provided a new hope for thalassaemic patients. These new chelators bring the 
improved quality of life by reducing or eliminating the use of daily subcutaneous 




pump administration. In addition, oral deferiprone has been proved to be effective in 
the removal of myocardiac iron (Meerpohl et al., 2010). 
 
1.1.3.2 Bone marrow transplant 
 
Allogeneic haematopoietic stem cell transplant (HSCT) from bone marrow  
(BMT) or umbilical cord blood (UCBT) is conceptually the simplest and the only 
approach so far that may lead to a definitive cure for -thalassaemia.  Patients who 
benefit the most from this treatment are those with early but severe transfusion-
dependent disease and have little co-morbidity since HSCT success rates are lower for 
older patients (~30%) or those who have reduced overall health status caused by 
inadequate chelation. A major complication associated with this approach is the low 
probabilities of finding a leukocyte antigen (HLA)-matching donor, preferably a 
sibling, to minimise the risks of graft rejection and graft-versus-host-disease (GVHD) 
(Sadelain et al., 2005). 
 
 BMT from unrelated donors has also been performed on a more limited scale 
with individuals with -thalassaemia and provided that selection of the donor is based 
on stringent criteria of HLA compatibility, and that individuals have limited iron 
overload, results are comparable to those obtained when the donor is a compatible 
sibling.  Unfortunately, to date there is still a limited number of cases benefitting from 
this approach - there are very few healthy volunteers willing to be BM donors, and 
therefore the chances of finding an HLA matched donor in the BM cell bank are 













1.1.3.3 Umbilical Cord blood stem cell transplantation 
 
A good alternative for couples who already have a child with -thalassaemia is 
Umbilical Cord blood (UCB) transplantation from a related donor.  UCB transplants 
are currently performed at a 10 times lower ratio than BM transplants, as the lower 
amount of transplanted HSCs is clinically reflected in a greater incidence of engrave 
failure and prolonged time to engraft. This risk is however, significantly offset by 
lower rates of acute GVHD given the lower number and mostly naïve T cells in the 
transplanted population (Stanevsky et al., 2009). 
The search for and HLA matching donor remains, although with less 
restriction when compared with BMT and the search is made easier with the existence 



































1.1.4 Global distribution of the pathology 
 
 
 Thalassaemia has a high incidence in a broad band extending from the 
Mediterranean basin and parts of Africa, throughout the Middle East, the Indian sub-
continent, South-East Asia, Melanesia and into the Pacific Islands. The carrier 
frequency for -thalassaemia in these areas ranges from 1% to 20%, but rarely 
greater, while that for the milder forms of thalassaemia is much higher, ranging 
from 10-20% in parts of sub-Saharan Africa, through to 40% or more in some Middle 
Eastern and Indian populations, to as high as 80% in northern Papua New Guinea and 
isolated groups in north-east India. The º-thalassaemias are more restricted in their 
distribution, occurring at high frequencies only in parts of South-East Asia and the 
Mediterranean basin and therefore pose less of a global health problem that 
the  thalassaemias (Weatherall & Clegg, 2001). The geographic distribution of the 














Figure 1.2 - Global distribution of  and  thalassaemia.  The world health 
organization (WHO) estimates that, on a global scale, at least 2.9% of adults are 
carriers for thalassaemia (Weatherall & Clegg, 2001). 
 
It is thought that all of these disorders have been selected because they protect 
carriers from the ravages of malaria and epidemiological evidence supports this 
hypothesis (Weatherall, 2010). 
 
 







Figure 1.3 - Global -thalassaemia distribution. 
+
 is more frequent in the general 
population whereas 
o
 is more prevalent in Greece and south east asia (Image taken 











Figure 1.4 - Global -thalassaemia distribution. The common mild mutations are 
shown in bold. -thalassaemia also occurs in the regions shaded in grey, but little is 
known about its molecular pathology in these areas. Mutations vary according to 
different geographic zones, mutation variation is shown in different colours (Image 

























1.1.5 What does the future hold for thalassaemia patients? 
 
 Recent medical advances bought a new hope for thalassaemia patients with 
iron chelation and bone marrow transplantation therapy. However, treatment options 
are still far from satisfactory; as blood transfusions entail frequent disturbance for the 
patient with regular hospital visits and allogenic BMT is still far for from being a 
feasible option for most patients. Furthermore, iron overload leading to cardiac 
disease remains the main cause of death in thalassaemia patients.  
 
Advances in genetic therapeutics open a new door for thalassaemia patients, 
offering the hope of new, alternative treatment requiring less hospital dependence and 


























1.2 Regulation of HBB expression 
 
 
The development of gene therapy strategies for the haemoglobinopathies 
requires a clear understanding of the molecular mechanisms of gene expression of the 
locus. 
 The HBB-like genes are arranged in a linear array on the short arm of 
chromosome 11. The cluster consists of five active genes (HBE, HBG-G HBG-
A HBD, and HBB) arranged in the order that reflects their expression during 
development (Figure 1.5, left hand panel) (Sadelain, 2006). 
 The embryonic ε-globin gene (HBE) is transcribed in the embryonic yolk sac 
in the first (6-8) weeks of gestation and is located at the 5‟ end of the cluster.  After 
the switch in the site of haematopoiesis from the yolk sack to the foetal liver, HBE is 
repressed and the two γ-globin genes (HBGy-Ay) located downstream of HBE are 
expressed. These two genes are expressed in very low quantities in the yolk-sack and 
mainly in the foetal liver derived erythrocytes until birth. In the second switch, which 
occurs shortly before birth and lasts until BM becomes the major site of 
haematopoiesis, coincides with the activation of the adult HBB gene at the 3‟ end of 
the cluster. HBG is also activated in erythroid cells derived from BM haematopoiesis 
although expressed at a much lower level (approximately 1% of total haemoglobin) 
(Levings & Bungert 2002).  
 
Erythroid specific promoters and enhancer elements have been described for 
each of the active genes. Transcriptional regulation that leads to differentiation and 
developmental stage specific expression in the locus is mediated by DNA-














Figure 1.5 - The structure of human locus. The five genes of the human 
HBB-like gene family are arranged in linear order reflecting their expression during 
development. The image also shows the DNaseI hypersensitive site core elements that 
constitute the locus control region (LCR) regulatory element comprising 200-400bp. 




1.2.1 Introduction to the  locus control region 
 
The most potent distal regulatory element in the HBB locus is the locus control 
region ( LCR), located within a 16kb stretch of DNA upstream of the -like 
genes. The LCR functions both as a powerful tissue specific enhancer and dominant 
chromatin remodelling regulatory element, able to overcome chromatin position 
effects and confer upon a gene linked in cis, physiological levels of expression 
directly proportional to transgene copy in mice (Fraser & Grosveld 1998, Li et al., 
1999). This has been shown to be the major cis regulator of all five -like genes, 
since its absence results in transcriptional suppression of all genes at all stages of 
development (Feng et al., 2005). 
The LCR is comprised of five separate 200-400bp core sequences that 
exhibit both erythroid-specific and ubiquitous transcription factor binding sequences 
together with extreme sensitivity to DNase I digestion in erythroid cells (Bulger & 




Groudine, 1999). These were identified as DNaseI hypersensitive sites (HS) in 
nuclear chromatin. In fact, the entire  locus remains in an inactive DNaseI - 
resistant chromatin conformation in cells within which these globin genes are not 
expressed. Studies have shown that sensitivity to DNaseI within the  locus in 
erythroid cells varies and depends upon the developmental stage of haematopoiesis 
(yolk sac, foetal liver, adult spleen) 
 It has been found that deletions of the LCR will lead to repression of HBB 
expression (Antoniou & Grosveld, 1999).Therefore, the LCR acts as an essential cis-
acting regulatory element that is required for expression of all genes from the HBB 
locus in vivo. 
 
The overall organisation and sequence of the LCR is conserved among 
several vertebrate species, adding further support to the vitally important role that this 
element plays in the regulation of expression of the HBB-like gene cluster (Hardison 
et al., 1997). 
 
 
1.2.2 Properties of the LCR 
 
The mechanism of activation and silencing of native HBB genes and 
transgenes during development has been under intense investigation for many years.  
 
The HBB promoter strongly depends on the LCR for high expression as its 
transcriptional activity is massively reduced (<1%) if the LCR is deleted. In fact, 
globin transgene constructs reveal strong position-of-integration effects in transgenic 
assays in the absence of the LCR. The incorporation of the LCR into these 
constructs has been shown to confer a chromatin remodelling capability and enhances 
globin gene expression maintaining a transcriptionally competent domain within an 
erythroid environment. LCRs are associated with tissue-specifically expressed genes 
and have a strong transcriptional enhancer regulatory function and also a dominant 
chromatin remodelling capability (Antoniou & Grosveld, 1999). 
 




The enhancer activity of the LCR is erythroid specific and studies have 
shown that this resides mainly in 5‟ HS2. Specifically, HS2 behaves as a classical 
enhancer and its activity can be detected in transient transfection assays, whereas 
transcriptional enhancing activity from HS3 and HS4 can only be detected after 
integration, within chromatin. It is generally considered that HS3 acts as the core 
chromatin opening element, as this is the only element that functions as a single copy 
transgene in mice, while HS1, 2 and 4 act as LCR-type elements only when present as 
multiple copies. This suggests that the LCR consists of two types of elements; the 
“core”, with the capacity of chromatin opening and the other HS sites - powerful 
enhancer elements that boost the transcriptional potency of HS3 (Antoniou & 
Grosveld, 1999). HS5 functions as a stage-specific (embryonic) insulator element (Li 
et al., 2002) 
The enhancer function of the LCR is thought to be mainly mediated by 
transcription factors binding to the core regions of the DNase I HS sites 1-5. HS1 to 4 
contain an array of ubiquitous and erythroid specific transfactor binding sites, with a 
conserved region within HS2 (TGCTGA(C/G)TCA(T/C) thought to be critical for 
strong enhancer activity This region is known to be a Maf recognition element 
(MARE) bound by multiple homodimeric or heterodimeric transcription factors in 
vivo (Talbot & Grosveld, 1991; Li et al., 1999).  
 
 The LCR is not the key factor in tissue specificity, which depends on both 
the LCR and globin promoters (Tolhuis et al., 2002; Li et al., 2002; Carter et al. 
2002). In addition, the LCR is also able to enhance the expression of linked 
heterologous non-globin gene promoters in erythroid cells. It can therefore be 
concluded that tissue specific control of basal transcription resides in the HBB 











 Mechanisms of  activation 
 
There have been four possible models of LCR-mediated gene expression 
proposed; looping, tracking, facilitated tracking and linking (Li et al., 2002). Several 
lines of direct experimental evidence have now shown the looping model to be correct 
(Palstra et al., 2008). 
 
The looping mode suggests that the 5‟HSs of the -globin LCR fold to form a 
holocomplex (Carter et al. 2002 Tolhuis et al., 2002). 
 
Initial studies performed using RNA-FISH TRAP provided evidence that the 
LCR HS1-HS4 exist in physical proximity to the actively transcribed Hbb genes 
with the intervening DNA looping out in mouse erythroid cells, with the HS2 site the 
one in most intimate interaction (Carter et al. 2002). Similarly, chromosome 
conformation capture (C3) performed by Tolhuis and colleagues showed that the 
murine Hbb LCR is in physical proximity to the active globin gene in vivo in 
expressing tissue with the intervening DNA looping out. Experiments revealed that 
there are cell-specific interactions within the bb locus and that the DNase I HS sites 
at both ends of the locus participate in these interactions. Interactions and looping 
were not observed in non-expressing tissue (brain) which led to the conclusion that 
multiple  sites acting over 130kb interact to form a cluster in the nuclear space and 
this is crucial in establishing an open chromatin domain and activating transcription, a 
structure coined as the “active chromatin hub” (ACH) (Tolhuis et al., 2002). 
 Together, these studies further support the looping model in that they show the 
LCR is only able to interact with one promoter at a time but it is free to move from 
gene to gene in a “flip-flop” mechanism between two or more promoters depending 
on the developmental stage, causing stable enhancer-promoter interactions - a key 
structure that sets up autonomous expression of genes irrespective of their position in 
the genome (Levings & Bungert 2002). The chromatin looping mechanism is 
represented in Figure 1.6.  
 
 







Figure 1.6 - Chromatin looping in the mouse Hbb  locus. In erythroid progenitor 
(left) a chromatin hub forms consisting of HS1 and HS4. In differentiated erythroid 
cells (right) an active chromatin hub incorporates the remaining LCR HS1-3. The 
globin genes join the holocomplex when they are being actively transcribed leaving 
the inactive genes looped away (Image taken from Dean, 2006). 
 
. 
The formation of a chromatin hub (CH) initially occurs through the 
interaction between CCCTC-binding factor (CTCF)-bound cis-regulatory elements, a 
transcription factor involved in gene insulation and boundary formation at 
transcription competent domain. Subsequently, the remaining HSs of LCR (HS1-3) 
interact with the CH to form an ACH to activate transcription of the -globin gene 
family members stably at different points during development (Palstra et al., 2008).  
Close association with nearby promoter and enhancer elements allows the 
delivery of LCR-bound transcription proteins and coactivators hat interact with the 
basal transcription apparatus to form a stable transcription complex, thus enhancing 
globin gene expression (Li et al., 2002). 
 
Erythroid specific transcription factors, such as ELKF and GATA-1 are 
involved in ACH stabilisation and LCR-promoter interaction respectively (Dean, 
2006; Palstra et al., 2008).  
 




1.2.4 Incorporation of the HBB elements into delivery vectors 
 
Despite their chromatin remodelling capabilities, the individual LCR 
elements used on their own do not completely negate silencing of a transgene and the 
use of multiple HS sites is required for maximum activity, which causes problems in 
viral vectors of limited cloning capacity. The use of severely paired down core 
regions can be detrimental to their function, resulting in only partial negation of 
insertion-site position
 
effects (Sadelain, 2006).  
Furthermore, it is known that the ACH model of enhancer-mediated promoter 
activation requires a minimum distance between enhancer and gene to allow DNA 
looping for full transcriptional activation (de Laat & Grosveld, 2003). This 
mechanism is therefore severely compromised in a compact, size constrained viral 
vector. 
 
The discoveries of globin controlling elements and the recent advances in 
globin regulation have contributed enormously for the development of efficient gene 
therapy vectors regulating HBB expression (see below). These functional observations 
represent key pieces in the erythroid-specific gene therapy puzzle, of which we are 
finally starting to perceive a clear image. 
 
 
1.2.5 HBB splicing mechanisms and the HBB expression cassette 
design 
 
The protein coding regions of most eukaryotic genes are interrupted by 
intervening sequences or introns. These intronic sequences are subsequently removed 
or spliced from the primary transcript as part of the maturation process to mRNA. 
Interestingly, however, the removal of introns from genes and their subsequent 
expression in both tissue culture cells and transgenic mice, results in very low levels 
of mRNA, which is not due to transcriptional insufficiency resulting from the absence 
of an intronic enhancer element. 
 




HBB has a three exon-two intron structure (Figure 1.7) and gene expression 
and mRNA levels decrease after splicing. Physiological levels of expression of HBB 
from a natural chromatin context by stable transfection in murine erythroleukaemia 
(MEL) cells under the control of the LCR, can only be achieved in the presence of 
the second intron (Antoniou et al., 1998). 
 
Studies suggest that the second intron of HBB is essential in promoting 
cleavage and polyadenylation (Antoniou et al., 1998; Millevoi et al., 2002). The 
efficiency of normal 3‟-end formation remained the same even when intron 2 is placed 
in the intron 1 position. But the efficiency is reduced to 16% and 30% when the 
second intron is replaced by other heterologous introns namely intron 1 or α-globin 






Figure 1.7 - Expression of   gene.  U5 and U3 represent untranslated regions at 
the 5' and 3' end, respectively.  
(Image taken from http://www.web-books.com/MoBio/Free/Ch5A4.htm). 
 




1.2.5.1 Additional elements to increase expression from the HBB 
cassette: the HBB transcription termination region ( term) 
 
Transcription termination in eukaryotes involves cleavage of the new 
transcript followed by template-independent addition of adenosine residues at its new 
3' end, in a process called polyadenylation. Termination is triggered following 
recognition of the poly(A)-addition (pA) signal by Pol II and subsequent pre-mRNA 
cleavage, which occurs either at the pA site or in transcripts at terminator regions. 
Failure in Pol II to terminate efficiently leads to inefficient pre-mRNA cleavage and 
polyadenylation, resulting in low gene expression (West & Proudfoot, 2009).  
 
Recent studies reported a transcriptional termination region located 600-
1200bp  3‟ of  the pA site of HBB, capable of increasing the efficiency of 
polyadenylation and pre-mRNA cleavage  (West et al., 2008; Dye & Proudfoot, 2001) 
– the HBB transcription termination region ( term). Studies have shown that  HBB 
transcription termination releases transcripts from the DNA template, which 
subsequently results in their processing and accumulation of stable cytoplasmic 
mRNA (Dye  & Proudfoot, 2001). The authors later reported a 10-fold HBB protein 
increase in HeLa cell pools in the presence of term (West & Proudfoot, 2009).  
During HBB transcription termination, the pA signal switches Pol II 
configuration after passing through the pA site, where the Pol II-associated 
unprocessed pre-mRNA is cleaved and released from the template. Finally, the 
cleavage occurs at the poly(A)-addition site and dissociates pre-mRNA from Pol II.  
Low efficiency of polyadenylation results into high amounts of unspliced pre-
mRNA accumulation and degradation in the cell nucleus. Transcription termination is 
thus a determinant of the efficiency of pre-mRNA 3′ end processing and the term 
region is a key element for efficient HBB pre-mRNA cleavage, polyadenylation and 















Figure 1.8 – Role of the HBB transcription termination region ( term) in pre-
mRNA cleavage and polyadenylation. Left panel; when termination is inefficient, 
pre-mRNA splicing is compromised and polyadenylated RNA species (1 and 2) are 
retained at transcription sites. These events are surveyed by the nuclear exosome, 
which degrades aberrant RNA and reduces gene expression. Right panel ; termination 
enhances gene expression by promoting more efficient pre-mRNA processing and so 














1.3 Gene therapy 
 
Gene therapy can be broadly defined as the treatment of a disease or medical 
disorder by the introduction of therapeutic genes into the appropriate cellular targets. 
These therapeutic genes can correct deleterious consequences of specific gene 
mutations or re-program cell functions to overcome a disease. For successful gene 
therapy, the exogenous therapeutic gene must be specific, efficient, and stably 
incorporated into the target cell.  
Gene therapy can actually be performed by both “viral delivery”, taking 
advantage of the infectious nature of viruses and “non-viral” by the use of naked 




1.3.1 Non-viral gene therapy 
 
Non-viral methods are essentially focused on the incorporation of “naked 
DNA” and oligonucleotide structures into the cell. This methodology presents certain 
advantages over viral methods, such as simple large scale production and low host 
immunogenicity. However, to date, non-viral gene therapy has failed to provide 
sufficient evidence of stable expression and delivery to be competitive over viral 
delivery. This report will focus on viral gene therapy and the use of lentiviral vectors 
for gene delivery. 
 
  
1.3.2 Viral gene therapy 
 
Viruses are intracellular obligate parasites and they have evolved as efficient 
vehicles for the delivery of DNA or RNA to target cells. Wild-type viruses infect their 
hosts and introduce their genetic material into the host cell as part of their replication 
cycle. This genetic material, hijacks the host cell normal replication machinery to 
serve the needs of the virus and the host cells eventually follow these instructions and 
produce additional copies of virus, leading to more and more cells becoming infected. 
This infection pattern leaded to the hypothesis that viruses could be used as vehicles 




to carry 'good' genes into a human cell. The removal of viral genes that induce the 
disease from the virus and the replacement of these with genes encoding the desired 
therapeutic product proved to be a viable and safe alternative to common therapeutics, 
and the use of viral mediated delivery opened a new door in the gene therapy field. 
To date, a large number of viruses with unique characteristics useful for gene 
therapy have been identified. This has led to the application of recombinant viruses 
such as adenoviruses, adeno-associated viruses, herpes viruses, poxviruses, 






Adenoviruses are non-enveloped viruses containing a linear double stranded 
DNA genome. To date over 40 serotype strains of adenovirus have been described, 
most of which cause benign respiratory tract infections in humans. The adenovirus 
life cycle does not normally involve integration into the host genome, instead they 
replicate as episomal elements in the nucleus of the host cell. Adenovirus wild type 
genome is approximately 35 kilobases of which up to 30 kb can be replaced with 
foreign DNA (Smith, 1995; Verma & Somia, 1997). This large vector capacity is 
being fully exploited by gene therapists. 
Adenoviral vectors are very efficient at transducing target cells in vitro and  in 
vivo, and can be produced at high titres (>10
11
/ml), However, transgene expression in 
vivo from progenitor vectors tends to be transient, limiting therapeutic  applications of 
the vector (Verma & Somia, 1997). 
 
 
1.3.2.2 Adeno-associated virus 
 
Adeno-associated viruses (AAV) are non-pathogenic human parvoviruses 
dependant on a helper virus, usually adenovirus, to proliferate. Their wild type 
genome is a single stranded DNA molecule, consisting of two genes; rep, coding for 
proteins which control viral replication, structural gene expression and integration 
into the host genome; and cap, which codes for capsid structural proteins. These 
viruses infect both dividing and non-dividing cells, and in the absence of a helper 




virus mostly integrate into a specific point of the host genome (19q 13-qter) at a high 
frequency (Kotin et al., 1990) proving stable and controlled expression.  
AAV gene therapy vectors can infect both dividing and quiescent cells and 
persist in an extrachromosomal state without integrating into the genome of the host 
cell. Success with these vectors has been reported recently for the correction of the 





Retroviridae is a family of single-stranded (ss) RNA spherical viruses of 
around 80-120 nm in diameter (Vogt & Simon, 1999). This family of viruses can be 
distinguished by three main characteristics: genetic information in RNA form; virions 
that possess reverse transcriptase enzyme; and a virion morphology that consists of 
two proteinaceous structures and a dense core, all surrounded by an envelope 
structure.  
The wild-type retrovirus consists of a lipid bilayer-enveloped particle 
comprising a homodimer of linear, positive sense, ssRNA genomes between 7 and 11 
kb in length. Following entry into target cells, retroviruses perform a journey from the 
cell surface to the nucleus while the RNA genome is retro-transcribed into linear 
double stranded (ds) cDNA (termed provirus) via reverse transcriptase enzyme. Once 
inside the nucleus, the provirus DNA integrates into the host cell genome via the 
action of integrase enzyme and is passed on to daughter cells upon cell division. 
The ssRNA genomes are converted to dsDNA and integrate, via long terminal 
repeats (LTR) located at both ends (3‟ and 5‟) in the target cell genome. The LTRs 
represent the two end parts of the viral genome that are connected to the cellular DNA 
of the host cell after integration consisting of  3‟ unique elements (U3), repeat 
elements (R)  and 5‟ unique elements (U5). These do not encode for viral proteins but 
harbour cis-acting elements important for provirus integration. Viral LTRs frame the 
coding genes; the tandem group-specific antigen (gag) gene coding for core and 
structural proteins of the matrix and nucleocapsid core, the polymerase (pol) gene 
coding for enzyme reverse transcriptase protease and integrase; and the envelope 
(env) gene coding for the retroviral coat proteins and containing information for the 




surface and transmembrane components of the envelope protein. The "classical" 
structural scheme of a retroviral genome is: 5'LTR-gag-pol-env-LTR 3 as illustrated 
of Figure 1.9. Other important components are the packaging signal (psi or ψ), 
required for the specific packaging of the viral RNA genome into newly formed 
virions (Watanabe & Temin, 1982), and the central polypurine tract (cPPT), which is 
the site of the initiation of positive-strand DNA synthesis during reverse transcription 




Figure 1.9 - General structure of an integrated retroviral genome. The long 
terminal repeats (LTRs) have sequences needed for the regulation and initiation of 
transcription. The sequence denoted ψ is required for packaging retroviral RNAs into 
mature virus particles. (Image taken from http://envmedical.com) 
 
Based on their genome organization, the Retroviridae are divided in simple 
and complex retroviruses, examples of which are oncoretroviruses, such as MLV, and 
lentiviruses, such as human immunodeficiency virus (HIV)-1, respectively. 
Lentiviruses include primate (human immunodeficiency virus HIV and simian 
immunodeficiency virus SIV) and non-primate (feline immunodeficiency virus FIV, 
bovine immunodeficiency virus BIV, caprine arthritis-encephalitis virus CAEV, 
equine infectious anaemia virus EIAV and visnavirus) retroviruses.  
 








Lentivirus infection is characterized by a long interval between the initial 
infection and the onset of serious symptoms, hence its name comes from the latin 
terms lent, latent meaning “slow” viruses. Lentiviruses are a subfamily and have more 
complex genomes than oncoretroviruses. This report will focus on human 
immunodeficiency virus (HIV). 
 
 
1.3.3.1 HIV virus 
 
1.3.3.1.1 HIV genome structure 
 
 
The HIV wild type genome consists of two identical unspliced ssRNA 
molecules of approximately 10 kb long located within a nuclear core surrounded by a 
nucleocapsid and a viral envelope core.  
Their genome is organized into the gag, pol, and env gene configuration 
(Figure 1.10). Gag encodes the structural proteins, whereas the pol gene encodes the 
enzymes that accompany the ssRNA. Of these, reverse transcriptase carries out 
reverse transcription of the viral RNA to DNA, integrase catalyses the integration of 
the proviral DNA into the host genome, and protease is involved in gag/pol cleavage 
and virion maturation (Katz & Skalka, 1994). Env encodes the viral envelope.  
Wild type HIV-1 contains two regulatory genes, tat and rev, essential for viral 
replication and gene expression. Tat protein activates the promoter in the HIV LTR so 
that viral RNA is produced efficiently, and Rev interacts with a region of viral RNA 
known as the Rev-responsive element (rre) and promotes the transport of viral RNA 
from the nucleus to the cytoplasm (Pluta & Kacprzak, 2009) 
Although possessing the retroviral basic genome organisation, HIV-1 
specifically contains four additional accessory genes, vif, vpr, vpu and nef, critical for 
in vivo replication and pathogenesis (Figure 1.10; Coil & Miller, 2004). The presence 
of the latter in therapeutic vectors raises safety concerns as the proteins they encode 
have cytotoxic or cytostatic activities; vpr induces G2 cell cycle arrest and nef alters 




cellular activation pathways. Cell surface molecules such as CD4 and the class I 
major histocompatibility complex are down-regulated by nef and vpu. Moreover, nef, 
vif and vpr are incorporated into viral particles and can enhance the immunogenicity 
of vectors. It is therefore important to ensure that lentiviral vectors (LV) are 
constructed in the absence of these genes, which have been shown not to be essential 







































Figure 1.10 – The HIV-1 wild type genome. A) shows the spatial representation of the 
virus, with the encoding proteins (gp41, p17, p24, p7.,etc.) surrounding te core containing 
the viral RNA and reverse transcriptase.  The virus is mainly composed by three genes 
(Gag, Pol and Env) encoding the packaging and envelope proteins of the virus flanked by 













1.3.3.1.2  HIV life cycle 
 
 
HIV replication starts when the viral envelope glycoprotein gp120 binds to a 
CD4 receptor and a secondary receptor on the cell surface after which conformational 
changes in the non-covalently associated gp41 subunit releases free energy sufficient 
to promote fusion of the viral particle envelope with the cell membrane. The viral 
core is then spilled into the cytoplasm and reverse transcription of the viral RNA 
occurs. The reverse transcription complex (RTC) is then transported towards the 
nucleus via the cellular protein dynein. When reverse transcription is complete and 
the provirus and several viral proteins form, the pre-integration complex (PIC) is 
allowed entry into the nucleus via the cellular protein LEDGE. After integration, 
transcription is conducted by RNAP II and enhanced by the viral protein Tat. 
Unspliced and partially spliced transcripts are stabilised by the viral protein Rev 




1.3.3.2 Development of lentiviral vectors                 
 To minimize the risk associated with manufacturing and use of LVs, all non-
essential genes coding for accessory proteins and responsible for virulence, should be 
removed from the vector sequence. Additionally the vector genome is usually split 
into several parts with limited sequence overlap to reduce to a minimum the 
possibility of independent recombination to form wild type viral particles and vector 
mobilization. The genes required for lentiviral vector generation are therefore 
separated on different plasmids that are co-transfected into HEK293T cells together as 
a complex aggregated with the help of a transfection agent (see Materials and 
Methods section). Hence, such a system typically consists of packaging expression 
cassettes (helper), a vector cassette (transfer vector) and an envelope expression 
cassette (Figure 1.11).   
 






Figure 1.11 - Lentiviral vector production protocol. As in oncoretroviral vectors, 
the viral genes gag, pol and env are replaced by the transgene of interest. The LTR 
and the packaging signal ψ are maintained for vector amplification and packaging. Of 
the lentiviral accessory proteins, only the rev responsive element (RRE) is maintained 
as an additional cis-acting sequence required for the nuclear export of unspliced and 
single-spliced viral RNAs in the presence of the Rev protein. Rev is expressed by one 
of the three packaging constructs. The two others encode the Gag/Pol or the Env 
proteins, respectively.  
(Image taken from http://www.addgene.org/) 




 The development of a stable cell line producing LVs has been reported. These 
STAR cells are derived from 293T or HT1080 human cell lines that were transduced 
with an MLV-based vector expressing a codon optimised version of gag and pol 
(lacking RRE) and then co-transduced with Tat and Rev being expressed from 
separate gammaretroviral vectors. The STAR cells were then stably transfected with 
plasmids expressing either MLV-A, GALV+, or RD114pro glycoproteins to allow for 
high plasticity regarding vector pseudotyping. The production of SIN and non-SIN 
versions of LVs in these cells is similar, with a high titre and stable for up to 3 months 
(Ikeda et al., 2003). 
 
1.3.3.2.1 Transfer plasmid 
The transfer vector plasmid contains the full-length vector RNA containing 
cis-acting elements for efficient packaging, reverse transcription, nuclear import and 
integration into the host genome. Typically, it contains the transgene expression 
cassette flanked with the LTRs at both ends of the genome, as in wild type virus, the 
neighbouring sequences act as cis-elements that regulate the virus during viral gene 
expression, packaging, transcription and integration, being essential for the viral 
infection of the host cell and genome integration.  
The expression cassette contains a gene of interest driven by an internal 
promoter usually positioned between the 3‟ Tat/Rev splice acceptor site and the 5„ 
LTR and contain non-coding cis-acting regulatory sequences needed for packaging 
and to increase the efficiency of gene transfer. The promoter can be constitutively 
active and derived from a virus [such as the LTR from the spleen focus-forming virus 
(SFFV), or the immediate early promoter from the cytomegalovirus (CMV)] or 
cellular genes [such as the phosphoglycerate kinase (PGK) or elongation factor 1α 
(EF1 α)]. These promoters are active in a range of different cell types. However, 
transcription can be restricted to a given cell type by the use of tissue-specific 
promoters, such as the human desmin promoter in skeletal muscle (Talbot et al., 
2010). Alternatively, the incorporation of microRNA target sequences in the 
transcript can also prevent expression in cells where those microRNAs are expressed 
(Brown et al., 2006). Multiple promoters can be included, each driving expression of 




a different transgene. However, this strategy has the potential problem of promoter 
suppression, where one of the transcripts is expressed more than the other (Emerman 
& Temin, 1984). 
 
The packaging signal (  or E) is located near the 5‟ end of the genome 
between the splice donor and the gag start codon, the primer binding site (PBS), 
important on first strand synthesis, and the 3‟ and 5‟ LTRs.  
 
 Additional modifications to this transfer vector included the incorporation of 
the central polypurine tract (cPPT) to enable the formation of a DNA flap during 
reverse transcription, facilitating nuclear translocation of the PIC in both dividing and 
non-dividing cells and providing a second site for initiation of DNA synthesis. This 
DNA flap has been shown to increase nuclear import of the viral DNA, thus 
increasing the transduction efficiency in both dividing and non-dividing cells 
(Follenzi et al., 2000; Zennou et al., 2000).  
 
 1.3.3.2.2 Packaging plasmid 
The packaging cassette expresses viral enzymes and structural proteins 
necessary for infectious particle formation.  
The original first generation LV system developed in 1996 contained the 
accessory proteins Vpu, Vpr, Vif Nef and the Rev and Tat regulatory proteins and 
functional components of the packaging plasmid. The evolution of the packaging 
cassette design and optimisation of the transfer vector eventually led to the removal of 
five proteins associated with HIV virulence - tat, nef, vif, vpr,  and vpu. 
These packaging constructs were further refined by eliminating all accessory 
proteins that are associated with virulence and toxicity and are not required for viral 
replication, eventually leading to the development of the second-generation packaging 
cassette (Zufferey et al., 1997). In this system only Rev and Tat proteins were 
expressed together with gag and gag-pol polyproteins. 




The packaging plasmid contains also the gag and pol genes, driven by a 
heterologous promoter. In order to improve the biosafety of the system and  overcome 
the problem of susceptible points for homologous viral recombination between the 
packaging and the transfer vector constructs,  rev was later placed on a second 
plasmid while tat was completely removed and its function replaced  using modified 
5‟ LTR elements containing strong constitutive RSV or CMV-derived promoters in 
the corresponding vector constructs  - these systems are often referred to as a third 
generation packaging cassette.  
 
Safety improvement in the design of the lentiviral packaging system is still an 
area of intensive research. Attempts to create hybrid LV systems exploiting the 
limited sequence homology between other viruses have been pursued. It was shown 
tat HIV-1 vectors can be packaged with SIV core particles and permutations between 
HIV-1 and HIV-2 packaging have been tested. Furthermore, lentiviral particles 
containing packaging genes from a recombinant adenoviral vector have been designed 
(Kuate et al., 2004). 
 
 The packaging plasmid contains the integrase protein responsible and 
essential for LV integration into the host cell genome. Mutations performed on this 
protein have given rise to the non-integrating packaging plasmids (see Section 
1.3.2.8). 
 
1.3.3.2.3 Envelope plasmid 
The HIV wild type env shows preferable transduction of CD4
+
 cells. As this 
protein is removed from the system, an additional plasmid expressing a heterologous 
glycoprotein is used during vector production. The envelope plasmid contains the 
gene involved in target cell recognition, the env gene. The normal HIV envelope is 
usually exchanged with glycoproteins from other viruses so that the vector tropism is 
extended to a wider range of cells other than lymphocytes. Pseudotyping of this type 
offers several advantages: increase of vector safety due to the elimination of sequence 
homology with the wild type virus, expands tropism of the pseudotyped vector with 




the targets cells, and improves vector stability allowing the production and 
concentration by centrifugation of high titre vectors of LV to produce the robust 
nature of the envelope and long-term storage. 
The most commonly used glycoprotein to pseudotype LVs in order to expand 
vector tropism is the glycoprotein from the vesicular stomatitis virus (VSVg). The 
receptor for VSVg, although still undetermined, appears to be ubiquitous in all cell 
types, explaining the broad host range of VSV (Schlegel et al., 1982; Coil and Miller, 
2004). Furthermore, VSVg pseudotyped vectors are highly stable and can be 





transducing units (TU) per ml, and enabling the production of serum-free, 
high-titre vector particles (Burns et al., 1993, Naldini 1996, Reiser et al., 1996,  
Poeschla et al., 1996). This envelope facilitates vector entry via the endocytic 
pathway which diminishes the requirement for viral accessory proteins for full 
infectivity. However, the mechanism responsible for cell binding and well as the 
cellular receptors involved in the glycoprotein cell recognition remain unclear. 
One drawback of the production of pseudotyped vectors using VSVg is that 
due to its fusogenic properties it is toxic to some mammalian cells if constitutively 
expressed (Burns et al., 1993). This means that producer cell lines expressing 
packaging proteins for long-term virus production require conditional production of 
this glycoprotein. Another drawback of this pseudotype is inactivation by human 
serum complement, preventing its use in vivo (DePolo et al., 2000). Furthermore, it 
has been reported that LV preparations pseudotyped with VSVg are contaminated 
with tubulovesicular structures carrying nucleic acids or proteins that may elicit an 
undesirable immune response (Pichlmair et al., 2007). 
 
 Other than VSVg, otherheterologous glycoproteins have also been used to 
restrict the tropism of LVs. The neurotropic properties of Lyssavirus, including the 
rabies and Mokola virus, have been studied. Vectors pseudotyped with those 
glycoproteins infect neurons preferentially (Mochizuki et al., 1998; Desmaris et al., 
2001). Retrograde transport has been achieved by the use of Rabies glycoprotein 
(Mazarakis et al., 2001).  




Another strategy to target specific cell types is the engineering of envelope 
glycoproteins. Viral envelope proteins have been modified to contain ligands or single 
chain antibodies (Hatziioannou et al., 1999). Using the second approach, by fusing 
single chain antibodies to the Sindbis glycoprotein, LVs have efficiently been targeted 
to melanoma cells (Morizono et al., 2005). 
 
 
1.3.3.3 Development of SIN vectors 
 
Virologists are well aware of the risks associated with viral recombination that 
can theoretically occur at the DNA level, especially during the mixing of co-
transfected plasmids, between transfected plasmids or between the proviral vector and 
a homologous chromosomal sequence in the target cell. A major issue regarding the 
biosafety of LVs remained: the possibility of transfer vector retaining the ability for 
transcription of the full-length genome after integration into the target cell.  
It is possible for the LV provirus to be mobilised by replication competent 
virus (for example, if the transduced cell were subsequently infected with wild type 
HIV-1). In addition, there is the possibility that the 3‟ LTR could induce aberrant 
expression of adjacent genes.  
 
The first self-inactivating (SIN) retroviral vectors were made in an MLV-
based vector (Yu et al., 1986; Yee et al., 1987). The first vector had a deletion of 
299bp in the U3 region, containing the enhancer and promoter CAAT box element 
with the second having the additional deletion of the TATA box. However, retroviral 
vectors display weak polyadenylation sites and deletion of U3 to generate SIN 
vectors increased the likelihood of read-through thus augmenting the potential for 
insertional mutagenesis (Furger et al., 2001; Zaiss et al., 2002).  
The same principle was used later in LVs design by Miyoshi and colleagues 
(Miyoshi et al., 1998) by deletion of a 133bp section from the U3 region of the 3‟ 
LTR, which removed the TATA box and other transcription factor binding sites, 
resulting in transcriptional inactivation of the proviral LTR in infected cells, both in 
vitro and in vivo. This adjustment showed no changes in the viral transcript levels of 




the producer cells, and no significant reduction in viral titre. In the study, expression 
of the transgene in vivo in both neurons and retinal cells was improved with this SIN 
vector due to the removal of transcriptional interference from the HIV-1 LTR 
promoter/enhancer. The study reported a deletion of the enhancer/promoter sequences 
in the U3 region of the 3‟ LTR (120-40bp U3).  
Similar results were obtained by Zufferey and colleagues (Zufferey et al., 
1999) with deletion of up to 400bp of the 3‟ LTR U3 region. Again, viral particle 
production was neither decreased nor was transduction efficiency lowered in vitro or 
in vivo. Furthermore, it has been demonstrated that in SIN vector transduced cells that 
were subsequently infected with wild type HIV-I, the vector was not mobilised 
(Bukovski et al., 1999). 
 
 The use of SIN LV significantly reduced promoter interference and also 
offered a potential safety advantage over traditional retroviral vectors. Specifically, 
upon reverse transcription, during the step of viral replication, the U3 will be 
duplicated in both LTRs, thus both LTRs are inactivated leaving only the very 5‟ end 
of the U3 for integrase recognition and function. Expression of the transgene will thus 
be controlled from an internal promoter. 
If the LTR deletion is sufficient, transcription of full-length vector RNA 
transcripts is markedly reduced in cells transduced with a SIN vector. This further 
minimises the risk of generate replication competent retrovirus and there is a rather 
incomplete U3 enhancer sequence in the proviral 5‟ LTR interfering with internal, 
heterologous promoters. This offers additional safety advantages as it is more difficult 
to re-generate a wild-type parental retrovirus via recombination. With the deletion of 
the viral transcriptional elements from the vector, synthesis of vector RNA will 
depend on site of integration (Kappes & Wu, 2001).  
 
Furthermore, the SIN design prevents transcriptional interference by the 
promoter/enhancer elements in the host genome, reducing the possibility of 
insertional activation and mutagenesis of adjacent coding sequences (such as 
oncogenes) either by transcription from the 3‟ LTR at the site of vector integration or 
LTR enhancer activation of a host gene promoter. In addition, to improve biosafety, 




the use of SIN vectors has two additional advantages; elimination of transcriptional 
interference by the LTR promoter, and the possibility to create tissue-specific and 
inducible vectors via appropriate internal promoters, which would be difficult in the 
presence of non-specific transcription from the LTR promoter. 
 
1.3.3.4 Infection by Lentiviral vectors  
The nuclear import machinery recognizes the cellular matrix and  docks the 
PIC complex to the nuclear pores, enabling the passage into the nucleus. Only a short 
fragment of the DNA is synthesised before the 5‟ end of the 5‟LTR is reached and 
then the complex shifts to the 3‟LTR of the RNA template where reverse transcriptase 
synthesises a new full ssDNA strand as template. The synthesis of the second ssDNA 
is initiated from two sites at the original (now degraded) RNA - the 3‟ polypurine 
tract (PPT) and the central PPT (cPPT), this process is decribed in detail in Figure 
1.12. 
The now dsDNA traffics towards the nucleus associated with viral proteins as 
linear double-stranded cDNA comprising the PIC (Herschlag & Brown 1999). 
Lentiviruses, unlike oncoretroviruses, rely on active transport of the PIC through the 
nuclear pore by the nuclear import machinery of the target cell, allowing the viral 
proviral genome to integrate into the host cell DNA without the necessity for cell 
division. The PIC traverses the nuclear membrane directly without requiring its brake 
down by cell division.   
Integrated wild type provirus is able to be transcribed into unspliced full 
length copies and multiple spliced copies from the 5´LTR. Unspliced copies are 
packaged into new virions whilst spliced versions are used as templates for translation 
to produce the viral proteins necessary for this process (Pluta & Kacprzak, 2009). 
A main advantage in the use of LV is therefore the easy access into the cell 
nucleus without the necessity for mitosis with increased probability for genome 
integration. 






Figure 1.12 – Reverse transcription of SIN vectors. (A) cellular tRNA hybridises 
with the primer binding site (PBS) on the vector RNA genome and reverse 
transcriptase makes a DNA copy of the U5 and R regions. (B) The vector U5 and R 
regions are removed by the RNase H activity of reverse transcriptase. (C) The cDNA 
hybridises with the complementary R region at the 3‟ end of the vector RNA genome 
and the remainder of the vector genome is copied into cDNA. (D) Most of the 
remaining vector RNA genome is removed by RNase H. A second cDNA strand is 
extended from the remaining viral RNA and the deleted U3 region of the 3‟ LTR 
copied. (E) The tRNA and remaining vector RNA are removed by RNase H. The 
copied PBS region in the second DNA strand hybridises with the PBS region on the 
first strand and both strands are extended. (F) A double-stranded DNA copy of the 










1.3.3.5 Long-term tissue specific expression 
 
For many diseases long-term and stable expression of a therapeutic transgene 
delivered tissue specifically is crucial. Unfortunately, progressive silencing of a stably 
integrated transgene over time in a cell line or in vivo commonly occurs. This gene 
silencing, commonly referred to as “position effect variegation” (PEV), is due to 
chromatin and DNA methylation mechanisms even though LVs preferentially 
integrate into open active chromatin within the target cell at the time of transduction. 




1.3.3.6 Insertional mutagenesis 
 
  The gamma-retroviral and lentiviral vector point of insertion into the genome 
cannot be targeted. However, integration in 60-70% of cases is now known to occur 
near or within actively transcribed genes. This includes integration within or near 
genes involved in regulating cell growth (Imren et al., 2004). As a result, problems 
arising from insertional mutagenesis are a possibility (Lutzko et al., 2003). 
 
Recently, the successful treatment of SCID-X1 and SCID-ADA by gene 
therapy has been reported (Cavazzana-Calvo et al., 2000; Michallet et al., 2000).  
 
X-linked severe combined immunodeficiency (SCID-X1) results from 
mutations in the IL2RG gene, which encodes the common cytokine receptor gamma-
chain (γc). The failure of γc signalling results in a classical phenotype characterised 
by the absence of T and natural killer (NK) cells, whilst B cells are present but 
poorly-functional (White et al., 2000). Unless patients are treated by haematopoietic 
stem cells (HSC) transplantation, they succumb to infections during the first years of 
life. The aim of two clinical trials using gene therapy for the treatment of this disease 
was immune reconstitution with autologous HSCs manipulated to express γc. The ex 
vivo procedure entailed isolating HSCs from patient and transduced with a 




gammaretroviral vector expressing γc. The cells were then infused back into patients 
and reconstitution of the immune system was monitored over time. Overall 20 
patients have been subjected to gene therapy correction (10 in Paris, 10 in London). 
However, 5 out of the 20 children enrolled in these two trials developed T-cell 
leukaemia-like conditions. In 4 out of the 5 cases this was due at least in part to the 
transgene activation of the LMO2 proto-oncogene, leading to aberrant, highly 
elevated translation of the protein, associated with childhood leukaemia (Cavazzana-
Calvo et al. 2000). Although there is already a strong advantage for the genetically 
modified cells to proliferate, the activation of LMO2 expression probably boosted this 
ability of the clones to the point of malignancy (Hacein-Bey-Abina et al., 2003a; 
Hacein-Bey-Abina et al., 2003b).  
 
This outcome prompted the scientific community to endeavour all necessary 
efforts to understand how viral vectors can cause insertional mutagenesis. Several in 
vivo and in vitro assays have been developed to investigate and quantify this process. 
A protocol has been adapted from the observation that primary bone marrow cells can 
be immortalised by infection with gammaretroviruses (Du et al., 2005). This in vitro 
method is able to quantify insertional mutagenesis that leads to transformation by 
comparison with background levels. It has been possible to establish that the 
transformation frequency detected with a SIN retroviral vector is lower compared 
with a non-SIN counterpart and that the cellular EF1  promoter used as internal 
promoter in a SIN retroviral vector does not give rise to detectable transformed cells 
(Zychlinski et al., 2008; Modlich et al., 2006). 
 
Until recently, very little was known concerning integration selectivity. 
Genome-wide studies using human primary cells are an obligatory step to accurately 
estimate risks. Studies performed by Wu and colleagues (Wu et al., 2003) confirmed 
that active gene vicinity appears to offer favoured sites for retroviral integration. 
However, it is important to refer that up to now, no other integration event affecting 
gene transcription leading to adverse effects has been reported in clinical trials 
involving retroviral vectors, which might suggest that the transgene or the target cell 
may have a influence in malignancy arising. There is therefore a need to achieve 
therapy with only 1-2 copies to minimise the risk of insertional mutagenesis.  




  The need for fewer vector copies per cell means that in the cases where high 
levels of expression per transgene copy are needed to achieve maximum therapeutic 
value, especially in the case of the haemoglobinopathies, it is essential to construct 
vectors that produce high levels of  or HBG. A key challenge for clinical 
therapies based on retroviral vectors is then to achieve stable transgene expression 
while minimising insertional mutagenesis whist avoiding silencing. A possible 
solution is the use of viral vectors with control elements that lack enhancer function 
(such as the UCOE; Zhang et al., 2007 & 2010) or to include elements with enhancer 
blocking activity into the vector to reduce the risk of oncogene activation.  
 
Alternatively, it is also possible to consider the development of mutant LV 
packaging plasmids, with a mutant integrase protein, which co-transfected with 
transfer and envelope plasmids generate defective properties of insertion, with 




1.3.3.7 Integration-defective lentiviral vectors  
 
 As described previously retroviral and lentiviral vectors can be made 
integration defective (ID) by mutation of the integrase coding sequence, resulting in 
normal DNA synthesis but lack of integration. ID-LV genomes persist in transduced 
cells as either non-integrated linear or mainly as double-stranded circular genomes. 
These are produced during the normal replication cycle, when a proportion of reverse 
transcribed double stranded DNA (dsDNA) lentiviral genomes undergo either 
intramolecular recombination of the LTRs or intramolecular end-ligation to form 
closed circles containing 1 (1-LTR circle) or 2 (2-LTR circle) copies of the LTR 
respectively  (Shank et al., 1978; Engelman, 1999) 
Studies demonstrating for the first time efficient and sustained gene expression 
in vivo with an integrase-deficient HIV-1 LV were conducted in Rpe65
rd12/rd12
 mutant 
mice, a rodent model of retinitis pigmentosa (Yanez-Munoz et al. 2006). This study 
showed that high efficiency of gene transfer and expression prompted by LVs can 
occur in vivo without a requirement for vector integration. In addition, this 




investigation demonstrated the potential advantage of non-integration allied with the 
greater transgene capacity of ID-LVs (compared to recombinant adeno-associated 
virus vectors) and their low immunogenicity. 
 
This system seems to be particularly feasible for gene therapy targeting post 
mitotic tissues, such as muscle, liver, brain and retina. However, for target tissues 
constantly undergoing cell division, such as the haematopoietic system and for 
diseases that require early treatment for good prognosis such as Duchenne muscular 
dystrophy, the success of a treatment with ID-LVs is only an option if the vectors can 
be maintained in replicating cells. The circular forms of dsDNA ID-LV genomes 
persist in transduced cells as episomal plasmid-like molecules from which efficient 
gene expression can still take place. However, as these are unable to replicate, and 
thus are gradually lost from actively dividing cell populations (akin to transiently 
transfected plasmids, adenoviral and AAV vectors). Therefore, a means of conferring 
replication and retention of ID-LV is required to allow their use in mitotic stem cell 
populations that are the target in the haemoglobinopathies. A possible solution for this 
problem is the insertion of effective origins of replication (ori) and retention elements. 
Development of systems that employ the SV40 Ori have shown encouraging results in 
the development of long-term episomal maintenance in vitro, but the system requires 
a transforming viral gene product Large T antigen for episomal maintenance 
(Piechaczek et al., 1999).  
 
 Despite this, the vector system has numerous applications. In two recent 
papers a Sleeping Beauty (SB) transposase‐mediated transposition is described, which 
was mediated using an ID-LV (Vinc et al., 2009; Staunstrup et al., 2009). Unlike 
retroviral integration, SB transposition shows little preference for specific genomic 
regions and therefore a reduced risk of insertional mutagenesis.  Similarly, platforms 
that enhance site specific integration such as zing‐finger nuclease systems, used a 
three ID-LV system where vectors carried either one of the two necessary zinc‐finger 
nucleases or the donor template (Lombardo et al., 2007). Successful gene correction 
was observed at the IL2RG locus and site‐specific integration into the CCR5 locus in 
50% of transduced cultured cells and 5% of human ES cells. Initial success is, 




however, still hampered by a very low efficiency in both systems (Banasik & 
McCray, 2009). 
 
  ID-LVs represent a class of novel viral vectors with emerging applications. 

































1.3.4 Success in clinical trials using viral vectors 
 
1.3.4.1 Trials of gene therapy for X-linked severe combined 
immunodeficiency (SCID–X1)   
 
 X-linked severe combined immunodeficiency disease (SCID-X1) is an 
inherited disease with absent T lymphocyte function, due to deficiency in the common 
cytokine receptor -chain ( c; IL2RG). IL2RG is an essential component of the IL-4, 
7, 9, 15 and 21 cytokine receptor complexes. A major breakthrough in gene therapy 
came in 2000 when successful treatment of 2 children suffering from SCID-X1 was 
achieved by the introduction of a normal functioning copy of the IL2RG cDNA in 
patient bone marrow HSC using a gammaretroviral vector based on murine Maloney 
leukemia virus (MLV) by an ex vivo delivery procedure (Hacein-Bey-Abina et al., 
2002; Escors & Breckpot, 2010; Cavazzana-Calvo et al. 2000). A similar and equally 
successful approach was employed in a trial in London (Gaspar et al., 2004).  
The efficacy and safety of the treatment has been demonstrated, as no 
evidence of replication retrovirus detected from the patients. At the end of the trials a 
total of 20 patients were treated; 10 in London and 10 in Paris. All patients responded 
well to treatment with eldest two patients now 15 years of age and in good health. 
However, in both clinical trials, 5 cases (4 in Paris and 1 in London) of a leukaemia-
type condition directly associated to the gene therapy itself were later reported. Upon 
detailed analysis, the cause of these severe adverse events was found to be due to  
retrovirus-induced insertional mutagenesis. In four cases provirus integration within 
or near the LMO-2 locus led to activation of LMO-2 causing the observed clonal 
acute lymphoblastic leukaemia (Hacein-Bey-Abina et al., 2003; Howe et al., 2008; 








1.3.4.2 Gene therapy for chronic granulomatous disease (CGD) 
 
Following a similar approach to the SCID-X1 clinical trials, the correction of 
X-linked chronic granulomatosis (X-CGD) was reported in 2006, again using gamma-
retroviral vector encoding gp91 phox targeting bone marrow HSC (Ott et al., 2006). 
Clinical efficacy was observed, together with clonal amplification of corrected cells, 
probably as a result of insertional activation of the MDS1-EVI1, PRDM16 and 
SETBP1 genes (Stein et al., 2010). In this trial a moderate dosage of busulfan (8 
mg/kg) was given prior to reinfusion of the transduced mobilised HSC (Ott et al., 
2006). The two adult males enrolled in the trial showed relatively high levels of 
corrected leukocytes  in peripheral blood (~20%) within the first months after the 
gene therapy procedure, which rose to as high as 80% over the first year. Vector 
integration sites revealed a highly restricted pattern, with the majority of vector 
integrants in the engrafted stem cells being near one of a few genes known to be 
involved in myeloid cell proliferation (MDS-1, PRDM16 or SETBP1). These two 
patients went on to develop a benign form of myelodysplasia, a pre-leukemic 
condition. After initial success with both patients showing clearance of chronic pre-
existing infections, one patient unexpectedly developed an acute infection from which 
they subsequently died. Examination revealed that although neutrophil counts had 
been maintained at normal levels therapeutic transgene function had been lost in both 
patients. The underlying mechanisms for the oligoclonal expansion and progression to 
myelodysplasia are not fully elucidated, but the retroviral vector used contained the 
gp91phox therapeutic gene under control of the SFFV LTR, which possesses potent 
enhancer activity in myeloid progenitor cells and it is thought that this led to trans-
activation of genes that promote myeloid cell proliferation. Molecular analysis 
showed that the promoter region of the SFFV element had become progressively 
methylated and silenced leading to observed failure of the therapy. However, the 
enhancer region of SFFV had remained unmethylated and active, thus retaining its 
ability to induce expression of the MDS-1, PRDM16 or SETBP1 promoters near the 
site of retroviral vector integration. The use of HSC target cells that that had been 
mobilised from bone marrow into the circulation by the myeloid growth factor G-CSF 
may have presented a large number of transcriptionally active myeloid-proliferative 




genes as integration targets. As with the SCID-X1 trials, it will be vital to understand 
how to avoid this unwanted complication while retaining the clear-cut clinical 
benefits that can be attained. In addition, the problem of therapeutic gene silencing 
that ultimately led to treatment failure (Ott et al., 2006; Stein et al., 2010) needs to be 
solved. In this regard very encouraging results have recently been reported with an 
A2UCOE-MRP8-gp91phox transgene that combines both stability and neutrophil 
specific expression (Brendel C et al., 2011)  
 
 
1.3.4.3 Gene therapy for Leber’s Congenital Amaurosis (LCA) 
 
Encouraging improvements of vision were reported in a genetic eye disorder  
leading to early childhood blindness - Leber‟s Congenital Amaurosis (LCA) - using 
AAV-2 vector mediated gene therapy (Bainbridge et al., 2006, Alexander et al. 2007). 
Approximately 10% of LCA cases are defective in the RPE65 gene, which is required 
for normal retinal cycling of vitamin A. Thus, gene addition gene therapy was carried 
out in this study by using AAV2 as a vector to replace RPE65 in retinal pigment 
epithelium (RPE). In pre-clinical studies in dogs, this treatment improved visual 
function, which was maintained for more than three years (Bainbridge et al., 2006). 
The results of a phase I clinical trial involving three young adult patients with early-
onset, severe retinal dystrophy by mutation in RPE65 have been reported (Bainbridge 
et al., 2006). There was no immune response reported but no clinically significant 
improvement in visual acuity and retinal response to flash light or electroretinography 
in all three patients. However, one of the patients has improved in retinal function and 
visual mobility in low light condition (Bainbridge et al., 2006). The safe outcome 
from this initial low dose cohort of patients has led to approval for vector dose 
escalation to levels expected to give consistent therapeutic effects. 
 
A similar clinical trial for LCA has also been conducted in the USA (Maguire 
et al., 2008). An AAV2 vector with an RPE65 therapeutic gene was used in this trial. 
Visual perception was observed to markedly improve in a dimly lit environment for 
all three patients treated. The improvement in pupillary light reflexes confirmed the 
increase in retinal sensitivity and visual acuity (Maguire et al., 2008). Importantly, no 




adverse effects were reported, including response to RPE65 protein. The safety and 
efficacy of the vector has persisted through to at least 1.5 years post-injection 
(Simonelli et al., 2010). 
Participants reported baseline vision of about 20/200 with statistically 
significant visual acuity improvement and significant increases in light perception. 
Light sensitivity measurements were also reported to increase, with the vector-treated 
eyes showing a greater pupillary response to light than at baseline and to the 
previously better seeing contralateral eye - Injections were performed on the patient's 
worse seeing eye. The positive initial findings with respect to both efficacy and safety 
using AAV-mediated gene therapy for LCA are exciting and encouraging (Chung & 
Traboulsi, 2009; Simonelli et al., 2010). 
 
 
1.3.4.4 First human gene therapy trial using lentiviral vectors – gene 
therapy  for X-linked adrenoleukodystrophy (ALD) 
 
More recently, the first clinical gene therapy trial employing a lentiviral vector 
for an inherited disease, X-linked adrenoleukodystrophy (X-ALD), has been reported 
(Cartier et al., 2009). X-ALD is a severe brain demyelinating disease caused by 
mutation of ABCD1 encoding the ALD protein, which is an adenosine triphosphate-
binding cassette transporter in the membrane of peroxisomes (Cartier et al., 2009). 
The lentiviral vector expressed a wild-type ABCD1 cDNA under the control of the 





 cells ex vivo and 
transplanted into three young ALD patients after
 
pre-transplant conditioning with 
myeloablative doses of busulfan
 
and cyclophosphamide. This gene therapy approach 
has been found to stop progression of the disease with the same efficacy as transplant 
of bone marrow HSC. The therapeutic effect has been achieved to correct the 
phenotype of ALD for 24 to 30 months (to date), with 9 to 14% of granulocytes, 
monocytes and T and B-cells expressing the ALD protein.  
Notably, this study demonstrated that lentiviral vectors can mediate significant
 
levels of gene transfer into human HSCs.  




1.4 Gene Therapy for the Haemoglobinopathies – past, present and 
future 
 
1.4.1 Review of gene therapy for haemoglobinopathies 
 
 
The transfer of a regulated  transgene into autologous bone marrow HSC 
is a highly attractive treatment. The strategy, simple in principle, raises major 
challenges in terms of controlling expression of the globin transgene, which ideally 
should be erythroid specific, differentiation and stage restricted, position independent 
and sustained over time at a sufficiently high level to be of therapeutic benefit. The 
gene therapy approach would resolve the problem of finding an HSC donor and 
eliminate the risk of graft-versus-host disease and graft rejection associated with 
allogeneic HSC (Quek & Thein, 2007). 
 
Achieving regulated  expression has represented a tremendous obstacle in 
the past 20 years. Early attempts using gamma-retroviruses showed tissue specificity 
but low and variable levels of  expression in murine bone marrow chimeras due 
to vector instability (Cone et al., 1987; Dzierzak et al., 1988). A new hope came with 
the discovery of the LCR. Initial efforts to incorporate LCR sub-fragments into 
oncoretroviral vectors significantly increased expression levels in murine 
erythroleukemia (MEL) cells but failed to abolish positional variability of expression 
(Sadelain et al., 1995). This finding suggested that a minimal LCR comprising the 
juxtaposed core elements did not provide full LCR function, but rather acted like an 
erythroid specific enhancer. 
 The later incorporation of larger LCR segments into retroviral vectors 
proved to be problematic, leading to vector instability and considerable genomic 
rearrangements and very low viral titre.  
 
 Tests with AAV vectors (Einerhand et al., 1995) were soon discarded as these 
have a cloning capacity of only 4.7kb and are therefore unable to accommodate the 
required transgene size – with only the „core‟ elements of the LCR capable of being 
inserted and therefore these failed to overcome positional variability of expression in 




murine models. Furthermore, AAV vectors were subsequently found not to integrate 
efficiently into the target cell genome, therefore providing only short-term expression 
in dividing cells. 
 
 
1.4.2 Targeting HSCs with lentiviral vectors - milestones 
 
Soon became evident that lentiviral vectors would be of great use in the 
development of erythroid-specific gene therapy vectors. LVs show distinct 
advantages: they transduce non-dividing cells, achieve relative genomic stability, are 
generally considered safe vectors with a self inactivating (SIN) design that results in 
the removal of the viral LTR upon proviral integration, and have a relatively large 
packaging capacity (up to 8kb). Indeed, LVs remain to date the optimal vector where 
stable integration into the target cell genome is required, and thus hold the greatest 
promises of therapeutic success. As they have proved to stably incorporate larger 
DNA inserts without rearrangements, this allows the incorporation of larger LCR 
fragments and chromatin insulator elements to be used in an effort to reduce position 
effects, with the ability to obtain sustained therapeutic levels of expression.  
 
The breakthrough which changed the general negative thoughts surrounding 
gene therapy for the haemoglobinopathies occurred when the laboratory of Michele 
Sadelain showed definitive proof of principle that an LV harbouring an optimised 
combination of proximal and distal HBB transcriptional control elements, could yield 
therapeutic levels of HBB expression and completely rescued the disease condition in 
in the th3 severe thalassaemia intermedia mouse model system (May et al., 2000). 
They reported a lentiviral cassette encoding an  containing its own promoter 
including both introns, the intragenic enhancer (located in intron 2) and 3' proximal 
enhancer (constituting an HBB-mini-gene) together with larger fragments of the 
LCR sites HS2, HS3 and HS4. This vector was termed TNS9 (Figure 1.13). 
 
 






Figure 1.13 - Diagram of the TNS9 globin lentiviral vector. The image shows the 
cassette incorporated into the transfer plasmid. The LCR sites (HS2, HS3, HS4) are 
located 1kb from the 3´LTR. Exons and introns of HBB are represented by filled and 
open boxes respectively. Note non-SIN vector configuration. (Image taken from May 
et al., 2000). 
 
The TNS9 vector has been shown to drive erythroid-specific expression of 
HBB at therapeutic levels in thalassaemic mice (May et al., 2000). At four months 
post-transplantation, mice harboured on average 0.5-1 vector copy per peripheral 
blood cell and showed haemoglobin levels of 11-13g/dl in comparison with 8-8.5g/dl 
in age-matched controls. The carefully considered combination of LCR HS sites 
together with HBB itself in this vector enhanced expression beyond levels previously 
achieved using arrayed minimal core elements (Rivella & Sadelain, 1998), yielding 
expression within a therapeutic range and at low copy number. This led to phenotypic 
improvement in heterozygous th3 -thalassaemic mice: delivery of ex vivo transduced 
autologous bone marrow cells maintained transgene expression for over a 40-week 
period (May et al., 2002). However, it should be noted that the TNS9 is of a non-SIN 
configuration and thus integrated proviral genomes of this vector will harbour intact 
5‟ and 3‟ LTR elements. Therefore, despite its apparent efficacy on safety grounds 
TNS9 cannot be employed within a clinical setting.      
The therapeutic levels of  expression achieved under this system soon 
paved the way for the development of other HIV-1 based LVs for gene therapy of the 
haemoglobinopathies. However, the TNS9 vector required at least one copy of the 
vector
 in every stem cell to correct severe murine β-thalassaemia requiring most or all 
of the HSCs to be modified suggested that inconsistent
 
globin expression could be 
occurring. A different study performed simultaneously (Rivella et al., 2003) further 
supported this concern: the administration of TNS9 to a mouse model with severe 




anaemia in which mice engrafted with -globin–null (Hbbth3/th3) foetal liver cells 
succumb to ineffective erythropoiesis within 60 days, only 1 of 6 animals 
demonstrated
 
a relatively high level of haemoglobin following the gene transfer
 
procedure despite nearly all the HSCs being genetically modified.
 
The remaining 





1.4.3 Correction of sickle cell anaemia mouse models 
 
Leboulch and colleagues were the first to demonstrate haematological
 
correction and diminished end organ damage in two  murine sickle cell model systems 
using
 
lentiviral-mediated HSC gene transfer of an anti-sickling variant
 
of the human 
HBB chain (Pawliuk et al., 2001). The authors reported a structural optimisation of 
the HBB/LCR lentiviral cassette, which resulted in high viral titres capable of 
engendering multiple events of chromosomal integration per HSC (average vector 
copy number
 
of 3). This led to a balanced expression at a sufficiently high and 
homogeneous level to provide expression similar to that observed in asymptomatic 
carriers (Pawliuk et al., 2001). This result was later confirmed by others (Levasseur et 
al., 2003) with a different sickle cell mouse model and a slightly different
 
anti-
sickling HBB vector cassette. Phenotypic improvement
 
with an average vector copy of 
2.2 resulted in haemoglobin tetramers
 
incorporating the transgene HBB chain at a 
level of 20% of
 
















Figure 1.14 - The lentiviral/anti-sickling HBB expression construct designed by 
the Townes lab (Levasseur et al., 2003). HS2(1203 bp), HS3 (1213 bp), and HS4 
(954 bp) sequences of the LCR, the 3‟ globin enhancer, the 266bp HBB promoter  
and the  anti-sicking 
AS3
-globin gene are shown.  
 
 
1.4.4  HBG-A-based lentiviral vectors  
 
Parallel efforts have also been made with the construction of LVs designed to 
improve foetal haemoglobin levels (HBGy-Ay). HBGy-A naturally switch off at birth 
but its known to ameliorate the clinical severity of both β-thalassaemia and sickle cell 
anaemia in adults in cases where hereditary persistence of foetal haemoglobin 
(HPFH) has been co-inherited with the severe haemoglobinopathy. In 2004 the 
Persons laboratory developed a HBG LV, having more extensive LCR-derived
 
regulatory sequences (Figure 1.15). This vector was shown to be less susceptible
 
to 
position effects, was able to produce higher and more consistent
 
levels of HbF protein 
with one vector copy per cell being curative (Hanawa et al., 2004). More recently, 
this same laboratory has made an additional significant contribution for HSCs in vivo 
selection. A foetal Haemoglobin/ methylguanine-methyltrasferase (MGMT) dual gene 
LV could be used effectively for in vivo selection of HSCs following cytotoxic drug 
administration, resulting in large increases in HBB expressing cells and resolution of 
anaemia in a mouse model of -thalassaemia (Zhao et al., 2009). This value compares 
favourably with their single-gene vector (Hanawa et al., 2004 - 2 g/dL per vector 












Figure 1.15 - Schematic diagram of the γ-globin/MGMT lentiviral vector used by 
Persons lab. (Image taken from Zhao et al., 2009).   
 
 
1.4.5 Modifications to the initial TNS9 cassette 
 
In 2004 the Lebouch laboratory developed an LV containing an anti-sickling 
HBB
A-T97G
 expression cassette that included a 2.7kb region of the LCR HS2, HS3 
and HS4 sites plus mini-HBB (Figure 1.16). This was used to transduce normal 
human haematopoietic stem cells cells and was capable
 
of establishing 
haematopoiesis in immunodeficient mice. Approximately 80% of the HSCs were 
genetically modified,
 
resulting in chimeric haemoglobin molecules incorporating 
human
 








Figure 1.16 - Schematic of the 
A-T97G  
LV  (Imren et al., 2004). It includes HS2, 
HS3 and HS4 LCR sites regulating expression of the HBB transgene placed in 
reverse orientation. 
The results of this study showed that efficient transduction of HSCs from 
normal cord blood engrafted into an immunodeficient mouse model expressed HBB in 
their erythroid progeny at sufficient levels to improve SCA and -thalassaemia 
phenotypes. However, even with this vector, multiple vector copies are needed per 
cell for a sufficiently high level of transgene expression and risks of insertional 
mutagenesis have highlighted the need to achieve therapeutic goals with minimal 
copies of proviral integrants per cell. Also, it is evident in this study that proviral 
integration occurs frequently within introns of actively transcribed genes that play 
crucial regulatory rules in haematopoiesis, which once again raises questions on the 
long-term safety of this vector (von Kalle et al., 2004).  
 
The laboratory of Punam Malik (Puthenveetil et al., 2004) showed the first 
evidence of effective genetic correction of β-thalassaemia phenotype using an in vitro 
and an in vivo xenograft model of human erythropoiesis with a cHS4-insulated globin 
vector, BG-I (Figure 1.17). The BG-I vector was used to transduce CD34
+
 cells from 
four patients with thalassaemia-major. Genetically modified thalassaemia major 
CD34
+
 cells were then transplanted into splenectomised 2Mnull-NOD-SCID 
(immunodeficient) mice and 3-4 months later, effective production of human 
glycophorin A–expressing erythroid cells were observed in the circulation. There was 






Figure 1.17 - The BGI vector (Puthenveetil et al., 2004). SIN lentiviral backbone 
containing a 1.2-kb cHS4 insulator (cHS4-I) element inserted to replace the 398-bp 




U3 promoter and/or enhancer deletion, a 3.1kb human LCR region consisting of 
hypersensitive sites (HS) 2, 3, and 4; HBB promoter (254 bp); the HBB gene (with a 
372-bp deletion in IVS2); and the 3' enhancer (3'E) were cloned in reverse orientation 
to the viral transcriptional unit.  
The use of the chicken HS4 element flanking an HBB cassette contributes to 
reduced variability of transgene expression, thus partially protecting the provirus from 
chromosomal position effects, and resulting in an overall 2 to 4 fold increase in 
average expression (Arumugam et al., 2007). This design, although promising, results 




In 2007, the Sadelain laboratory published a report claiming that the addition 
of HS1 of the LCR in their basic TNS9 LV design did not improve HBB expression, 
but the addition of HS4 in addition to HS2 and HS3 improved the expression from 27 
to 41% per vector copy. However, the results of this report should be analysed with 
care with regards to the vector design; one familiar with the LCR looping 
mechanism and chromatin hub formation cannot but wander if this result is, in fact, 
based on the interaction of HS1 or a merely a consequence of the increased 
physiological distance of the LCR form the HBB in the vector improving ACH 
formation and enhanced gene expression.  
 
 
  An HBB transgene under control of a minimal 2.7-Kb HS2 and HS3 LCR 
element combination has been shown to produce efficacious amounts of HBB protein 
(Miccio et al., 2008). This report showed sufficient data to demonstrate that only 
these 2 LCR elements are sufficient for stable transgenic expression in tissue culture 
erythroid-specific cells. Studies performed with this  “GLOBE” LV  have shown it 
capable of correcting of β-thalassaemia in mouse model systems achieved by in vivo 
selection of genetically corrected erythroblast progenitors, differentiating from a 
relatively limited number of transduced HSCs,  providing high transcription levels of 











Figure 1.18 - The GLOBE vector (Miccio et al., 2008). Human β-globin gene, β-




The GLOBE vector (Figure 1.18) has also recently been shown to correct the 
globin chain imbalance following transduction of CD34
+
 cells from -thalassaemia 
patients (Roselli et al., 2010). Firstly, the authors demonstrate at the ex vivo 
manipulation required for successful transduction do not affect the viability of CD34+ 
cells and  proceeded to demonstrate that at low copy number lentiviral transduction of 
CD34+ is capable of correcting -thalassaemia and restore erythropoiesis upon 
differentiation in vitro. Finally, the authors analysed vector integration sites and their 
proximity to proto-oncogenes, reporting that, together with a CMV-GFP vectors, the 
therapeutic vector integrates preferably within transcriptionally active genes, with no 
bias towards integration in proximity of oncogenes. More importantly, despite 
integration within or near active genes GLOBE did not give rise to increased host 




More recently it has also been published the first clinical trial for -
thalassaemia involving LVs employing BM HSC ex vivo procedure, coupled with full 
myelo-ablative conditioning (Cavazzana-Calvo el al., 2010). An 18year old patient 
with transfusion dependent HbE/ -thalassaemia was treated with an LV containing a 




functional HBB. The patient underwent a high dose of chemotherapy to eliminate all 
diseased HSCs before being administered with their own genetically modified HSCs. 
The HSCs containing the transferred HBB gradually gave rise to healthy blood cells 
and the levels of normal HBB protein increased with 10-20% of reconstituted HSCs 
containing the transferred HBB, although only 1/3 of Hb was from the LV with the 
remaining 2/3 coming from high endogenous HbF (1/3) and HbE (1/3). One year after 
the treatment the patient no longer needed blood transfusions.  
 
Furthermore, 50% of genetically modified cells and consequent increased 
levels of HBB seen in this patient, were a result of clonal dominant expansion of a 
single myeloid progenitor with a site of LV integration within the HMGA2 gene 
resulting in expression of an exons 1-3 truncated product at markedly higher levels. 
HMGA2 encodes a protein regulating gene expression and its disturbance has been 
reported as potential oncogenic (Fusco et al., 2007). Therefore, regardless of the 
author‟s claims of therapeutic success, this study reports a clear example of a 
fortuitous insertional mutagenesis event contributing to therapeutic. An outcome 


































1.4.6 Gene therapy for the haemoglobinopathies – future challenges 
 
 
Results from several patients in recent gene therapy trials published to date in 
which LVs were used to transduce HSCs indicate that although clinical success can be 
achieved, the overall levels of engraftment with genetically modified HSCs that are 
currently possible are likely to be in the 10-15% range. While these levels may be 
sufficient to procure clinical improvement and transfusion independence in patients 
with thalassaemias, higher levels of gene transfer will be needed to cure patients with 
thalassaemia major. Nevertheless, collectively, these data supports the conclusion that 
HBB transgene expression can be reasonably regulated in the progeny of LV 
transduced stem cells, although position effects, transgene silence leading to 

























1.5 In utero Gene Therapy 
 
In utero gene therapy is the administration of a given vector cassette pre-
natally in order to provide early therapeutic intervention and/or ameliorate a genetic 
defect, and thereby provide permanent somatic gene correction before birth.  
 
1.5.1 “Proof of principle”, landmarks and progress of in utero gene 
therapy 
  
The first proof-of-principle came in 1990 (Maria Hatzoglou et al., 1990). In 
this study the authors report that a replication-incompetent retroviral vector injected 
intraperitoneally into foetal rats in utero mediated expression of human growth 
hormone. This experiment paved the way and provided substantial grounds for in 
utero gene therapy with the following years seeing a large number of in utero marker 
gene experiments using several different vectors, different animal models, with 
successful gene delivery to various foetal tissues. 
 
The first report of a curative gene therapy protocol in utero involved injection 
of an adenoviral vector into the amniotic fluid of  CFTR knockout (KO) mice (Larson 
et al., 1997). The injection resulted in dramatic improvement in survival of KO mice, 
even though CFTR expression was very limited. This report was heavily criticised in 
the literature at the time as relatively few data were presented with intermediate end 
points, such as specific mechanisms of longer-term effects of transient CFTR 
messenger RNA (mRNA) or protein expression or electrophysiologic correction of 
cAMP-activated chloride transport (Flotte, 2008). Also, this study has not been 
reproduced independently since.  
 
In 2003 was performed a direct injection of an LV expressing the human 
bilirubin UDP-glucuronyltransferase (UGT1A1) gene under control of the 




phosphoglycerate kinase promoter into the liver of the Gunn rat foetus (Seppen et al., 
2003). The Gunn rat is a model for the very rare autosomal recessive human condition 
Crigler Najjar disease Type I (CN I), with bilirubin UDP-glucuronosyltransferase 
deficiency caused by mutations in the gene encoding UGT1A1 on human 
chromosome 2. The disease manifestations include neurotoxicity caused by toxic 
levels of bilirubin accumulating in the patient's blood leading to severe brain damage 
shortly after birth, and results in infant death in the absence of continual phototherapy 
and liver transplantation.  
Direct pre-natal intra-hepatic injection of an LV delivering the corrective 
transgene resulted in a significant reduction (45%) of bilirubin levels for the 1 year 
duration of the study (Seppen et al., 2003). In patients with CN I, such reduction 
would convert severe CN I disease to the milder CN II form. However, the absolute 
levels of unconjugated bilirubin observed in rats and humans are not comparable, and 
it is therefore not clear if the protein‟s expression levels would be sufficient for a 
therapeutic effect in man. 
Successful restoration of rhodoposin synthesis and electrophysiologically 
measured visual functions in a mouse model of Leber's Congenital Amaurosis (LCA), 
a congenital retinal blindness caused by mutations in the RPE65 gene has also been 
reported (Dejneka et al., 2004). Subretinal application of an AAV2 vector expressing 
human RPE65 in utero resulted in efficient transduction of retinal pigment 
epithelium, restoration of visual function, and measurable rhodopsin. This was 
achieved in two of the 13 pups that survived to adulthood. Limited numbers are most 
likely due to technical difficulties of topical gene delivery to the retina. It is also 
noteworthy that RPE65 expression could be observed after 5/6 months. The retinal 
epithelium is virtually non-dividing and the AVV2 vector was able therefore to persist 
episomally. 
Further successful applications in utero using an AAV vector have been 
reported (Rucker et al., 2004). Intraperitoneal in utero application of an AAV2 vector 
expressing the lysosomal enzyme acid alpha glucosidase (GAA) was delivered to 
foetuses of a mouse model of Pompe's disease. The transgene restored enzyme levels 
in the diaphragm of these animals, prevented glycogen accumulation in this muscle 
and restored diaphragm contractility up to 6 months postpartum. 




More recently Waddington and colleagues has led the field of in utero gene 
therapy applications. In 2004 they performed an in utero administration of an LV via 
the foetal vitelline yolk sac vessel, a route that delivers a large proportion of the 
vector directly to the liver. Therapeutic levels of human Factor IX of between 18 and 
32% of normal values were obtained which resulted in permanent amelioration of the 
bleeding disorder in Factor IX knocked out (KO)  mice (a model for human 
haemophilia B). The KO mice have no functional Factor IX, and restoration of levels 
to 5% of normal corresponds in humans to a mild haemophiliac phenotype and 40% 
to phenotypic cure. Determination of Factor IX blood levels allowed the monitoring 
of transgene expression in the individual treated animals over their lifetime. 
Importantly, animals were kept alive for a long observation period and no antibodies 
against the human protein were found even after adjuvant stimulation, whereas strong 
antibody responses were observed after the same challenge on haemophiliac mice not 
treated in utero. In liver biopsies, human factor IX expression was detected in groups 
of neighbouring cells suggesting clonal propagation of human Factor IX-expressing 

























1.5.2 In utero gene therapy over adult gene therapy 
 
The approach is based on the hypothesis that gene therapy performed in utero 
may prevent irreversible modifications that are likely to occur during foetal 
development, and avoid early onset organ damage. A pre-natal intervention avoids the 
development and progress of severe manifestations. Additionally, the foetal system is 
especially susceptible for successful gene therapy due to its immunologic naiveté. 
Adult gene therapy often causes an immune response that restricts transgene 
expression. In utero gene therapy takes advantage of the low predisposition for 
immune response and the transgenic protein would be recognised as “self” in the early 
stages of gene transfer in the foetal period and avoid an immune response  
An in utero approach also takes advantage of the high proliferative status and 
expansion of foetal stem cells, which may result in gene expression in a large 
proportion of daughter cells.  The relatively small amount of genetically engineered 
stem cells required,  together with the administration of a relatively small amount of 
vector could result in much higher adult expression levels than what would be 
achieved by adult vector administration - highly attractive conditions within a gene 
therapy context, where the mass production of vector/stem cell numbers are limiting 
factors (Waddington et al.,  2004; Coutelle et al., 2003). 
 
Although foetal gene therapy will not replace post-natal gene therapy, it 
constitutes a preventive approach to otherwise incurable diseases and would therefore 



















1.5.3 In Utero procedures 
 
 
1.5.3.1 The search for the optimal vector 
 
 The ideal vector for foetal gene therapy would introduce an appropriately 
transcriptionally regulated gene into the cells of all organs relevant to the genetic 
disorder by a single safe application (David & Peebles, 2008). 
 To date, none of the current vector systems are capable of successfully 
meeting these criteria, although many have characteristics that can be beneficial for a 
foetal approach. Lentiviruses, specifically, appear as ideal candidates in part due to 
the possibility of pseudotyping with different envelope proteins, allowing gene 
transfer to be more restricted to specific tissues and the possibility of high titre 
production.  
Vector selection to minimise the risk of oncogenesis is crucial for in utero 
gene therapy. It has been reported that equine infectious anaemia virus (EIAV)-based 
lentiviral vectors have higher frequency to cause liver tumours in mouse models, 
while no tumour was observed from SIN HIV-based vectors (Themis et al., 2005). 
These studies are important since they suggest that liver tumour development is not 
caused by either injection procedure or the expression of the transgene alone, but just 
the vector itself (Themis et al., 2005).  
 
 
1.5.3.2 Routes of administration 
 
Development in vector technology has been accompanied with the 
development of minimally invasive methods of vector delivery. Studies in sheep have 
adapted ultrasound guided injection techniques. Ultrasound guidance has also been 
used in non-human primates to deliver gene therapy into the amniotic cavity for direct 
injection of the lung and liver parenchyma (David & Peebles, 2008). In mice, several 




routes of application have been considered, mainly depending on the target disease; 
Direct injection into muscle and ocular tissues have been performed, intraperitoneal 
injections, via the portal vein; but is the injection of therapeutic LV into umbilical or 
yolk sac blood vessel, allowing the virus to gain efficient access to the foetal liver via 
the circulation that holds promise for people with haemoglobinopathies.  
 The foetus is surrounded by an interior amniotic membrane and nutrients are 
supplied through umbilical blood vessels in human, or the yolk sac vessels from the 
parietal yolk sac in mice. The foetal liver is the major haematopoietic organ and 
therefore the site of HSC residence during gestation. In principle it is an excellent 
target for gene therapy as it could provide maximum output of systemically required 
transgenic proteins such as Factor VIII and Factor IX, in haemophilia. LVs delivered 
in utero via the yolk sac blood vessels are able to transduce not only hepatocytes but 
also HSC in foetal liver before these cells migrate to bone marrow.  
 
Many of the techniques used in animal models have successfully been used in 
human medicine. Fibre-optics and ultrasound guidance is routinely used for foetal 
surgery/direct access to the human foetal circulation. Intrauterine blood transfusions 
are regularly performed by injection into the intrahepatic umbilical vein and 
intraperitoneal injection of foetal liver stem cells has been achieved in humans from 





















1.5.3.3 Time of intervention 
 
 Studies in vivo have proved that effective expression of a given transgene can 
be greatly compromised by the gestational time of delivery. The “optimal delivery 
period” is then variable, depending on the animal model used and route of 
administration of the vector. 
 Studies performed with mice tend to take advantage of the immune response, 
aiming vector administration at the end of the second gestational trimester.  
Clinical data (Coutelle, 2008) has shown that vector administration before the second 
trimester of gestation - a “pre-immune” stage of development - can avoid the 
immediate inflammatory and immune response to a transgenic protein and induce 
immune tolerance to the transgene vector. It has been suggested that the vectors can 
be introduced into the human foetus before the second trimester to avoid 
inflammatory and immune responses and increase tolerance to transgenic protein. 
  
The relevant time windows for the different application routes in humans 
remains to be established with respect to technical feasibility, foetal physiology and 
the development of the foetal immune system (David & Peebles, 2008). For instance, 
the human immune system develops from 12 to 14 weeks of gestation, with T 
lymphocyte maturation observed at this stage. Thus, it might be necessary to deliver a 
transgene before this gestational time, which greatly limits the routes of application. 
Experiments in non-human primates are likely to prove very useful test systems prior 


















1.5.4 Problems associated with an in utero approach: ethical and 
safety concerns 
 
Long-term adverse effects from pre-natal gene therapy are still not proven and 
unknown and it is extremely important to access the potential risks of in utero gene 
therapy thoroughly, both from a scientific, and ethical point of view. Most fears 
revolve around the acute toxicity and immunogenicity of the vector transgene, the 
possibility of germ line transmission and the danger of insertional 
mutagenesis/oncogenesis - some of the general risks associated with gene therapy. 
One major concern regarding an in utero approach is the increased risk of inadvertent 
germ line transmission of the integrated transgene sequence. Vector integration into 
germ cells, if it occurs, is likely to be random, and such an event could potentially 
affect progeny conceived from such a germ cell.  
Studies suggest that if vector administration is performed around the 2
nd
 trimester of 
pregnancy, germ cells are by then well compartmentalized in their definitive organs, 
and could therefore be reached only via the bloodstream.  It‟s true that vector 
sequences have been detected in the gonads of in utero injected animals, but 
transgene expression has never been found in purified sperms or in the offspring of 
these animals (Waddington et al., 2005).  
  However, evidence for lentiviral transduction of a subpopulation of gonadal 
cells isolated by laser capture micro=dissection was recently reported to occur in 
female rhesus monkey foetuses after intraperitoneal vector administration (Lee et al. 
,2005). 
 When a vector enters the foetal circulation there is a risk of it crossing the 
placental barrier into the maternal bloodstream. There is wide variability in placental 
structure among different species and only the nature of the maternal barrier will 
determine the likelihood of this event. Nevertheless, rodents and humans share the 
same class and the most permissive type of placenta (hemochorial) whereas sheep 
have a much less permissive (synepitheliochorial, small placentomes) placenta type, 
which suggests that studies on these animals, although informative, might not be 
physiologically relevant to humans. 




The calculated frequency of naturally occurring endogenous insertional mutations in 
humans of about 1 in 8 individuals is substantially higher than the suggested upper 
tolerable limit of 1 insertion event per 6000 sperm due to a gene delivery protocol 
(Kazazian, 1999).  
 
Gene therapy is not the only intragenic protocol likely to induce germline 
modifications. It is well known and documented such events happen with exposure to 
UV light and high doses of chemotherapy, to name but a few. As often with new 
therapeutics, only when they become efficient are potential side effects and hazards 
observed. Therefore, ethical concerns in relation to the balance of potential benefit 
and harm of an in utero approach are entitled to exist. The ethics of foetal somatic 
gene therapy have been reviewed (Wagner et al., 2009). Whether or not a given 
disease is given approval for intrauterine intervention is a subject of criterion studies. 
It is important to reiterate that, to date, there is no evidence for germ line transmission 
by in utero gene therapy and therefore, the scientific community shall accept the 
risk/benefit associated with the procedure and advance with care performing 
appropriate animal experimentation with long-term post-natal follow-up before any 




























1.5.5 Targeting HSCs: in utero gene therapy for the 
haemoglobinopathies 
 
Success of adult gene therapy for genetically inherited diseases using stem 
cells has been hampered mainly by inefficient transduction and the inability to 
achieve long-term expression of therapeutic genes,  
Current clinical protocols of gene therapy in patients with genetic diseases are 
based on ex vivo transduction of lymphocyte or hematopoietic stem/progenitor cells 
from cord blood or bone marrow, followed by autologous transplantation of these 
engineered cells back into the patient. Initial trials showed the feasibility and safety of 
gene therapy using cord blood cells in patients with ADA-deficiency, 
For gene therapy to hematopoietic cells in the foetus, two different strategies are 
being pursued in parallel: 
 
 
1.5.5.1 Ex vivo transduction of HSC  
 
The approach consists in targeting autologous self-renewable HSCs from the 
bone marrow for defect gene correction or replacement by ex vivo, and then re-
transplanting the genetic modified HSC back to patients/models. This methodology is 
especially attractive for the treatment of haematopoietic disorders caused by single 
gene defect, such as, -thalassaemia and sickle cell disease (Persons, 2009).  
 
A successful ex vivo strategy requires harvest of an adequate number of foetal 
HSC in the first trimester, efficient gene transfer to harvested cells in vitro, followed 
by re-infusion with or without expanding the transduced stem cells. A limiting factor 
of this technique is the narrow window in which the whole procedure must be 
performed (confirming genetic diagnosis, perform HSC harvest and in vitro 
transduction, and re-instilling transduced cells into the foetus). 
 
 
The major advantage of this method is that the risk of germ line transduction 
is avoided when compared with in vivo gene delivery where the whole foetus is 




exposed to high titre gene vector constructs. Also, the manipulation of transduced 
cells outside of the receptor‟s body allows pre-transplantation monitoring, increasing 
the chances of transgene long-term gene expression. On the other hand, technical 
difficulties in obtaining enough stem cells together with laborious procedures of 
purification and contamination avoidance remain a challenge.  
 
More recently the laboratory of Anna David reported a new approach using 
amniotic fluid stem cells as an alternative autologous source of cells with HSC 
potential. These can be readily harvested and the results obtained showed low foetal 
loss rates (Shaw et al., 2011), but such haematopoietic potential has only been 
reported in the murine system and its still unknown whether a translation into human 




1.5.5.2 Direct vector administration in vivo 
 
In this approach the gene containing vector is transfected directly into the 
foetus, leading to in vivo transduction of HSCs in the liver. 
 
 Direct vector administration in vivo for the treatment of the 
haemoglobinopathies was first attempted in 1998 by IP retroviral delivery to early-
gestation sheep foetuses. The authors reported long-term transduction of HSC (Porada 
et  al., 1998), and more recently by retroviral IP delivery to first trimester non-human 
primate foetuses (Tarantal et al., 2006). This study reports that the vectors targeted 
mononuclear cells in the peripheral blood and bone marrow at a low frequency of 
between 0.5 and 4%. 
 
 To date the only report on in utero gene therapy for thalassaemia aims to 
correct a mouse model of -thalassaemia (Han et al., 2007). In this study the authors 
deliver a lentiviral vector derived from the TNS9 vector (Figure 1.13). All elements 
in the original vector remained except for the replacement of the β-globin gene with 
either the human α-globin gene or a cDNA fragment containing a eGFP reporter. 




 Human α-globin gene expression was detected in the liver, spleen, and 
peripheral blood, reaching its peak at 3–4 months post-injection, reaching 20% in 
some recipients. However, the expression declined 7 months post injection. 
 
Colony-forming assays performed on BM cells showed low abundance of the 
transduced human α-globin gene and the lack of its transcript, a demonstrating that 
the vector used could not transduce hematopoietic stem cells adequately to sustain 
gene expression. Regardless, this study proves that lentiviral vectors can be an 





























1.5.6 Future challenges 
 
Although great progress has been made there are many remaining challenges 
for pre-natal and cellular therapy. The proof-of-principle for foetal gene therapy for 
many disorders has been demonstrated in rodent and in large animals, but safety 
concerns regarding the risk of insertional mutagenesis means that no human in utero 
gene therapy trials have been reported or are planned at present (Coutelle, 2008).  
Further development of the technique regarding long-term efficacy as well as safety 





























1.6 Aim of the Project 
 
Gene therapy advances have been slow and disrupted by complications 
associated with transgene silencing, variable expression and PEV. Lentiviral vectors 
are promising tools for gene delivery due to their relatively large packaging capacity 
and ability to infect a range of different cell types. However, recent studies in the 
search for the optimal LVs once again raised safety concerns regarding insertional 
mutagenesis and potential future heath complications of patients submitted to gene 
therapy treatments (Cavazzana-Calvo et al., 2010). The search for the optimal vector 
makes more sense than ever, as the current lentiviral design for gene therapy for the 
haemoglobinopathies is still clearly far from ideal. 
 
This project addresses the major issues associated with lentiviral gene therapy 
for the haemoglobinopathies and aims to develop a therapeutic globin vector capable 
of overcoming silencing and to provide sustained long-term, cell specific and 
reproducible expression with minimum genome disturbance.   
 
1) Previous studies have successfully reported the use of ID-LVs to overcome 
integration disturbance in retina (Yanez-Munoz et a., 2006), muscle (Apolonia et al., 
2009) and neurons (Rahim et al., 2009). To date, only ubiquitous expressing 
transcription units have been studied and shown to provide good expression from ID-
LV. We hypothesise if the efficient expression seen with ID-LV can be extended to a 
tissue specific therapy system. In particular, if ID-LVs are feasible to be used in an 
erythroid context. 
2) In utero direct injection has been developed by others with encouraging 
outcomes in pre-clinical model systems addressing a broad spectrum of genetic 
disorders (Dejneka et al., 2004: Rucker et al., 2004: Waddington et al., 2004) and one 
documented attempt at in utero gene therapy for -thalassaemia (Han et al., 2007). 
We Hypothesize if sustained and reproducible level of expression can also obtained 
when an LV expressing human HBB is delivered in utero into wild-type mice, and if  
sufficient expression be obtained to attempt rescue a KO model of -thalassaemia 











































2.1.1 Commercial kits 
 
EndoFree Plasmid Maxi kit (QIAGEN
®
, Hilden, Germany) 
HighSpeed Plasmid Maxi Kit (QIAGEN
®
) 
Human Hemoglobin ELISA Kit (Bethyl Laboratoreis Inc., Montgomery, TX  USA) 
Luciferase Assay System (Promega, Madison, WI, USA) 
QIAEX II Gel Extraction kit (QIAGEN
®
) 
QIAquick Gel Extraction kit (QIAGEN
®
) 
QIAprep Spin Miniprep kit (QIAGEN
®
) 
QIAzol Lysis reagent (QIAGEN
®
) 
QuickChange® II Site-Directed Mutagenesis kit (Stratagene
® 
Santa Clara, CA, USA) 
Quick Ligation 
TM 
kit (New England Biolabs – NEB®, New England, USA ) 
RNeasy Mini kit (QIAGEN
®
) 
TOPO® TA Cloning kit for Subcloning (Invitrogen
TM
 , Carisbad, CA, USA) 
Wizard
®
 Genomic DNA purification kit (Promega)  
 
2.1.2 Equipment  
 
Avanti J-20 Centrifuge (Beckman Coulter, High Wycombe, UK) 
Becton Dickinson FACS Calibur (Franklin Lakes, NJ, USA) 
BioDoc-It UV transilluminator system (Ultra-Violet products- UVP Ltd. , Upland, CA, 
USA)  
Biofuge Pico microfuge (SORVALL ®, New Castle, Delaware, USA) 
BioPhotometer (Eppendorf, Hamburg, Germany) 
Boyle‟s apparatus (British Oxygen Company, UK) 
Centrifuge Universal  Legend RT (SORVALL ®) 
Dyad thermocycler (MJ Research Inc., St Bruno (Quebec), Canada)  




Flourescence light Microscope, Eclipse TS100 (Nikon, Melville, NY, USA)  
Gene Quant II spectrophotometer (GE Healthcare Bio-Science Corp., Piscataway, USA) 
Gel Pulser/Micro pulser 0.2cm cuvettes (BioRad®, Hercules, CA, USA)  
IVIS cooled charge‐coupled device (CCCD) camera (Caliper Life Sciences, Hopkinton, 
MA, USA) 
Legend RT centrifuge (SORVALL ®) 
Light Microscope, TM (Nikon) 
L8-60M Ultracentrifuge (Beckman Coulter) 
Micro Centrifuge Pico Biofuge (SORVALL ®) 
Multitron shaking incubator (Infors AG, Bottmingen/Basel, Switzerland)  
Nano-Drop 1000D (Thermo Scientific, Waltham, Massachusetts, USA ) 
Protean Minigel system (BioRad®) 
Research CO2 Incubator (LEEC, Silver Spring, Maryland, USA ) 
Shaking Multitron Incubator (Infors AG) 
Thermanox® coverslips (Nalge Nunc Int. Penfield, New York, USA ) 
Ultra-Turrax T25 homogeniser (Janke and Kunkel, IKA  Labortechnik. Staufen, 
Germany) 
UV transilluminator (UVP Ltd.)  
UV spectrophotometer Gene Quant II - Pharmacia Biotech Ultrospec 2000 (Analytical 
Instruments LLC, Golden Valley, MN) 
 
2.1.3 General chemicals and reagents 
 
2.1.3.1 General chemicals and reagents used in cloning procedures 
 
Ampicillin (Sigma-Aldrich, St.Louis, Missouri, USA) 
β-Agarase (Cambrex Corp. East Rutherford, NJ, USA) 
Bovine serum albumin (Sigma-Aldrich) 







D‐luciferin salt (Gold Biotechnology Inc., Saint Louis, MI, USA ) 
DEPC treated water (Invitrogen
TM
) 




Ethanol (BDH Merck Ltd., Poole Dorset, UK ) 
Ethidium bromide (Sigma-Aldrich) 
Glycerol (Sigma-Aldrich)  
Isoflurane (Abbott Laboratories, Abbot, IL, USA) 
Isopropanol (BDH Merck Ltd.) 
MgCl2, 25mM (Promega) 
NEB buffer 1 (NEB
®
) 
NEB buffer 2 (NEB
®
) 
NEB buffer 3 (NEB
®
) 










SDS-running buffer (10x) (GeneFlow Ltd. Staffordshire, UK) 
SYBR® Premix Ex Taq™ II mastermix (Lonza Group Ltd., Basel, Switzerland) 
Taq Polymerase (Promega) 
Tris Base (Sigma-Aldrich) 
TE buffer solution (Invitrogen
TM
) 
Tris Base (Sigma-Aldrich) 
Tris-HCl (BDH Merck Ltd.) 
Tween-20 (Sigma-Aldrich) 
T4 DNA ligase (NEB
®
) 
T4 DNA ligase buffer (NEB
®
) 






2‟ – deoxynucelotide triphosphates, 100mM (dNTPs) (GE Healthcare Bio-Science Corp., 




2.1.3.2 Reagents used in tissue culture experiments 
 
Dimethyl sulphoxide – DMSO (Sigma-Aldrich) 
Foetal calf serum (PAA) 
Dulbecco‟s Modified eagle Medium (DMEM) + Glutamax (PAA, San Diego, CA, USA) 




Phosphate buffered saline (PBS) (Sigma-Aldrich) 
Phosphate buffered saline + Calcium and Magnesium (PBS +) (Sigma-Aldrich) 
Polyethylenemine (PEI) (Sigma-Aldrich) 
Polybrene (Sigma-Aldrich) 
Magnesium cloride – MgCl2 (Sigma-Aldrich)  
Streptavidin/horse radish peroxidase (streptavidin-HRP) (DakoCytomation, Glostrup  
Denmark) 
TMB+ substrate chromagen (DakoCytomation) 
Tripsin TrypLE express (Invitrogen
TM
) 
Trypan blue (Sigma-Aldrich) 
 









2.1.5 Bacterial strains  
 
DH5α Chemically competent E.coli (InvitrogenTM) 
GeneHogs Electrocompetent E.coli (Invitrogen
TM
) 
TOP10 One Shot® Electrocompetent E.coli (Invitrogen
TM
)  







2.1.6 Prepared solutions 
 
2.1.6.1. Solutions for cloning procedures 
 
Loading buffer (DNA) (10x) 
0.5 ml 1M Tris-HCL pH7.6 (BD) 
25 ml glycerol (Sigma-Aldrich) 
0.5 ml 10% sodium dodecyl sulphate - SDS (Sigma-Aldrich) 
0.05 g Orange G (Sigma-Aldrich) 
Make up to 50 ml with ddH2O 
 
LB (Luria-Bertani Media) 
10 g bacto-tryptone (BD) 
5 g bacto-yeast extract (BD) 
10 g NaCl (BDH Merck Ltd.) 
Make up to 1 Litre with ddH2O 
Sterilise by autoclaving 
 
LB Agar 
Add 15 g/ Litre bacto-agar (BD) to LB 
Sterilise by autoclaving 
 
50x Tris-Acetate-EDTA (TAE) 50x electrophoresis buffer  
0.9ml Tris base (electrophoresis grade) (BD) 
285.5 ml glacial acetic acid (BD) 
500 ml 0.5M ethylenediaminetetraacetic acid (EDTA) (BD) 
Make up to 50 L with ddH20 and ajust to 7.2 
 
Tris glycine buffer (10x) 




30 g Tris base (Sigma-Aldrich) 
Make up to 1 Litre with ddH20 
 
200 ml methanol (BDH Merck Ltd.) 
Make up to 1 Litre with ddH20 
Sodium acetate  
3M sodium acetate adjusted to pH5.2 with glacial acetic acid 
Sterilise by autoclaving 
 
 
2.1.6.2 Solutions used for growing mammalian cells 
 








DMEM supplemented with 4.5g L-ananyl-L-glutamine, 4.5μg/l 
of glucose, 10μg/ml of penicillin and streptomycin, 10% (v/v) 




1 tablet of PBS (Sigma-Aldrich) at 7.5 dissolved per 100ml of 
ddH2O 
 











2.1.6.3 Other solutions 
 
Immunofluorescence buffer  
PBS containing 0.1% sodium azide and 0.2% BSA 
 
FACS buffer 
PBS containing 4% paraformaldehyde 
 
Lysis buffer (for animal procedures) 
10mM Tris-HCl, pH7.5 
 10mM NaCl 
3mM MgCl2, 
0.1% Triton X-100 
 0.1M sucrose  
 fresh 0.5mM dithiothreitol (DTT) 
 





0.05% Triton X-100  
 
SET buffer 
50μl 10% sodium dodecyl sulphate - SDS  













2.1.7.1. Restriction enzymes  
 







































































2.1.7.2  Other enzymes  
 
Calf intestinal alkaline phosphatase – CIP (NEB®) 
DNA Polymerase I - E. coli (NEB
®
) 
DNA Polymerase I, large (Klenow) fragment (NEB
®
) 
DNase I - RNase-free (NEB
®
)  








2.1.8 DNA Molecular size markers  
 
                                        
1kb molecular size ladder from                      1kb molecular size ladder from 
               Invitrogen
TM









2.1.9 Tissue culture cell lines  
 
 
Cell line / Species K562 (Human) 
reference Lozzio and Lozzio, 1975 
Derivation myelogenous Leukemia cell line, which is bcr:abl positive  
 
Derived from a 53 year old female CML patient in blast crisis 
Morphology Leukaemia 
Growth characteristic Non-adherent (suspension cells) 
Characteristics Can spontaneously develop characteristics similar to early-
stage erythorcytes, granukocytes and monocytes but easily 
killed by natural killer cells as they lack the MHC complex 
required to inhibit NK activity. Constitutive expression of 
episilon and globin 
 
 
Cell line / Species Human Erythro-leukaemia (HEL)  
 
reference Martin and Papayannopoulou, 1982 
Derivation Derived from the peripheral blood of a Hodgkin‟s disease 
patient. 
Morphology Leukaemia 
Growth characteristic Non-adherent (suspension cells) 
Characteristics Capable of globin synthesis and mainly expresses globin 
chains, small amount in embryonic chains (  & ) but no -
globin chains. Although it does not express globin, it 







Cell line / Species HEK 293T  (Human) 
 
reference Graham et al., 1977 
Derivation Derived from human embryonic kidney cells and transformed 
with adenovirus V DNA 
Morphology Fibroblast 
Growth characteristic Adherent 
Characteristics Contains a stably integrated SV40 Larger T-antigen gene, 
which allows for episomal replication of transfected plasmids 
containing the SV40 origin of replication. 
 
Cell line / Species Murine erythro-leukaemia – MEL (Mouse) 
 
reference Singer et al., 1974 
Derivation Pro-erythroid leukaemia cells transformed with Friend virus. 
Morphology Pro-proerythroblast  APRT-tetraploid 
Growth characteristic Semi –adherent 
Characteristics dimethylsulphoxide (DMSO) to terminally differentiate along 
the erythroid pathway. 
 
Cell line / Species C2C12 (Mouse) 
reference Yaffe & Saxel et al., 1977 
Derivation myoblast cells from muscle 
Morphology fibroblast 
Growth characteristic Adherent 
Characteristics Can be induced to terminally differentiate into fused 
myofibres 
 








Method Dilution Company 
CD3-PE 
 
Rat Cellular staining 1/500 BD Bioscience 
CD11b-APC 
 
Rat Cellular staining 1/500 BD Bioscience 
CD19-PerCP 
 
Rat Cellular staining 1/500 BD Bioscience 
Ter119-APC 
 
Rat Cellular staining 1/500 BD Bioscience 
Fc Block 
 
Rat Cellular staining - BD Bioscience 





Goat GFP-ELISA 1/5000 AbCam, 
Cambridge UK 
 

















Pro software, version 5.2.1(BD) 
Primer 3 
SDS version 2.2.2  (Applied Biosystems, 2004) 
Sequencing Analysis Software, Version 5.1.1 (Applera) 
National centre for Biotechnology Information (NCBI), http://www.ncbi.nlm.nih.gov 
Vector NTI 10 (Invitrogen
TM
) 
7900HT Fast Real Time PCR System   



























2.2.1 Plasmid sub-cloning 
 
In this context cloning refers to the generation of novel gene expression vectors 
and was accomplished as follows; appropriate insert and vector DNA fragments were 
covalently ligated. A ligation mixture containing the recombinant plasmid was 
transformed into bacteria and plated onto agar plates containing an appropriate antibiotic, 
where individual bacterial colonies grow in the presence of the circular plasmid replicon. 
Recombinant DNA was obtained through cell lysis and recovery of recombinant DNA 
with subsequent characterisation by restriction enzyme digestion and agarose gel 
electrophoresis. Large quantities of recombinant plasmid DNA were obtained by 
inoculating large cultures of the designed construct. Cell clones containing the correct 
plasmid were then stored long-term as a glycerol stock.  
 
 
2.2.1.1 Preparation of plasmid DNA from bacterial hosts 
 
Bacterial stocks of the DNA were streaked onto agar plates containing 100μg/ml 
of the appropriate antibiotic and grown overnight at 30 or 37ºC. Single colonies were 
subsequently picked and inoculated into 5 ml or 220-500 ml Luria Bertani broth (volume 
depends on the vector copy number) containing 100 μg/ml of the appropriate antibiotic 
for mini-preparation or maxi-preparation of DNA respectively. Cultures were expanded 
at 30 or 37ºC in a shaking incubator overnight. Mini- or maxi-preparation of DNA was 
performed using the appropriate QIAGEN
®
 kit and eluted in ddH20 as per the 
manufacturers' protocols. Concentrations of DNA were then determined using a UV 
spectrophotometer as described in section 2.2.1.8.. Integrity of DNA was accessed by 






2.2.1.2 DNA digestion by Restriction Endonucleases  
 





1-40μg DNA (concentration of DNA depended on 
individual experimental     requirements) 
appropriate Restriction Endonuclease (NEB
®
) 1 unit/μg DNA l 
Buffer (1,2,3 or 4 NEB
®
) 10 of total reaction volumel 
Nuclease-free Water Todisered total volumel 
 
Table 2.5 – Restriction Digests 
   
Digestions with two enzymes were carried out simultaneously using a compatible 
buffer or performed sequentially with an intervening phenol-chloroform extraction and 
ethanol precipitation/purification step. 
 
 
2.2.1.3 DNA blunting reactions 
 
For generation of blunt-ended digested DNA products, T4 DNA polymerase was 
used. T4 DNA polymerase catalyses the synthesis of DNA in the 5' to 3' direction and 
also has 3' to 5'exonuclease activity. For blunt-ending of 5' overhang ends, 1 unit of T4 
DNA polymerase was added per 1 µg of purified DNA, along with 100 mM dNTPs and 
1x T4 ligase reaction buffer.  The reaction was incubated at 12ºC for 15 m. To stop the 
reaction, a final concentration of 10 mM EDTA was added, which was then incubated at 
75ºC for a further 15 min to heat inactivate the enzyme. For removal of 3' overhangs 







2.2.1.4 Isolation/Purification of DNA fragments 
 
DNA fragments were separated by agarose gel electrophoresis (containing 
0.005% ethidium bromide) and excised under long wavelength UV light (360 nm).  
 
The QIAQuick Gel Extraction Kit (QIAGEN
®
) was used according to 
manufacturer‟s instructions. Briefly, the gel slice was solubilised and passed through an 
anion exchange chromatography column, followed by washing and elution of DNA from 
column. The DNA was then eluted using in ddH2O. 
 
 
2.2.1.5 Agarose gel electrophoresis  
 
DNA was fractionated on 0.7% agarose gels made with 0.5x TAE gel buffer in 
the presence of ethidium bromide (0.5 g/ml final concentration). These were placed into 
an electrophoresis tank containing TAE buffer solution (refer to materials) with the same 
concentration of ethidium bromide as the gel. 
Samples loaded were supplemented with gel loading dye (Orange G) and in case of small 
sample volumes, ddH2O was added to a final volume of 20 l. 
 
Routinely, at either side of each set of samples were loaded 1 kb DNA Ladder  
(section 2.1.8) used for sizing linear double-stranded DNA fragments by comparison with 
the migrating distances against the molecular size standard. 
  
 
2.2.1.6 Phenol:Chloroform extraction  
 
An equal volume of phenol : chloroform : isoamyl alcohol reagent was added to 




for 10min at 13,000rpm. The upper, aqueous nucleic acid-containing phase was removed 
to a fresh tube without disturbing the proteinaceous layer at the interphase. 
 
An equal amount of chloroform was then added to the decanted aqueous phase 
and mixed thoroughly before centrifugation for 10min at 13,000rpm to further remove 
residual phenol. The upper phase, containing purified DNA, was removed to a fresh tube 




2.2.1.7 Ethanol precipitation 
 
DNA solutions were made 0.3M with sodium acetate to which was then added 2.5 
volumes of 100% ethanol. The solution was vortexed and incubated at -20 for up to one 
hour. Alternatively, 0.6 volumes of isopropanol were added to the nucleic acid solution 
and left to precipitate for 15 minutes.  
 
Precipitated DNA was recovered by centrifugation and ethanol supernatant 
removed. The DNA pellet was then washed with 70% ethanol to remove isopropanol 
excess salt and again recovered by centrifugation. The pellet was left to air dry for 5 
minutes before re-suspension in ddH20. 
 
 
2.2.1.8 Estimation of nucleic acid concentration 
 
The concentration of DNA samples was quantified by using a Gene Quant II 
spectrophotometer. An optical density (OD) reading at 260nm with an absorbance unit of 






Nucleic acid concentration was also measured using a Nano-Drop instrument. 
Volumes of 1µl of DNA / RNA were loaded for absorbance quantification.  
 
Less accurate concentration estimates were obtained by electrophoresis on 
agarose gels and comparing the intensity of the desired DNA fragment against a 
commercially available and quantified DNA size ladder (section 2.1.8).  
 
 
2.2.1.9 Oligonucleotide hybridization 
 
Complementary single stranded oligonucleotides obtained commercially were 
mixed in a 1:1 molar ratio in PNK buffer and denatured by incubation at 95ºC for 2min in 
ddH2O to a final volume of 50µl. The mixture was then allowed to cool down to 30
o
C 
gradually to allow annealing of complementary strands. The reaction was then stored at -
20C for later use.  
 
 
2.2.1.10 Phosphatase treatment of vector 
 
Ligation of DNA requires the formation of phosphodiester bonds between the 
5‟phosphate group and 3‟hydroxyl group of the ends of the DNA strands. To prevent 
self-ligation of digested vector and the formation of vector-vector concatemers formed 
during ligation reactions when fragments have the same cohesive termini at both ends, 
the vector DNA should preferably be de-phosphorylated. Restriction digest reaction 
volumes were increased by 10μl with fresh 10x restriction endonuclease buffer, 10x BSA 
and ddH20. Calf-intestinal phosphatase (CIP) was then added at a concentration of 0.5 
units per 1μg of DNA. For 5‟overhang ends, CIP treatment was performed at 37ºC for 1 
h. For 3‟overhangs and blunt-ended DNA fragments, CIP-treatment was performed at 
37ºC for 2 h. CIP cannot be fully heat-inactivated so CIP-treated DNA was either 







 TA PCR cloning 
 
Cloning of PCR products into the TOPO® TA cloning vector was performed as 
described in the manufacturer‟s protocol.  PCR products were amplified using 
proofreading Expand High Fidelity
PLUS
 DNA polymerase. To incorporate suitable 
restriction sites into the PCR products for use in subsequent cloning procedures, 
restriction site recognition sequences were included into primer sequences.  
 
 
2.2.1.12 Polyadenyladenylation of PCR products for TOPO
®
 TA cloning 
 
Since the high fidelity polymerase used to generate PCR products for TOPO® TA 
subcloning procedures does not adenylate the ends of the PCR products, adenylation of 
the PCR products was a necessary requirement for cloning into the TOPO vector.  




Phosphorylated DNA Oligonucleotide 100 pmol (5 pmol/µl) 
10X 5´ DNA Adenylation Reaction Buffer 2 µl 
1 mM ATP 2 µl 
Mth RNA Ligase 2 µl (100 pmol) 
Nuclease-free Water to 20 µl 
 
Table 2.6 - Polyadenyladenylation of PCR products for TOPO
®
 TA cloning 
 
The adenylation reaction was left to Incubate at 65°C for 1 hour followed by 







2.2.1.13 Ligation of DNA fragments 
 
The concentrations of insert and vector were determined by agarose gel 
electrophoresis.  
Ligation of DNA fragments was performed using the Quick Ligation
TM
 Kit according to 
manufacturer‟s instructions (NEB®). A total of 50 ng of vector were mixed with a 3-fold 
molar excess of insert. Total volume was adjusted to 10 μl with dH2O and then to 20μl 
with 10 μl of 2X Quick Ligation Buffer. The reaction was briefly centrifuged after which 
1μl of Quick T4 DNA Ligase were added to the reaction followed by, again, brief 
centrifugation.The reaction was left to incubate at room temperature (25°C) and 
transformed after 5 minutes. 
 
Alternatively, T4 DNA ligase enzyme was used;  For cohesive (sticky) ends, 1 µl 
of T4 DNA Ligase in a 20 µl reaction, and/or for blunt ends, 1 µl of T4 DNA Ligase in a 
20 µl reaction for 2 hours. This reaction was left to incubate overnight at 16ºC.  
 
 
2.2.1.14 Generation of electrocompetent E.coli cells 
 
E.coli strain were streaked onto an agar plate and grown at 37ºC overnight. A 
single colony was then used to inoculate 10ml of LB and grown overnight at 37ºC, which 
was subsequently employed to inoculate 1L of 2x YT media the following morning. 
Cultures were grown to OD600 0.5-0.8 and then placed on ice for 15-30 min. Following 
centrifugation at 3700 xg for 15 min, pelleted cells were resuspended in 1L ddH2O. 
Cultures were again centrifuged and the pellet resuspended in 500 ml of ddH2O. After 
another spin, cell pellets were resuspended in 20 ml 10% glycerol. The cells were 








2.2.1.15 Transformation of bacterial competent cells by heat shock 
 
A 50ng aliquot of DNA ligation product was mixed with 25 l of either TOP 10 or 
DH5  competent cells thawed on ice from their usual -80
o
C storage, taking care to avoid 
repetitive pipeting and violent shaking. The mixture was left to incubate for 30 minutes 
followed by a heat shock at 37ºC for 60 seconds, to allow DNA uptake by cells. The 
sample was then returned on ice for a further 2 minutes after which 500 l of LB medium 
was added. The cells were allow to grow at 37ºC for 60 minutes in a shaking incubator 
(recovery phase) after which they were platted onto antibiotic containing agar plates and 
left to grow overnight at 37ºC. Colonies were picked with a sterile loop and used to 
inoculate 5ml of LB media supplemented with 100μg/ml antibiotic (ampicillin) followed 
by  incubation at 37º C in a shaking incubator overnight. 
 
 
2.2.1.16 Transformation of ligated DNA by electroporation 
 
Competent cells (30-100ml aliquots) were thawed on ice for 10 minutes, to which 
was then added 2μl of the ligation products transfect to a pre-chilled electroporation 
cuvette and incubated on ice for a further 30-60s. Following placement in the Genepulser 
II apparatus, an electric pulse of 25μF capacitance, 2.5kV and 200 Ohm resistance was 
delivered to the cells. The cells were then placed in 950μl of LB broth and incubated for 
15 minutes to 1 hour at 37ºC. Aliquots of  100μl of cells were then plated onto agar plates 
with ampicillin (100 mg/ml) and incubated overnight at 37ºC.  
 
 
2.2.1.17 Storage of bacterial clones 
 
A 500μl of cultured cell clones (known to contain the correct plasmid) was made 







2.2.1.18 Extraction of plasmid DNA by alkaline lysis 
 
Solutions used for plasmid preparation: 
 
Solution Description Function 
P 1 
 (added 10 g/ml RNase A) 
15mM Tris-HCl (pH 
8) 
10mM EDTA 
bacterial pellet re-suspension 
P 2 0.2M NaOH 
1% (w/v) SDS 
Lysis of bacterial membrane and 
denaturation of double-stranded DNA 
P 3 3M potassium acetate (pH 5.5) Neutralisation and renaturation of 
plasmid DNA (but not bacterial 
DNA) 
 
Table 2.7 - Solutions used for extraction of plasmid DNA by alkaline lysis 
 
Plasmid DNA was extracted from the bacterial cultures using the alkaline lysis 
protocol (Birnboim & Doly, 1979) as described below. From each bacterial culture 1.5ml 
were transferred into a microcentrifuge tube and spun for 1minute at 13 000rpm. 
Supernatant solution was removed and the cell pellet was resuspended in 100μl of P1 by 
repeated pipetting. P2 (100μl) was then added followed by gentle mixing by inversion 
and incubation at room temperature for 1-2 minutes, or until the mixture became clear 
(through bacterial lysis). P3 (100μl) was then added to the mixture, gently inverted until 
no viscous mixture was visible. The mixture was the subjected to a phenol:chloroform 
extraction followed by ethanol precipitation.  
 
 
2.2.1.19 Large scale plasmid preparation 
  
Plasmid DNA was prepared from overnight cultures grown in LB broth 




clonal population of bacteria.  A large yield of purified plasmid DNA was obtained 
through use of column purification with the Plasmid Maxiprep Kit (QIAGEN
®
) 
according the manufacturers instructions. Plasmid constructs to be used for lentiviral 
vector generation, the Endofree plasmid Maxiprep kit (QIAGEN
®































2.2.2. Tissue culture 
 
2.2.2.1 Propagation of Adherent Cell Lines 
 
All adherent cell lines were maintained in Dulbecco‟s modified eagle medium 
(DMEM) containing GlutaMAX supplemented with 10% (v/v) sterile, filtered fetal calf 
serum (FCS) and 1% (v/v) penicillin/streptomycin (referred to as complete DMEM). 
Cells were grown in T80 (80 cm
2
) or T175 (175 cm
2
) tissue culture flasks with vented 
caps in 37°C incubators in a 5% CO2 atmosphere.  
 
Cells were passaged when 80‐90% confluent (as indicated by orange indicator 
dye de-colourisation); Confluent adherent monolayers were detached from culture flasks 
by medium removal, washing with 1x PBS solution followed by incubation for 5 minutes 
at 37°C with trypsin/EDTA. Complete DMEM was added for resuspension and a 
proportion of the medium discarded depending on desired cell density. Fresh medium 
was added at the desired volume (depending on the flask used). 
 
 
2.2.2.2 Propagation of Non-Adherent Cell Lines 
 
Non‐adherent cell lines were maintained in DMEM media containing GlutaMAX 
supplemented with 10% (v/v) FCS and 1% (v/v) penicillin/streptomycin (referred to as 
complete RPMI). Cells were grown in T25 (25 cm
2
), T80 or T175 tissue culture flasks 
(standing upright) in 37ºC incubators in a 5% CO
2
 atmosphere. Cells were passaged 
following media colour‐change; the cells were transferred to 15 ml centrifuge tubes and 
centrifuged at 1200 rpm in a tabletop centrifuge for 5 minutes, washed with PBS, diluted 
1:10 or 1:20 in fresh complete DMEM and transferred to new tissue culture flasks. 
 
For confluent suspension cells, medium was directly discarded and replaced with 




2.2.2.3 Freezing of  tissue culture cells in Liquid Nitrogen 
 
A cell pellet containing was obtained as previously described. This pellet was re-
suspended in 1ml growth medium containing 10% DMSO and transferred to a 1.5 




2.2.2.4 Recovery of cells from Liquid Nitrogen storage 
 
Vials were thawed quickly at 37ºC from liquid nitrogen storage and diluted in 
10ml of complete medium. The cell suspension was then centrifuged at 1500 rpm for 5 
minutes with subsequent removal of DMSO containing supernatant and re-suspension of 
the cell pellet in growth medium, and cultured as before 
 
 
2.2.2.5 Cell counting 
 
A cell suspension in 10ml of complete medium was prepared and cells counted 
with a standard haemocytometer.  
 
2.2.2.6 Stable Transfection of Mammalian Cells by Electroporation 
 
Plasmid DNA for transfection was isolated using the QIAGEN
®
 Plasmid Maxi 
Extraction Kit. The plasmid DNA was linearised using a suitable restriction 
endonuclease. Phenol-chloroform extraction and ethanol precipitation was then carried 






Transfection was carried out by electroporation (Chu et al., 1987) with 1-3x10
7
 
cells in log phase growth. The cells were harvested as described above and resuspended 
in 700 l of additive-free DMEM. This was added to the 100µl DNA mixture and 
incubated at room temperature with periodic shaking for 10 minutes. The DNA was 
introduced into the cells by electroporation using the BioRad Gene Pulser Unit, set to 
deliver a transient electrical pulse of 975 F at 250V. After electroporation, the cells were 
allowed to stand at room temperature for further 10 minutes before transfer to fresh 
complete DMEM and incubation at 37 C. 
 
Stably transfected cells were selected for and maintained by growth in the 
presence of an appropriate antibiotic (geneticin sulphate) at a concentration of 800 g/ml, 
added 24 hours post transfection. 
 
 
2.2.2.7 Induction of differentiation of MEL cells 
 
Murine erythroleukaemia (MEL) cells were induced to undergo terminal erythroid 
differentiation by maintaining a log phase growth culture in complete DMEM containing 














2.2.3 HIV-1 based Lentiviral vector production  
  
Production and assays of second generation lentiviral vectors was conducted 
following Naldini protocol (1996). Lentiviral particles were generated by transient 
transfection of HEK293T cells seeded in T175 flasks so that the cells were 80-90% 
confluent at the time of transfection (2x10
7
 cells per flask).
  
 
The following amounts of DNA were added to 5 ml of Optimem per T175 flask 
and filtered through a 0.2 µm acetate membrane syringe filter (Nalgene).  
 
 
Plasmid vector Quantity 
Transfer vector 50μg 
PMD2.VSVG (VSV-G envelope) 16μg 
Packaging plasmid 32μg 
 
Table 2.8 – Plasmids used in lentiviral vector production 
 
1µl of a 10 mM stock of the synthetic polycation transfection reagent 
polyethylenimine (PEI) was added to 5ml of Optimem and filtered through a 0.2µm filter. 
DNA and PEI solutions were then mixed in a 1:1 ratio and incubated at room temperature 
for 20 min. The cells were washed with 10 ml Optimem and 10 ml of the PEI/DNA 
complexes were then added per T175 flask. The cells were incubated at 37ºC for 4hours 
followed by replacement of the transfection medium with 25 ml of complete DMEM 







2.2.3.1 Harvesting of lentiviral particles 
  
Around 48 hours post-transfection the medium was harvested and replaced with 
20ml fresh stock so the virus could be harvested for a second time 72h post-transfection. 
The harvested medium was cleared of debris by low-speed centrifugation at 2500rpm for 
10 minutes and filtered through a 0.2 µm filter and then centrifuged at 4ºC for 24h at 
3700xg. The supernatant was decanted and the tubes were inverted onto tissue to drain 
the remaining supernatant. 50 µl of DMEM without supplements or Optimem was added 
to the viral pellet and incubated on ice for 20 min. The viral pellet was then resuspended 
by repeated pipetting and centrifuged for 10 minutes at 4000rpm to remove cell debris 
and impurities,. 5-10 µl aliquots were then stored at -80ºC.  
 
 
2.2.3.2 Lentiviral vector titration  
 
For each viral harvest, 4 wells of a 24-well plate were seeded with 2x10
5
 
HEK293T cells and transduced with serial dilutions of concentrated virus in order to 





the initial viral titre was 1x10
8 
infectious units (IU)/ml. The MOI indicates the number of 
viral particles per cell. Specifically, 2µl viral concentrate was added to the first well to 




per ml. For the remaining 







respectively. To the 1 ml in each well, a further 1 ml of DMEM 
medium was added containing 16µg/ml (w/v) of the cationic polymer polybrene to give a 
final concentration of 8µg/ml. The 5th well was left untransduced to act as a negative 
control. 
 
At 72h post-transduction, the cells were harvested (using trypsin if adherent cells 
were used for titration) and centrifuged at 1000rpm for 2 minutes. The cell pellet was 




fluorescence activated cell sorting (FACS) analysis tube. Tubes were covered in foil and 
stored at 4 C to awaiting FACS analysis 
 
2.2.3.2 Image capture of eGFP reporter gene expression 
 
Cells expressing enhanced green fluorescence protein (eGFP) were examined 
under a Nikon Eclipse TS100 fluorescence microscope via blue light excitation using a 
Osram 50W mercury vapour bulb. Fluorescent images were taken using an Olympus SP-
350 8MG pixel digital camera. 
 
2.2.3.4 Viral Titer quantification 
 
Viral titre was simultaneously calculated by both FACS and from integrated viral 
vector copy number in tissue/cell genomic DNA by quantitative polymerase chain 
reaction (qPCR).  
  
 
2.2.3.4.1 Quantification of viral titre by Fluorescence Activated Cell 
Sorting (FACS) analysis 
 
Individual samples were analysed with a Beckton Dickinson FACS Calibur 
instrument and CellQuest Pro software. Levels of eGFP fluorescence were analysed by 
detecting light emission at 525nm wavelength (colour spectrum range FL1), using 
untransduced cells to gate for positive signal. Specifically, samples of at least 10
4 
cells 
suspended in 800µl 1% formaldehyde in PBS, were analysed for various parameters 
followed by construction of plots to visualise the analysis. Using parameters of size 
versus granularity, untransduced cells were used to gate particular subsections of the cell 
population such that only healthy, live cells were included in the analysis. Similarly, 




untransduced cells were used as a negative reference to gate for positive eGFP signal. 
Settings, such as voltage and current, were then fine-tuned according to a known eGFP 
positive cell sample to avoid overlap in the FL1 (green fluorescence) and FL2 (red 
fluorescence) wavelength ranges, as  true eGFP florescence is determined by emission at 
525 nm (FL1). As untransduced cells autofluoresce to some extent in the FL2 range, it is 
important that detection of each range remains independent of one another to ensure 
accurate detection of eGFP fluorescence. Therefore, detection in the FL1 range was 
adjusted manually so that it was independent of emission in the FL2 range.  
 
For the assessment of viral titre, a cell sample transduced at a predicted MOI 
1x10
-1
 would be expected to show a 10% eGFP positivity level. Similarly, a sample of 
predicted MOI 1x10
-2 
would be expected to have a positivity level of 1% and so on. Any 
deviation from this expected percentage positivity would thus be used to determine the 
actual titre. For example, if the sample of predicted MOI 1x10
-2 
has a 2% positivity level, 
the titre in this case would in fact be 2x10
8 
IU per ml, rather than the estimated 1x10
8
 IU 
per ml. Viral titre was calculated from the sample/s showing between 5-10% GFP 
positive cells (MOI 0.05-0.1). This is because in a cell sample of low transduction giving 
5-10% cells, signal from each GFP positive cell is more likely to derive from a single LV 
integration event rather than from multiple copies. A 5-10% positivity of a cell sample is 
therefore more likely to be directly proportional to viral copy number (that is, a 1:1 ratio). 
This ensures that a more accurate titre can be calculated.  
 
2.2.3.4.2 Quantification of viral titre by TaqMan qPCR 
As an alternative to titre quantification by FACS, titre can also be quantified by 
determining integrated viral vector copy number in tissue/cell genomic DNA or un-
integrated proviral vectors by real-time quantitative polymerase chain reaction (qPCR; 
TaqMan). This methodology for titer estimation is particularly important for therapeutic 




cassette. Total genomic DNA was extracted from transduced tissues or cells and then 
diluted to an optimal concentration (20-50ng/µl).  
 
TaqMan probes depend on the 5'- nuclease activity of the DNA polymerase used 
for PCR to hydrolyse an oligonucleotide that is hybridised to the target amplicon. 
TaqMan probes are oligonucleotides that have a fluorescent reporter dye attached to the 
5' end and a quencher coupled to the 3' end. Probes are designed to hybridise to an 
internal region of the PCR product. In the unhybridised state, the proximity of the fluor 
and the quench molecules prevents the detection of fluorescent signal from the probe. 
However, during the PCR reaction, when the polymerase replicates a template on which a 
TaqMan probe is bound, the 5'- nuclease activity of the polymerase cleaves the probe, 
which decouples the fluorescent and quenching dyes (refer to Figure 2.1, below)  








(image taken from http://www.servicexs.com/plaatjes/TaqMan_RT-PCR_assay) 
 
The qPCR reactions were set-up in a 96-well reaction plate and analysed by using 
Bushman‟s late reverse transcriptase (LRT) primer/probe set (Bushman et al., 2001); 
Bushman primers were designed to amplify a 120bp fragment of the HIV vector 
backbone between the right 5‟ LTR sequence and the 5‟ end of the gag gene, downstream 
of the cppt element, such that only integrated DNA or provirus forms that have 
completed the two template switches of reverse transcription are detected (in Figure 2.2, 
below) these were designated in the host lab as the “LRT primers” 
 
As a reference, a clonal cell line with an independently determined viral copy 
number of one was used as a standard and repeatedly loaded together with samples 
analysed to act as internal reference. Both standards and samples were diluted to 
concentrations between 20-40ng/µl in deionised distilled water (ddH2O) – these were 
accurately determined using the Nanodrop Sofware, although variations in the samples 
concentrations are not likely to affect the accuracy of the analysis as the reaction was 
performed in parallel with an endogenous internal control.   
 
Primers and probes used: 
LRT forward:  5‟ TGTGTGCCCGTCTGTTGTGT  3‟ 
LRT reverse:  5‟ GAGTCCTGCGTCGAGAGAGC  3‟ 
LRT probe:  5‟ – (FAM) – CAGTGGCGCCCGAACAGGGA – (TAMRA)  3‟ 
 
Volumes loaded per well: 
Total volume: 20µl 
DNA sample: 2µl 
Forward primer: 0.375 µl (3.75 µM of a 10 µM/µl stock) 
Reverse primer: 0.375 µl (3.75 µM of a 10 µM/µl stock) 
 
LRT probe: 1µl (2mM of a 2 µM/µl stock) 








Figure 2.3 - Diagram showing position of Bushman’s (LRT) qPCR primer/probe set 
 
The endogenous human (GAPDH) or mouse (Gapdh) glyceraldehyde-3-phosphate 
dehydrogenase gene was used to determine absolute numbers of genomes present in each 
qPCR reaction using a primer/probe set amplifying  an 73bp fragment of the 5‟ end of 
exon V of the exogenous GAPDH gene ( refer to Figure 2.3 below).  
   
GAPDH Primers and probes used: 
GAPDH forward:  5‟ ACCACAGTCCATGCCATCACT 3‟ 
GAPDH (human) reverse:  5‟ GGCCATCACGCCACAGTT 3‟ 
GAPDH (mouse) reverse:  5‟ GGCCATCACGCCACAGCTT 3‟ 
GAPDH probe:  5‟ – (FAM) – CCACCCAGAAGACTGTGGATGGCC – 
(TAMRA)  3‟ 
 
Volumes loaded per well: 
Total volume: 20µl 
DNA sample: 2µl 
Forward primer : 1 µl (3.75 µM of a 10 µM/µl stock) 
Reverse primers: 1 µl (3.75 µM of a 10 µM/µl stock) 
GAPDH probe: 2µl (4mM of a 2 µM/µl stock) 
TaqMan Master Mix with ROX (PrimerDesign): 10 µl 
 
U3 R U5 RRE 
120bp 
 






Figure 2.4 - Diagram showing position of the Glyceraldehyde-3-phosphatase 
dehydrogenase (GAPDH) qPCR primer set 
 
 
The PCR reaction was conducted under the following cycling conditions: 
 
Stage 1: 50℃ 2min 
Stage 2: 95℃ 10min 
Stage 3: 95℃ 15sec and 60℃ 1min (40 cycles)  
 
Quantification was carried out by Sequence Detection Systems software (SDS version 




2.2.3.5 Lentiviral vector cell line analysis 
 
All lentiviral vectors were tested in vitro on appropriate cell lines, erythroid 
specific, pro-erythroblast MEL cells, and non-erythroid specific cell-line, HEK293T 
cells. Cells were seeded at a density of 5 x10
5
 cells per well 12h prior to transduction  at 
MOI of 1 or less depending on the vectors experimental requirements.. Transduction was 
carried out in 12 wells plates with total volume of 1ml medium. Cells were harvested  
Exon VI 
73bp 




72h post-transduction for genomic DNA extraction (2.2.5.1.1), RNA extraction 
(2.2.5.1.1), total protein extraction (2.2.5.1.1) and FACS analysis (2.2.3.4.1). Ongoing 
cell line analysis and erythroid induction were collected at different time points (eg. day 
































 All animal work was carried out under United Kingdom Home Office regulations 
and was complaint with the guidelines of the Imperial College London ethical review 
committee. All animal experiments were carried out according to the institutional 
guidelines for animal use and manipulation. . 
 
 
2.2.4.1 Neonatal injections 
 
Neonatal delivery was carried out on wild type MF1 strain mice. Gene transfer 
was performed on hypothermia anaesthetised neonatal mice by intra-vascular 
administration through the superficial temporal vein within the first 48 h of life using a 
32-gauge needle and transdermal approach (Chandler & Venditti, 2009). A volume of 
40ml of viral suspension with 1-5x109 IP per ml were injected per pup.  
 
Mice were marked for identification either by tail clipping or foot carbon marking 
and allowed to recover in a warm cage. Injected mice were bled via tail vein post-
injection and were sacrificed at appropriate time-points when individual tissues were 
collected for molecular analysis. All mice showed normal tissue morphology. 
 
 
2.2.4.2 In utero injections 
 
In utero delivery was carried out on wild type MF1 strain mice. Pregnant females 
at the appropriate desired gestational age were anesthetised with Isoflurane. A midline 
laparotomy (1-1.5cm) was performed to expose horns of the gravid uteri. The yolk sac 
vessels of individual embryos were visualised under a dissecting microscope. Vector 
injection was done by inserting a glass needle (70-80µm) attaching to an Hamilton 
microliter syringe. A volume of 20ul of 1-5x10
9




into each embryo via the vitteline vessel.  Injected foetus were marked in utero, for post-
partum identification, by injection of colloidal carbon into the flank.  
After injection, the uteri were returned into the abdominal cavity and the abdomen was 
closed with silk suture.  Mice were allowed to recover in a warm cage.  
 
Born pups were marked for identification after birth either by tail clipping or foot 
carbon marking. Injected mice were bled via tail vein post-injection and culled at 
appropriate time points for molecular analysis 
 
 
2.2.4.3 In vivo Blood collection 
 
Animals were placed under isoflurane anesthesia, and with a scalpel a small 
excision was cut on the base of the tail. Blood samples were added to anticoagulant 
solution (0.109 M sodium citrate buffer) vortexed and centrifuged. Samples were kept on 
ice until analysis 
 
 
2.2.4.4 Animal sacrifice by cardiac puncture 
 
Mice were sacrificed by cardiac puncture so that the maximum amount of 
circulation blood was obtained, 250days after in utero injection. Briefly animals were 
placed under isoflurane anaesthesia and a 22-gauge needle coupled with a 1ml syringe 
was inserted in the centre of the mouse thorax. Blood was withdrawn slowly to prevent 
the heart collapsing. 
As before, blood samples were added to anticoagulant solution (0.109 M sodium citrate 







2.2.4.6 Homogenate of tissue cells 
 
Individual tissues were embedded in PBS solution and macerated using the 
sonicator to obtain a smooth solution, without suspension particles, from which DNA 
could be extracted 
 
 
2.2.4.7 Extraction of Bone marrow cells 
 
Bones were carefully cleaned from adherent soft tissues and the tip of each bone 
was removed with a scalpel. The marrow was harvested by inserting a 27-gauge syringe 
needle into one end of the bone and flushing with DMEM solution. 





















2.2.5 Gene Expression analysis 
 
2.2.5.1 Sample extraction from Tissue culture cells and mouse tissues 




 cells were harvested and resuspended in 1 ml SET buffer 
and incubated at 42 C for 16h for protein denaturation. Genomic DNA was then 
recovered by phenol: chloroform extraction and ethanol precipitation. Alternatively the 
Promega Wizard DNA Purification Kit was used to extract genomic DNA from the cell 
pellet according to manufacturer‟s instructions.  
 
 
2.2.5.1.2 Extraction of RNA from mammalian cells 
 
Total RNA was extracted from a minimum of 5 x10
6
 cells, harvested and 
resuspended in 500µl of TRI Reagent
 in accordance with the manufacturer‟s instructions.    
 






) were resuspended in protein extraction solution and incubated for 
10 minutes at room temperature. Tissue (1-50mg) was homogenised in 500µl protein 
extraction solution. The cell/tissue homogenate was then centrifuged for 5 minutes at 









2.2.5.2 Vector copy number determination  
 
Analysis of samples for vector copy number determination was performed as 
described previously for titer estimation, using LRT and GAPDH primers (section 
2.2.3.4.2). Copy number was determined by comparison with a reference sample known 
to contain a single viral copy per genome. 
 
 
2.2.5.3  Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR)  
 
2.2.5.3.1 cDNA synthesis 
 
cDNA was synthesised from total RNA using SuperScript® III Reverse 
Transcriptase and random hexamers as per the manufacturer‟s instructions.  Briefly, 
cDNA synthesis reactions contained 1 g of total RNA with 100ng of random hexamers 
and 100 mM DTT which was incubated at 94°C for 90 sec. Following incubation on ice 
for 2 min, reverse transcription was carried out in a final volume of 20 l in the presence 
of 1mM dNTPs, 10 URNAsin, 200 U molony murine leukemia virus reverse 
transcriptase and 1
st
 strand buffer.  
Cycling conditions were 
23°C 10 min 
 37°C 40 min  
and 94°C 5 min 
Following synthesis samples were diluted 1:6 in sterile water and stored at -20°C until 
required. 
 
2.2.5.3.2 Reverse transcriptase PCR  
 
Reverse transcriptase PCR reactions were carried out in a final volume of 20 l 




(containing 2.5mM MgCl2) and 2 µl DMSO. SYBR Green binds double-stranded DNA, 
and upon excitation emits light. Thus, as a PCR product accumulates, fluorescence 
increases. 
The designed primers span a 164bp region starting from the 3‟ end of Exon2 of 
the HBB gene to exon 3, allowing amplification to occur only in cDNA fragments 
(Figure 2.4)  
 
HBB RT-PCR primers: 
RT-PCR globin gene Forward: GATCCTGAGAACTTCAGGCT (20) 
RT-PCR globin gene Reverse: AGGCAGAATCCAGATGCTCA (20) 
Thermocycling conditions 
95ºC 15 min,  
x25 95ºC 10 s 
65ºC 40 s 
 72ºC 40 s  
 
 
Figure 2.5 - Diagram showing position of the HBB RT-qPCR primer set. The primers 
are designed to span a 164bp region starting from the 3‟ end of Exon2 of the HBB gene to 
exon 3. A HBB DNA, not amplyifeid by the set of primers B cDNA fragment that can be 
amplified by the primer set. 
 
GAPDH internal primers used are described in section 2.2.3.4.2, Figure 2.3. 
Exon 3 
164bp 
Exon 2 Exon 1 






2.2.5.3.3 Expression levels quantification  
 
Quantification was carried out by Sequence Detection Systems software (SDS 
version 2.2.2 Applied Biosystems, 2004). Taqman amplification results in 
amplification curves of which log phase depended on initial amounts of vector in the 
sample. The estimation of expression levels was obtained by comparison with standard 


























2.2.5.4 Sandwich Enzyme linked Immunosorbent Assay (Sandwich 
ELISA)  for eGFP Quantification  
 
eGFP ELISA was carried out by using Matched-Pair Antibody Set for ELISA. 
Briefly, eGFP protein was captured by the coated eGFP specific affinity-purified primary 
antibody on the wells of a microtitre plate. Captured proteins bound to a peroxidase 
conjugated secondary antibody expressed by incubation with TMB+ substrate 
chromagen. Upon development time points of  10 and 20min  the green colour indicative 
of protein presence was quantified with a microplate reader at the wavelength of 490nm 
and compared with  standards. The colour generated is proportional to the concentration 
of GFP present in the sample. Each sample was duplicated in the assay. 
 
 




0.16% Na2CO3 (w/v), 0.29% NaHCO3 (w/v) 
Block buffer 
 
1% BSA (w/v) in 1XPBS 
 
Table 2.9 - Constituents of Buffers Used in eGFP ELISA 
 
2.2.5.4.1 Preparing Protein Samples 
 
Total protein from both cells and tissue transduced with eGFP lentiviral vectors 
was quantified using the colorimetric Bio-Rad Protein Assay Kit I, which uses the 
Bradford Assay for protein quantification (Bradford et al., 1976). Absorbance was 
measured  at 595nm and the quantification of protein levels per sample was determined 




serum albumin (BSA). Standard references were used to create a standard curve which 
was used to fit the absorbence data for known concentrations of BSA to a linear 
regression model using Microsoft  Excel (where R
2≥ 0.9).  
 
Calculation of protein concentration of unknown samples was then carried out. 
Aliquots of 2µg were then prepared for eGFP ELISA by addition of wash buffer to a total 
volume of 100ul. 
 
2.2.5.4.2 Application of Primary Antibody 
 
Mouse monoclonal anti-eGFP antibody was diluted 1/10,000 in bicarbonate 
buffer and 100µl added to each well of a flat bottomed, high binding 96 well plate, which 
was sealed and incubated overnight at 4 C, followed by washing with 250µl of wash 
buffer (repeated three times). Block solution (300µl) was then added to each well and the 
plate incubated for a minimum of 1h at 37 C followed by washing with 250µl of wash 
buffer (repeated three times). Then, 100µl of sample or standard in wash buffer was 
added to each well, including a negative control of wash buffer alone.  
 
2.2.5.4.3 Preparing GFP Standard Curve 
 
1µg of recombinant eGFP Protein was diluted to 1ml wash buffer. Then, 40µl of 
this was added to 1 ml wash buffer and serial dilutions carried out to create the following 
range of GFP dilutions; 40, 20, 10, 5, 2.5, 1.25, 0.63, 0.32 pg/μl to act as standard 
references.  
 
After addition of 100µl of sample and standards (in triplicate), the plate was then 
sealed and incubated for 1h at 37 C followed by washing with 250µl of wash buffer 





2.2.5.4.4 Application of Secondary Antibody  
 
Biotin-conjugated goat polyclonal anti-eGFP secondary antibody (Abcam ) was 
diluted 1/5,000 in block solution and 100µl was added to each well. The plate was then 
sealed and incubated for 1h at 37 C followed by washing with 250µl of wash buffer 
(repeated three times). Streptavidin/horse radish peroxidase was then diluted 1/5,000 in 
block solution and 100µl added to each well, containing the primary antibody/protein 
sample/secondary antibody „sandwich‟. The plate was then sealed and incubated for 1 
hour at 37 C followed by washing with 250µl of wash buffer (repeated three times). 
Then 100µl of TMB+ substrate chromagen was added to each well and the plate 
incubated for 20-30 minutes at room temperature in the dark to allow colour change of 
the biotin-bound substrate chromagen catalysed by HRP. A 100µl volume of 3M H2SO4 
was then added to each well and the plate gently tapped to ensure thorough mixing. 
Addition of H2SO4 ends the HRP-catalysed colour change, the extent of which depends 
on eGFP levels. Absorbence of light of 450nm wavelength was then measured for each 
sample on the Bio-Rad model 680 Microplate Reader at 10 and 30 minutes timepoints.  
 
2.2.5.4.5 Fitting the Data to a Linear Regression 
 
The eGFP quantification of unknown protein samples was carried out by fitting 
the absorbance measurements of eGFP protein standard to a linear regression using 
Microsoft  Excel. This standard curve (where R
2≥ 0.9) was then used to calculate eGFP 










2.2.5.5 Sandwich Haemoglobin ELISA for HBB quantification 
 
Haemoglobin ELISA was carried out by using Human Hemoglobin ELISA Kit . 
Briefly, this kit is based on a sandwich ELISA; Human hemoglobin present in the test 
sample is captured by anti-human hemoglobin antibody that has been preadsorbed on the 
surface of microtiter wells. After sample binding, unbound proteins and molecules are 
washed off, and a biotinylated detection antibody is added to the wells to bind to the 
captured hemoglobin. A strepavidin-conjugated horseradish peroxidase (SA-HRP) is then 
added to catalyze a colorimetric reaction with the chromogenic substrate TMB (3,3‟,5,5‟-
tetramethylbenzidine). The colorimetric reaction produces a blue product, which 
absorbance at 450 nm is proportional to the amount of hemoglobin analyte present in the 
sample and a four-parameter standard curve can be generated. The hemoglobin 
concentrations in the test samples can then be quantified by interpolating their 
absorbance from the standard curve generated in parallel with the samples.  
 
2.2.5.5 1 Sample dilution and standards preparation 
 
Whole Blood was diluted as recommended per manufactur‟s instructions 
(1:50,000). For standards preparation  200-ng  human Haemoglobin was reconstitute with 
1.0 ml of 300 μl of 1X Dilution Buffer and serial dilutions carried out to create the 
following range of human haemoglobin 66.6, 22.2, 7.4, 2.5, 0.82, 0.27, and 0 ng/ml to act 
as standard references. 
 
After addition of 100µl of sample and standards (in triplicate), the plate was then 
sealed and incubated for 1h at 37 C followed by washing with 250µl of wash buffer 








2.2.5.5 2 Incubation with Detection Antibody 
 
A volume of 100μl of Detection Antibody to each well containing standard, 
sample or blank. The well plate was sealed and incubated for 1 hour at room temperature, 
20-25°C, followed by washing with 250µl of wash buffer (repeated four times).  
 
2.2.5.5.3 Incubation with strepavidin-conjugated horseradish 
peroxidase HRP Solution  
 
A volume of 100 μl of HRP Solution was added to each well containing standard, 
sample or blank, which was sealed and left to incubate plate for 30 minutes at RT, 
followed by washing with 250µl of wash buffer (repeated four times). 
 
2.2.5.5.4 Incubation with chromogenic substrate (TMB)  and Stopping 
the Reaction 
 
A volume of 100μl of TMB Substrate Solution into each well and the enzymatic 
reaction was allowed to develop a blue color at RT in the dark for 30 minutes. The 
reaction was stopped by adding 100μl of Stop Solution to each well.  
 
2.2.5.5.5 Fitting the Data to a Linear Regression 
 
HHB quantification of unknown protein samples was carried out by fitting the 
absorbance measurements of Haemoglobin protein standard to a linear regression using 
Microsoft  Excel. This standard curve was then used to calculate Haemoglobin 







2.2.5. 6 Bioluminescence detection assays 
 
2.2.5.6.1 In vivo Bioluminescent Imaging for Intravenous Injection 
 
Mice were treated according to approved UK Home Office and institutional 
guidelines at Imperial College London. Mice were anesthetised with isoflurane using 
Boyle‟s apparatus, and injected intraperitoneally with 300μL 15mg/mL D‐luciferin salt. 
Mice were left for 5 minutes exactly and then imaged for bioluminescence by the IVIS 
Imaging 50 Series (Xenogen) system Caliper Life Sciences Ltd, Runcorn, UK). After 
acquiring a gray‐scale photograph a bioluminescence image was obtained with a 12‐cm 
field of view, a binning (resolution) factor of 1 or 8, and a 1/f stop and open filter. Signal 
intensities were calculated with Livingimage 2.50 software (Xenogen) and expressed as 
photons per second per centimetre squared per seradian (photons/second/cm2/sr).  
 
2.2.5.6.1 Ex Vivo Luciferase Assay 
 
Quantification of luciferase protein for ex vivo tissue homogenates was carried out 
using the Luciferase Assay System (promega) as per manufacturers instructions. Tissue 
was freeze‐thawed in 1X Lysis buffer, homogenized, and cell debris removed by 
centrifugation. 20μL of homogenate is added to a 96‐well, clear/flat bottom plate. 100μL 
of luciferase mix is then added to each well and the resulting light emission measured 
using a luminometer for 30 seconds and reported in relative luciferase units (RLU).  
 
Homogenate is then diluted 1:250 and a Bradford protein assay (BioRad) carried 
out as per the manufacturers instructions in a clear 96 well microplate to determine the 
protein concentration of each homogenate in μg/mL. Luciferase quantification in tissue 







2.2. 5. 7 Cellular Staining 
 
Analysis of animal samples of peripheral blood, bone marrow and speenocytes 
was conducted by staining the sample with appropriate antibodies.  
 
Collected peripheral blood sample (50µl) or 5x105 bone marrow cells (upon 
animal sacrifice) was washed with 1ml of Immunofluorescence buffer and centrifuged for 
5min at 1500rpm. To reduce background binding, and increase mouse specificity of the 
antibody, cells were incubated with 2.5µl of Fc Block away from light for 10min at 4
o
C 
followed by an IF buffer washing step and resuspension (100µl).  
 
Samples were then divided and incubated with 2.5µl of 200ng/µl control isotype 
antibody (PE, APC or FITC as appropriate) or 200ng/µl of specific antibody (Ter119-
APC, CD3-PE (T cells), CD19-PerCP (B cells), CD11b-APC (monocytes) for 30min, 
again, away from light at 4
o
C.Individual samples were then washed with 1ml IF buffer 















COMPARATIVE STUDY TO ACCESS THE ABILITY OF BOTH UBIQUITOUS 
AND TISSUE SPECIFIC ELEMENTS TO EXPRESS WITHIN AN 
















3.1. Aims of Chapter Three 
 
 Design new ID- LVs containing tissue specific regulatory sequences 
 Compare expression of newly designed ID-LVs with ubiquitous expressing 
constructs  

























Efficient and sustained transgene expression has been previously been reported in 
non-mitotic cells with use of non-integrating lentiviral vectors (Yanez-Munoz et al., 
2006; Apolonia et al., 2009). These vectors offer advantages over currently used 
integration proficient vectors as they avoid side effects caused by genome integration 
namely insertional mutagenesis and its consequent potential cell transformation. 
 
Reports to date have shown that expression from an integration defective vector 
can be achieved with ubiquitous viral promoters such as that of spleen forming focus 
virus (SFFV) and the human cytomegalovirus (CMV). It is, however, still unclear 
whether genomic promoters of either housekeeping or tissue specifically expressing 
genes can function from within an integration defective context. 
 
In this study we conducted a comparative analysis to access the ability of both 
ubiquitous and tissues specific genomic regulatory elements to express in an integration 
deficient LV context.  
As a ubiquitous expressing promoter we employed the generic SFFV promoter 
(Demaison et al., 2002); and as examples of tissue specific control elements we 
employed:  
 
a) For potential gene therapy for the haemoglobinopathies, a vector 
combining HBB and its control elements;  
b) and, for potential muscle gene therapy vectors with transgenes under 










3.2.1 The human -globin gene (HBB) promoter and its locus control 
element (LCR) 
 
HBB is part of a multigene family on the short arm of chromosome 11 with 
expression restricted to the erythroid lineage. Expression is basal in erythroid progenitor 
cells but upregulated to very high levels during terminal differentiation, the rate of which 
is dependent on the upstream hypersensitive (HS) sites of the globin locus control region 
(LCR; Levings & Bungert, 2002). 
 
The HBB core promoter has been narrowed down to approximately 200bp, and 
consists  of several elements, one of which is located 160bp upstream of the transcription 
start site and which has been shown to increase the efficiency of the promoter after 
murine erythroleukaemia (MEL) cells have been induced to differentiate (Antoniou et al., 
1988). This region contains the (-30) TATA box, (-70) CAAT box and (-90) CAC box 
motifs necessary for efficient transcription (deBoer et al., 1988). 
 
The HHB promoter expression is largely controlled by its potent LCR. The human 
LCR is located between -5kb and -16kb upstream of the first gene within the HBB-like 
cluster namely -globin (HBE) and comprises 5 regions of extreme DNaseI 
hypersensitivity (designated as HS1-5). In this study, we used solely the two most 
transcriptionally potent LCR elements HS2 and HS3 to augment expression from a linked 
promoter (Miccio et al., 2008). 
 
 
3.2.2 The human desmin promoter 
 
The desmin gene (DES) promoter region used in this study is 1.7kb in length and 
has been shown to function in all muscle cell types, especially skeletal muscle (Tam et 
al., 2006; Talbot et al., 2010). DES is an intermediate filament protein, synthesis of 





 first muscle-specific structural protein detected in the heart and somites and its 
developmental regulation is orchestrated by its promoter in combination with its locus 
control region (LCR; Raguz et al., 1998; Tam et al., 2006). Desmin expression increases 
several-fold upon cell differentiation into myotubes (Li & Paulin, 1991). 
 
The DES promoter requires a 280bp enhancer for high-level expression located 
between -973bp and -693bp. This enhancer has been shown to be necessary to confer 
correct developmental and tissue-specific expression within skeletal muscle. This area 
consists of three regions, two positive and one inhibitory, which, from analysing 
expression driven from combinations of these regions in myoblasts and myotubes, have 
been shown to cooperate to achieve high expression (Li & Paulin, 1993). 
 
 
3.2.3 The muscle creatine kinase (CKM) promoter/enhancer 
 
Muscle creatine kinase (CKM) is a key metabolic enzyme of skeletal muscle and 
has been shown to be upregulated 17-fold upon muscle differentiation.  
 
The mouse Ckm promoter has been extensively characterised. The native, as well 
as various optimised forms of the promoter/enhancer region have been used to drive 
skeletal muscle specific expression of both reporter and therapeutic mini and micro-
dystrophin genes in the mdx mouse model of Duchene muscular dystrophy delivered by 
both AAV (Salva et al., 2007; Gregorevic et al., 2004) and lentiviral vectors (Li et al., 
2005). Mouse Ckm is therefore one of the current promoters of choice in the field of 
muscle gene therapy. In this study we used a 1kb region from -1061bp to +28bp from the 
human CKM transcription start site, which contains the proximal promoter and a 292bp 
enhancer element between -933 to -641bp that has been shown to confer developmental 







3.3 Findings prior to this study 
 
Prior to this project the host lab and collaborators developed a novel LV 
(GLOBE) where HBB is under the control of a minimised promoter and LCR elements 
HS2 and HS3 (Miccio et al., 2008; Figure 3.1). This GLOBE LV has been shown to be 
able to express therapeutic levels of HBB in a mouse model of -thalassaemia (Miccio et 
al., 2008) and correct the / -globin chain imbalance in cells derived from patients with 




Figure 3.1 - Diagram of the GLOBE LV construct. The construct comprises a 
minimised HBB promoter-gene combination under the control of LCR elements HS2 and 
HS3. This construct is 9.5kb in length. 
 
Results obtained demonstrate that LCR sites HS2 and HS3 coupled with the 
prooter-gene combination are sufficient to completely revert the phenotype of severe -
thalassaemia intermedia in mice (Miccio et al., 2008). The assessment of therapeutic 
efficacy of this LV was analysed in the -thalassaemic th3/+ mouse model of this 
condition, which exhibits chronic anaemia, anomalies in red cell size and shape, 
splenomegaly, extramedullary hematopoiesis (EMH) and iron accumulation in liver and 
spleen. Differentiated progeny of th3/+ HSCs, LV-transduced with GLOBE showed a 
significant increase (79-100%) of donor red blood cells expressing HBB, which remained 
stable up to 9 months after transplantation together with extreme reduction of iron 
deposition in the spleen and liver (Miccio et al., 2008). Furthermore, the studies 





in vivo selection of genetically corrected erythroblastic progenitors, differentiating from a 
relatively limited number of transduced HSCs (Miccio et al., 2008). 
 
Further in vitro assays were performed to evaluate GLOBE vector efficacy and 
safety.  Using CD34
+
 cells from -thalassaemia patients, it was demonstrated that the ex 
vivo manipulation required for successful transduction does not affect cell viability. In 
addition, at low GLOBE vector copy number per CD34
+
 cell was sufficient to correct -
thalassaemia globin chain imbalance and restore erythropoiesis upon differentiation in 
vitro. Finally, as is the case with other lentiviral and retroviral vectors, GLOBE integrates 
preferably within transcriptionally active genes within the target cell population at the 
time of transduction, with no bias towards integration in the proximity of oncogenes 
















3.4 Lentiviral Vectors used in this study 
 
3.4.1 Construction of a GLOBE variant containing an eGFP reporter 
gene 
 
In vitro functional gene analyses are greatly expedited with the easy identification 
of a transgene transfected into a cell pool. An easy identification requires the 
incorporation of a readily assayable reporter gene within the vector. Enhanced green 
fluorescent protein (eGFP) is a protein that aids in the determination of the function of a 
gene cassette of interest by attaching its coding region to the promoter region, allowing 
easy detection of transgene expression: the synthesis of eGFP protein when exposed to 
fluorescent light emits green light. In gene therapy, the presence of a reporter gene in the 
transfected therapeutic vector allows easy and efficient detection of transduced cells, as 
these will emit green light when exposed to a UV source.  
 
The minimised HBB gene in GLOBE was replaced with a cassette containing the 
promoter driving expression of an eGFP reporter gene linked at the ATG 
translational start site within exon 1. The removal of the mini-gene from GLOBE 
was achieved using restriction sites situated at either side of the gene; ClaI at the 5’ end 
and SwaI at 3’, both unique sites in the GLOBE vector plasmid. The digestion of this 
construct with both enzymes released the HBB fragment of approximately 1.5kb with the 
remaining 8kb plasmid vector backbone, containing the LCR sites HS2 and 3, with the 










































Figure 3.2 - Digestion of GLOBE1 to release HS2 and HS3 loaded in a large well. 
GLOBE vector digested with ClaI and SwaI releases a 1.5kb fragment (containing HBB) 
and an 8kb vector backbone containing LCR elements HS2 and HS3. The upper 8kb 
DNA band was excised from the gel and purified. Invitrogen 1kb DNA size ladder is 
shown on the left. 
 
A 1.3kb DNA fragment containing the HBB promoter linked at the ATG 
translational start site to an eGFP reporter gene ( -eGFP) was isolated from a plasmid 
vector available in the host lab (MA891) comprising ~6kb. The -eGFP fragment was 
excised as an EcoRI (blunted) plus ClaI digestion and purified by preparative agarose gel 








Figure 3.3 - MA891 plasmid was digested with EcoRI (blunted) and ClaI. Digestion 
products were resolved by electrophoresis on a preparative agarose gel. The lower band 















































1.5kb HBB fragment 
MA891 plasmid backbone  
1.5kb -eGFP fragment 






(1.5kb) comprising the -eGFP fragment was excised and purified for further cloning. 
Invitrogen 1kb DNA size ladder is shown on the right.        
             The -eGFP and GLOBE vector backbone fragments were ligated employing 
various insert:vector ratios and reactions used to transform DH5  E. coli by the heat 
shock method and plated to grow on ampicillin agar plates. Individual bacterial colonies 
were picked and grown overnight in ampicillin-containing LB medium as 5ml mini-
cultures. Plasmid DNA was then isolated from a 1ml aliquot of the cultures by the 
alkaline lysis procedure. The final construct was designated LCR-Globin-eGFP (MA925 





Figure 3.4 - Diagram of the GLOBE-eGFP (LCR-Globin-eGFP) construct. The 
minimal HBB gene was replaced in GLOBE1 (Figure 3.1) with a fragment containing 
the 265bp HBB promoter driving expression of a 1.38kb eGFP reporter gene linked at the 
















3.4.2 Design of constructs containing ubiquitous expressing promoters 
 
The spleen forming focus virus (SFFV) promoter driven LV cassette (universally 
named SEW; Figure 3.5) was generated and successfully used in collaborators’ 
laboratories (Demaison et al, 2002) and its successful use in ID LV has been documented 
(Yanez-Munoz et al. 2006; Apolonia et al, 2009).  We decided to modify this vector and 
augment its expression in the erythroid lineage with the addition of LCR sites HS2 and 
HS3, as present in the GLOBE vector. 
 
_______________________________________________________________________
Figure 3.5 - SEW lentiviral vector. The spleen focus forming virus (SFFV) LTR 
promoter/enhancer drives expression of an eGFP reporter gene. WPRE, the woodchuck 
hepatitis virus post-transcriptional regulatory element. Arrow denotes direction of 
transcription.  
The Friend spleen focus-forming virus (SFFV) is a highly pathogenic retrovirus 
that exclusively induces erythroleukemia in susceptible strains of mice within weeks of 
inoculation (Ruscetti, 1999). A number of studies have been performed using its LTR 
promoter/enhancer as an internal promoter in LV cassettes as it has been reported that it 
enhances long-term expression in primary human hematopoietic cells in vivo (Demaison 
et al, 2002). 
The SFFV promoter is cloned in SEW upstream of the eGFP reporter gene 
(Figure 3.5). The vector also contains the Woodchuck hepatitis virus post‐transcriptional 
regulatory element (WPRE), known to improve vector potency and increase transgene 
expression levels by facilitating the nuclear export of unspliced RNA to the cell 





Direct incorporation of the LCR HS2 and HS3 elements into SEW by blunt-end 
ligation proved to be a difficult cloning step. As an alternative strategy we inserted an 
oligonucleotide polylinker sequence upstream the LCR HS2/HS3 fragment in a 
previously designed sub-clone (MA89) to facilitate its isolation and subsequent sticky-
end ligation into SEW. 
MA89 is a construct with a pBluescript backbone containing LCR HS2/HS3 
elements inserted into in the plasmid’s polylinker SmaI site, which destroyed upon 
insertion (Figure 3.6). 
 
_______________________________________________________________________ 
Figure 3.6 – Incorporation of an Oligonucleotide sequence into pBluescript SmaI 
site. The oligonucleotide sequence introduced 5’ of HS3 in MA89 at the NotI site, 
contains EcoRI and XhoI sites, facilitating the removal of the LCR fragment as either an 
EcoRI or XhoI fragment (Figure 3.7) 
   5’      GCCCGCTACGTACTCGAGGAATTC               3’ 
   3’                 CGATGCATGAGCTCCTTAAGCCGG    5’ 
Not I            Sna BI      Xho I     Eco RI        Not I 
(compatible end)                                                       (compatible end) 
             does not re-form the Not I site 
_______________________________________________________________________ 
Figure 3.7 – The Oligonucleotide sequence  
MA89 (6kb) was linearised with Not I, whose ends are now compatible with those of the 





 The MA89 vector and the oligonucleotide were ligated and used to transform 
DH5 E. coli by the electroporation. Individual colonies were picked and grown as 5ml 
mini-cultures overnight. Plasmid DNA from the cultured cell colonies was isolated by the 
alkaline lysis extraction procedure and subjected to diagnostic restriction enzyme 
digestion using EcoRI and products resolved by agarose electrophoresis (Figure 3.8).   
 
                     (B) 
____________________________________________________________________________ 
Figure 3.8 – Digestions of mini preparatios obtained from the MA89/oligonucleotide 
ligation. EcoRI was used to release the LCR insert if oligonucleotide insertion was 
successful. (A) Samples 1 and 6 show the desired 2.7kb band containing the LCR HS2 
and HS3 sites. NEB 1kb ladder is shown on the far right lane.(B) Diagram showing that 
 the successful insertion of the polylinker oligonucleotide would give rise to a band of 
2.7kb (size of LCR HS2-HS3 sites).  
Plasmid from colonies 1 and 6 showed the desired 2.7kb LCR HS2-HS3 fragment 





















Figure 3.9 - Analysis of colonies 1 and 6 obtained from MA89/oligonucleotide 
ligation. (A) Lines 1, 2 and 5 refer to colony 1 (blue) digested with NotI (1), XhoI (2) and 
SnaBI (5). Lines 3, 4 and 6 refer to colony 6 (green) digested with SnaBI (3), XhoI (4) 
and NotI (6). Lines 7, 8 and 9 refer to the original MA89 vector (red) digested with XhoI 
(7), SnaBI (8), and NotI (9). (B) Diagram explaining fragments obtained upon digestion 
with NotI, SnaBI and XhoI. 
Confirmation tests were made by digesting the individual colony DNA with NotI, 
XhoI and SnaBI, the remaining sites present in the inserted oligonucleotide polylinker. 
Digestion with these showed positive results for the presence of the oligonucleotide 
polylinker and LCR HS2 and HS3 sites in the new vector (Figure 3.9) with isolation of 
the 2.7kb fragment by SnaBI (lines 3 & 5) and plasmid division into 2 3kb fragments by 
XhoI. Please note that colony 6 is partially undigested. The oligonucleotide sequence 
provides new restriction sites namely EcoRI, SnaBI and XhoI 5’ of HS3 in MA89. The 







ladder   1    2     3    4    5     6     7     8     9 
NEB 1kb molecular size marker 











3.4.2.1 Incorporation of the LCR HS2-HS3 elements into the SEW 
vector 
The SEW plasmid was linearised with EcoRI and treated with calf intestinal 
phosphatase (CIP) to avoid vector re-ligation. The vector was then purified and 
precipitated ready for the insert take up. 
The LCR fragment was removed from the MA945 construct via EcoRI digestion 




Figure 3.10 - Digestion of MA954 with EcoRI. The upper band is the pBluescript 
vector and lower band the 2.7kb LCR HS2-HS3 fragment.  
 
The initial EcoRI digestion of MA954 (Figure 3.10) was followed by a ScaI 
digestion. This cuts within pBluescript and allows clearer separation of the LCR and 
plasmid vector backbone after digestion with EcoRI. The digestion products were then 
resolved by agarose gel electrophoresis and the desired band excised and purified. 
A ligation reaction of the EcoRI linearised SEWs and LCR HS2-HS3 fragment 
was performed using a 3:1 insert ( LCR) to vector (SEW) ratio. The ligations were 


















transformed into electrocompetent LD GOLD E coli cells and spread on agar plates 
containing ampicillin and left to incubate overnight at 37ºC.  
 Colonies obtained were used to inoculate 5ml mini-cultures and incubated 
overnight. The mini-scale cultures were then subjected to alkaline lysis extraction of 
plasmid DNA. Plasmid DNA obtained from each culture of cell clones underwent 
appropriate diagnostic restriction enzyme digests and subsequent agarose electrophoresis 




Figure 3.11 - Digestion of plasmid mini-preps obtained from SEW/ LCR HS2-HS3 
fragment ligation with EcoRI. Mini-preps 3, 4, 5, 6, 7 and 10 were potentially correct 
giving the expected 2.7kb LCR HS2-HS3 fragment and were selected for further 
analysis. 
 
The plasmid mini-preparations were digested with EcoRI, which if correct would 
release the 2.7kb LCR fragment. On agarose gel analysis colonies 3, 4, 5, 6, 7 and 10 
were potentially correct (Figure 3.11) and were selected for further analysis.  
Selected individual plasmids preparations that gave a positive result from the 
EcoRI digestion (Figure 3.11) were digested respectively with AgeI (to double-confirm 
the presence of the insert) and Bam HI, which determines the insert orientation. AgeI 
disgests both the plasmid and the insert (A lanes, Figure 3.12) BamHI recognises a 
sequence in the original vector immediately 3’after the LCR HS2-HS3 fragment 
insertion and in the insert at its 5’ end, in the polylinker just before HS3 (HS2/HS3 







diagram, Figure 3.6). If the insert is placed in the original vector in the correct 
orientation; that is, resulting in the order HS3-HS2-SFFV promoter, the Bam HI digestion 
releases the LCR fragment (lanes 3B, 4B and 6B of Figure 3.12). On the other hand, if 
the insert has ligated in the reverse orientation, the two recognition sequences will be 
placed very close to each other and only a 12 kb fragment will be visible upon the gel 





Figure 3.12 - Analysis of plasmid mini-prep numbers 3, 4, 5, 6 , 7 and 10 from 
SEW/ LCR ligation (Figure 3.11). Plasmids were digested with either AgeI (A) or   
BamHI (B). 
  
Plasmids from colonies 3, 4 and 6 show the correct diagnostic digests (Figure 
3.12). Colony 4 was selected for further use and this new construct was designated as 
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 Figure 3.13 - Diagram of the LCR-SEW vector. The LCR together with the SFFV 




























3.4.3 Addition of another HB construct into this study 
 
As described previously (section 1.2.5), studies have shown that intron 2 of HBB is 
essential for promoting efficient mRNA 3’end formation (cleavage and polyadenylation) 
(Antoniou et al., 1998; Millevoi et al., 2002). With this in mind we decided to incorporate in 
this study a vector where the eGFP reporter gene is inserted between exons 1 and 2 of HBB. 
Although this HBB-eGFP cassette lacks parts of exons 1 and 2 as well as intron 1, it 
crucially retains intron 2. Therefore, this transcription unit consists of the following 
components; LCR HS2-HS3 sites, 265bp HBB promoter, 3’ half of HBB (partial exon 2, 
intron 2 and exon 3) and eGFP cDNA sequence inserted between exons 1 and 2 (Figure 
3.14). This -eGFP vector (MA951) was generated by Vincent Kao in the host 
laboratory.    
Generally, this expression vector design has been demonstrated to express a range 
of heterologous protein types rapidly and easily, including secreted products (Needham et 





Figure 3.14 - Diagram of the HBB-eGFP vector (MA951). Vector courtesy of Vincent 










3.4.4 CK-M and DES constructs 
 
Expression from ubiquitous regulatory elements from within an ID-LV context 
has been extensively documented (Apolonia et al., 2009; Yanez-Munoz et al., 2006). 
However, there is a lack of knowledge with regards to expression from tissue specific 
elements within this system. 
 
We therefore decided to broaden our study to also test muscle specific vectors as 
well as erythroid HBB cassettes in an ID-LV configuration. LVs  containing respectively 
human DES and CK-M promoter-enhancer elements driving expression of an eGFP 
reporter gene that were already available in the host laboratory  having been produced by 






Figure 3.15 - Desmin and CK-M LV vectors. (A) SIN LV with an internal Desmin 
promoter driving eGFP. (B) SIN LV with internal CK-M promoter driving eGFP. Both 












3.5 Analysing HBB tissue specificity in an integration deficient LV 
context 
 
This study was performed in K562, a human myelogenous leukaemia cell line 
(erythroleukemia type) derived from a 53 year old female patient with chronic 
lymphocytic leukaemia. This is a robust line of suspension cells with recent studies 
showing that K562 blasts are multipotential, hematopoietic malignant cells that 
spontaneously differentiate into recognisable progenitors of the erythrocyte, granulocyte 
and monocytic series. However, these cells do not require differentiation in order to 
display an erythroid character as they constitutively express embryonic -globin and 
foetal -globin, making them a good test system for this experiment.  
 
 
3.5.1 Lentiviral vector preparation and transduction of cell lines 
 
Lentiviral vectors were produced by transient co-transfection of HEK293T cells 
with 3 plasmids (the lentiviral vector, pMD.G2 [envelop plasmid], and pCMVΔ8.91 
[packaging plasmid] employing polyethylenimine (see section 2.2.3). Viral vector titre of 
eGFP-containing preparations was determined by transducing K562 cells with serial 




3.5.2 Transduction of K562 cells with integration proficient and 
integration deficient LV constructs 
 
Lentiviral vectors containing eGFP under control of the different HBB-based 
combinations and SFFV promoters were used to transduce K562 cells at a multiplicity of 





cell and therefore minimise the frequency of cells harbouring multiple integrations. 
Pictures of trasduced pools taken under fluorescent light emission microscope can be 
found in Figure 3.14. 
A total of 3 pools of transduced cells per construct were generated with identical 
amounts of virus to control for experimental reproducibility. Cells were collected and 
analysed for eGFP expression by flow cytometry at 3, 6 9 and 15 days post-transduction. 
In addition, cells were harvested at the same time points and DNA isolated for 



















































































Figure 3.14 - Images of GFP expression in K562 cells transduced with different LVs.  
Capture of the eGFP expression of K562 cell pools transduced in both integration 
proficient and deficient configuration. The pools were transduced with an equal initial 
viral amount (MOI of 3).  Exposure: t = 7s, f/4. Magnification:   SEW & LCR-SEW (ID 























3.5.3 Comparison of percentage of eGFP positive cells  
 
Figure 3.15, shows the percentage of eGFP positive cells in the pools of 
transduced K562 cells with the exclusive HBB-based vectors (GLOBE-GFP and HBB-
eGFP) and the SFFV promoter driven vectors (LCR-SEW and SEW) in both integration 
proficient (IP) and deficient (ID) vector configurations. 
 
The vectors in IP configuration showed a decrease in the number of eGFP 
positive cells by 3-fold over a period of 21 days, with all but the LCR-SEW reaching a 
plateau stage in the last days of the experiment. All 3 sample wells showed similar values 
with small variability (Figure 3.15, upper panel). 
 
The percentage of eGFP positive cells transduced with the ID vectors also 
decreased over time but on this occasion reached values close to zero by the end of the 
21-day period of the experiment (Figure 3.15, lower panel). A decrease in eGFP positive 
cells was evident with all constructs starting from between 3 and 6 days post-
transduction. However, in the case of both SFFV driven vectors a higher level of positive 
cells was maintained over the last two time points, even though the error bars in the ID 
graph (Figure 3.15, lower panel) are larger when compared with those in the IP analysis 
(Figure 3.15, upper panel), implying more variability between well samples. 
 
The initial drop in eGFP positive transduced cells in ID configuration was 
expected since these vectors remain in the nucleus as episomal DNA circles and are 
eventually lost by cellular division (see section 1.3.37).  
 
3.5.4 Mean Fluorescence Intensity (MFI) 
 
Figure 3.16 shows the different values obtained in Mean Fluorescence Intensity 
(MFI) for the constructs in both IP and ID configurations. The MFI measures the spread 






In the IP-LV experiment (Figure 3.16, upper panel) the population of positive 
cells retained expression at the same intensity throughout the experiment until the last 
analytical point. This consistent expression for all constructs can be interpreted as 
indicating no changes in active eGFP reporter gene expression from the transduced 
population of cells. 
 
In an ID-LV context (Figure 3.16, lower panel) the intensity of expression 
decreases by an average of 1-fold of the initial MFI. 
 
Interestingly, the vectors built as ID express initially with a much lower intensity 
than those in an IP configuration; at the first time point (day-3) IP vectors express within 
the range of 20-50 whereas the ID vectors show a range of MFI of 10-20.  
This observation raises questions about the feasibility of ID-LVs in the study of globin 
disorders. For any given therapy a given amount of initial intensity of expression is 
required – the search for a therapeutic approach for the haemoglobinopathies has shown 
that at least 30% of the vectors are needed to initial express. 
 
 
3.5.5 Coefficient of Variegation (CV)  
 
The coefficient of variegation (CV) is a normalised measure of dispersion of a 
probability of distribution of a given sample population. This accounts for the variation 
between individual cells in a given cell pool; that is, how much does each gated cell 
differ from another in level of expression.  
The CV measurement only makes sense in positively transduced cells, hence why 
it’s only possible to generate a graph with the IP-LV constructs (Figure 3.17). The 
results show that both constructs driven by a tissue specific promoter (HBB) interact with 
the HBB regulatory elements, causing sample variation. However, when a ubiquitous 





reduced. Interestingly, when HS2 and HS3 elements of the HBB LCR are added to SFFV 
the variation between samples diminishes considerably (LCR-SEW), which suggests that 
the inclusion of an HBB element accounts for the consistent expression and 


























Figure 3.15 - Percentage of K562 GFP positive cells in cell pools transduced with both 
IP (upper panel) and ID (lower panel) LV vectors at MOI 3 over a period of 21 
days. eGFP expression was determined by flow cytometry of K562 cell pools harbouring 
integration proficient (IP) and deficient (ID) lentiviral vectors containing and eGFP 
reporter driven by HBB, 3’ globin HBB and SFFV promoters. Points in the graph 
represent an average obtained for 3 pools (n=3) and the error bars the standard error of 
the mean. 
Statistical analysis was performed using one way ANOVA to detect statistical differences 
between population means. The decrease of expression in ID vectors (timepoint 3 to 
6days, lower panel) is highly significant when compared with the mean population in the 
same graph at different timepoints (P-value <0.001). Furthermore, the comparison of  
population means both in IP and ID graphs shows that the decrease of expression in ID 






















Figure 3.16 - Mean fluorescence intensity (MFI) of K562 cells transduced with both 
IP (upper panel) and ID (lower panel) LV vectors at MOI 3 over a period of 21 
days. MFI shows lower values in ID configuration when compared to IP vectors. 
However, readily detectable expression from erythroid-specific ID-LV is observed. 
Points in the graph represent the average obtained for 3 pools (n=3) and the error bars the 

















Figure 3.17 - Coefficient of variegation (CV) of eGFP reporter gene expression in 
K562 cells transduced with IP vectors at MOI 3 over a period of 21 days. CV of 
expression decreases with the addition of the erythroid-specific LCR elements to the 
ubiquitous SFFV promoter. Points in the graph represent an average number obtained for 











3.5.6 Vector copy number variation 
 
Determination of average LV copy number per cell of a given sample was only 
determined once the experiment reach its final stages.  
 
According to the results obtained (Figure 3.18), the K562 cells transduced with 
the IP-LVs containing the HBB elements are maintained and accumulate in the cell pool. 
In contrast the cells transduced with the SFFV vector show a decrease in average copy 
number per cell over the 15-day period of the analysis.  
In an ID-LV context (Fig. 3.18, lower panel), as expected the average vector copy 
number per cell markedly decreases over the 15-day period of the experiment due to 






















Figure 3.18 - Copy number variation in K562 pools transduced with IP 
(upper panel) and ID (lower panel) vectors (n=3). DNA extracted from transduced 
wells was used to determine average LV copy per cell.  The copy number increases in an 
IP configuration in correlation with % of positive cells with an exception for the SFFV 
driven vector. Vector expression regardless of vector copy number can be explained by 
the presence of the WPRE element, known to increase transgene expression by 
facilitating the nuclear export of unspliced RNA to the cell cytoplasm (Zufferey et al., 
1999). 


































3 days after transduction
15 days after transduction



































3 days after transduction





3.6 Analysing muscle specificity in an ID-LV context 
 
As referred to previously the evaluation of tissue specific expression from an ID-
LV context was extended to include vectors containing muscle-specific regulatory 
elements. The use of muscle specific vectors requires a different type of cell to be used. 
In this study we chose to use the murine myoblast cell line C2C12 (Section 2.1.9, Chapter 
2). These are a commonly used model system to study DES expression and other muscle 
specific systems, as the cells can easily be induced to fuse to form terminally 
differentiated myotubes in order to examine myogenic expression systems.  
 
 
3.6.1 Lentiviral vector preparation and transduction of C2C12 line 
  
Again, LV vectors were produced by transient co-transfection of HEK293T cells 
with 3 plasmids (the lentiviral vector, pMD.G2 [envelop plasmid], and pCMVΔ8.91 
[packaging plasmid]), employing PEI methodology. Viral vector titre was determined by 
transducing C2C12 cells with serial dilutions of the viral stock and monitoring expression 















3.6.2 Transduction of C2C12 cells with integration proficient and 
integration deficient LV constructs 
 
LVs were used to transduce C2C12 cells at MOI 3 in an attempt to achieve 
transduction of 1 vector copy per cell. A total of 3 pools of cells were transduced with 
identical amounts of virus per construct to monitor experiment reproducibility. 
Transduced cells were collected and pools were analysed by flow cytometry at 3, 6 9 and 
15 days post-transduction. 
DNA isolated from the cell pools was used to determine average vector copy number per 
cell. 
 
3.6.1 Comparison of percentage of eGFP positive cells 
 
Wells transduced with both muscle-promoter driven vectors (DES, CKM) were 
kept in culture for 15 days and were analysed for eGFP expression at 3, 6, 9 and 13 day 
time points. 
The muscle constructs in an IP configuration showed a relative constant eGFP 
expression along the time period of the experiment (Figure 3.19, upper panel). In an ID 
configuration (Figure 3.19, lower panel), the results show a visible decrease in the 
percentage of GFP positively expressing cells, again indicating ID vector dilution upon 
successive cell division.  
 
Both the DES and CK-M vectors showed the same pattern of expression over time 
in both in IP and ID configurations. As IP-LV both DES and CK-M gave expression per 
sample that decreased only slightly at each time point but with percentage of GFP 
expressing cells having possibly reached a plateau value by day-15 with the DES 
construct. With ID-LV, both DES and CK-M vectors suffered an abrupt loss between 
day-3 and day-6 and then a more gradual decline thereafter. It would be interesting to 
repeat this experiment for a longer period of time to access if expression with both IP- 






Studies with ID-LV configurations in skeletal muscle tissue in vivo have been 
reported previously (Yanez-Munoz et al., 2006; Apolonia et al., 2009). However, these 
studies were performed with non-muscle specific ubiquitous expression cassettes. In 
addition, due to the fact that, unlike tissue culture cells, in vivo myofibres are post-mitotic 
loss of expression was not so pronounced.  
 
 
3.6.2 Mean fluorescence intensity 
 
Both DES and CK-M muscle constructs maintained the initial intensity of eGFP 
expression throughout the study until the da-15 time point (Figure 3.20). However, it is 
interesting to notice that despite similar profiles in terms of percentage of eGFP positive 
cells (Figure 3.19), actual MFI differed significantly between the 2 muscle vectors in an 
IP context with DES showing a 2-fold higher level of expression than DES (Figure 3.20, 
upper panel).  
This higher MFI conferred by the DES construct over CK-M is not due to 
differences in vector copy number as these values between the two sets of transduced 
cells were very similar at both 3- and 15-days post transduction  
In an ID-LV context the muscle constructs have comparable MFI values 
throughout the experimental period (Figure 3.20, lower panel) with comparable average 
vector copy number per cell (Figure 3.22, lower panel). Again, as noted before with 
other vectors used in this study, the MFI of a given muscle vector in an ID configuration 
was always found to be lower when compared with the same vector built in an IP context.  
 
3.6.3 Coefficient of variegation  
 
Figure 3.21 shows that CV values were comparable and consistent over the 21-

















Figure 3.19 - Percentage of C2C12 eGFP positive cells in pools transduced with LVs in 
both an IP (upper panel) and ID (lower panel) configuration at MOI 3 over a period 
of 21 days. GFP expression was determined by flow cytometry analysis of C2C12 cell 
pools harbouring lentiviral vectors of both DES and muscle creatine kinase (CK-M) 
promoter driven constructs. Again,  one way ANOVA to detected  statistical differences 
between population means in an ID and IP context (P-value <0.05). Points in the graph 
































Figure 3.20 - Mean fluorescence intensity (MFI) of C2C12 cells transduced with 
Desmin and CKM LV in both IP (upper panel) and ID (lower panel) configurations. 
Cells were transduced at MOI 3 and eGFP expression monitored by flow cytometry at 
































Figure 3.21 - Coefficient of variegation exhibited by C2C12 cells transduced with 
DES and CK-M IP-LVs at MOI 3 over a period of 21 days. Error bars refer to the 




























3.6.4 Vector copy number  
 
DNA was isolated from cell samples and used to determine average vector copy 
number per cell at the different time points of the experiment (Figure 3.22). The vector 
copy number per cell in the IP-LV transductions was similar with both DES and CK-M 
constructs and did not alter significantly from initial 3-day time point to the final sample 
taken at 15-days. Both muscle constructs decreased their amount of vectors per well the 
upper panel on Figure 3.22, shows a vector copy number decrease from 6 to 5 for DES 
and 7 to 5 for CKM.  
 
Unsurprisingly, the average vector copy number per cell in samples transduced 
with ID-LV decreased significantly, as these episomal vectors were expected to be 
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_____________________________________________________________ 
Figure 3.22 - Copy number variation in C2C12 cell pools transduced with IP (upper 












3.7.1.1 Comparison of HBB driven IP-LV and the inclusion of an HHB 
specific element into a ubiquitous expression promoter  
 
It is interesting to note that despite the inclusion of the 3’ half of HBB with a 
heterologous cDNA sequence into the GLOBE-GFP vector, the 3’GLOBE-GFP construct 
did not show any significant increase in expression over the sense orientation construct 
(GLOBE-GFP). The two vectors have similar profiles for GFP expression and MFI, with 
comparable copy numbers.  
  
Interestingly, the LCR-SFFV vector shows a lower value for CV (Figure 3.17), 
better than both HBB-based vectors (3’GLOBE-GFP and GLOBE-GFP) and the SFFV 
promoter alone (SEW), with far less variation between individual samples (reduced error 
bars). These results show the specificity of the LCR element and show that the element 
dominantly interacts with a heterologous viral, which is able to largely negate 
interference nearby host gene elements at the site of vector integration, thereby enhancing 
erythroid expression. The obvious differences between the two SFFV driven constructs 
are caused by the presence of the LCR. 
 
 
3.7.1.2 Comparison of muscle specific IP-LV  
 
The muscle specific LVs tested in this study show similar with regards to eGFP 
positive cells and copy number. The 2 vectors differ only as the CK-M driven vector 
showed higher values of MFI in IP context, suggesting that the expression per copy 







All vectors used in this study either ubiquitously expressing (SFFV driven) or 
tissue specific (HBB and muscle DES / CK-M specific), were produced without major 
complication and expressed from both IP an ID configurations. As initially expected, the 
expression of ID constructs decreased significantly following successive rounds of cell 
division and reached values close to zero in some vector configurations.  
Nevertheless, this study demonstrates that tissue specific as well as ubiquitously 
promoters can express from an ID context initially, even if at low intensity levels. 
 
 
3.7.2.1 Vector ability to express in an integration deficient configuration 
can be extended to a tissue specific context 
 
All constructs are able to express initially in an ID configuration. This expression 
is though, in general at a lower level per vector copy when compared to the same cassette 
packaged as a standard integration LV.   
ID expression is variable; note, for instance, the size of the error bars in Figure 3.15 
(lower panel) and Figure 3.19 (lower panel) indicating high variability between pool 
samples). 
 
3.7.2.2 Comparison of ID-LV driven by muscle specific promoters 
 
Overall both muscle constructs express when in an ID-LV configuration, at least 
at early time points following transduction, however this expression drops 3 days after 
transduction. To be sustained and harbour expression for a longer time period in an ID 
context, muscle driven vectors must transduce at higher MOI values (MOI of 1 used in 





3.7.2.3 HBB LV constructs versus muscle LV constructs in ID 
configuration 
 
According to the results presented over a period of 15 days, the percentage of 
eGFP positive cells in HBB driven constructs drops more abruptly from day-3 following 
transduction (Figure 3.15)  when compared with the muscle specific DES and CK-M 
vectors (Figure 3.19). Although, it is should be noted that the initial vector copy number 
for both muscle vectors in C2C12 cells is 10 and 14 respectively for DES and CK-M, 
(Figure 3.22) which is higher than the values for obtained for the HBB driven constructs 
(Figure 3.18). Therefore, it will take longer for dilution of ID-LV through cell division in 
the case of the muscle than the HBB LVs.      
It is therefore possible to say that according to our results, the higher the initial 
copy number values of a transduced cell population, the slower the drop in vector in the 

















3.7.3 Concluding Remarks 
 
 Our experiments provide evidence that the utility of ID-LV can be extended to 
provide tissue-specific as well as varying degrees of ubiquitous therapeutic gene 
expression depending on the control elements used. 
 
 Expression levels from all vectors analysed in an ID-LV configuration is always 
lower than the corresponding vector in an IP-LV configuration.    
 























3.8 Consequences for potential use of ID-LV for gene therapy of the 
haemoglobinopathies 
 
During this series of experiments the results obtained with non-integrating 
lentiviral vectors although positive, showed that expression from within an ID context is 
far lower per vector copy than with the same construct delivered through a standard 
integrating configuration.  
Given these results is was clear that a high vector copy number per cell would 
have to be delivered to achieve a therapeutic effect for the haemoglobinopathies. This is 
in addition to assuming that the problem of ID-LV replication and retention can also be 
solved.  
It was therefore decided that that the construction of a therapeutic globin LV in an 
integration deficient configuration would fail to provide therapeutic values for rescue of 
erythropoiesis and the project certainly needed to evolve into other research pathways. 
With all this in mind, we decided to focus our attention on the improvement and 






















COMPARATIVE ANALYSIS OF UCOE-BASED LENTIVIRAL VECTORS IN A 

















4.1. Aims of Chapter Four 
 
 Perform a comparative analysis of UCOE-based lentiviral vectors in a murine 
neonatal intravascular delivery model system 
 

























Ubiquitous chromatin opening elements (UCOEs) consist of methylation-free 
CpG islands extending over dual divergently transcribing promoters of housekeeping 
genes and have been found to be resistant to heterochromatin-mediated silencing 
(Antoniou et al., 2003; William et al., 2005; Lindahl Allen & Antoniou, 2007). Recent 
work has shown that the human HNRPA2B1-CBX3 UCOE (A2UCOE) gives rise to 
reproducible and stable expression that is resistance to silencing from within a self-
inactivating (SIN) lentiviral vector context (Zhang et al., 2007; Zhang et al., 2010). 
 
In the search for the optimal vector to be employed for haematopoietic cell 
marking following in utero delivery, we conducted experiments via intravascular delivery 
in day-old neonatal mice to assess the reproducibility and stability of expression from a 
series of UCOE-containing lentiviral vectors either alone or linked to the human 
Cytomegalovirus (CMV) promoter/enhancer. 
 
 
4.2.1 The UCOE element 
 
The Ubiquitous Chromatin Opening Element (UCOE) used in these studies is an 
enhancer-less element that consists of a methylation-free CpG island encompassing dual 
divergently transcribed promoters of the heterogeneous ribonucleooprotein HNRPA2B1 
(A2) and chromobox homologoue 3 (CBX3) housekeeping genes (Antoniou et al., 2003; 
Williams et al., 2005). 
 
This UCOE is able to give constant and stable transgene expression in tissue 
culture cells (Antoniou et al., et al., 2003; Williams et al., 2005; Zhang et al., 2007 & 
2010) and in mice (Katsantoni et al., 2007; Zhang et al., 2007 & 2010). In addition, it is 
also able to avoid transcriptional silencing and position effect variegation (PEV) 





(Antoniou et al., 2003). These observations imply that this UCOE functions as a 
dominant chromatin remodeling or opening element to prevent transgene silencing. 
However, only transgene constructs extending over both HNRPA2B1 and CBX3 
promoters, and not HNRPA2B1 alone, is able to give stable transgene expression and 
prevent from silencing (Antoniou et al., 2003).  
 
In 2003 Antoniou and colleagues (Antoniou et al., 2003) showed for the first time 
that transgenes containing a 2kb fragment spanning the dual divergently transcribed 
promoter region of the HNRPA2B1-CBX3 (driving expression of a eGFP reporter gene) 
was sufficient to prevent transcriptional silencing and a variegated expression pattern 
when integrated into heterochromatin.  
 
More recently it has been shown that the same  2.2kb HNRPA2B1-CBX3 UCOE 
(A2UCOE) within an LV context produces a consistently high and stable expressing 
population of cells that were not prone to gene silencing in vitro and in HSC and 
peripheral blood cells in vivo (Zhang et al.,. 2007; Zhang et al., 2010). This is in marked 
contrast to LVs containing either SFFV or CMV-regulated constructs (eGFP transgene), 
which showed extensive silencing. These results suggest that this HNRPA2B1-CBX3 
UCOE (A2UCOE) was efficiently able to abolish progressive silencing and PEV of a 
stably integrated transgene over time in a cell line or in vivo and also reflects its dominant 
chromatin opening function. Furthermore, ex vivo delivery of an A2UCOE-IL2RG LV to 
HSC of a murine model of SCID-X1 was able to completely rescue the disease condition 
at low (1/cell) vector copy number (Zhang et al., 2007). 
Most recently, the A2UCOE has been shown to stabilise expression from the 
neutrophil-specific MRP8 promoter without compromising specificity and with an 
A2UCOE-MRP8-gp91phox LV able to efficiently rescue the disease phenotype in a 







4.2.2 The Cytomegalovirus (CMV) promoter 
 
The human cytomegalovirus promoter (CMV) is a ubiquitous promoter that 
contains a strong enhancer region and despite its vulnerability to position effects, is 
commonly used to drive reporter genes in various tissues and cells. It was therefore used 
as a constitutive comparison in this study. The construct used was a 7.4kb Sin-18 
























4.3 Vectors in this study 
 
In this comparative study we used LVs previously constructed in the Antoniou 
group and/or by collaborator laboratories. We chose to use the A2UCOE given the 
reports of consistent and reproducible expression obtained with this element in HSC and 
peripheral blood cells in vivo ((Zhang et al., 2007; Zhang et al., 2010; Brendel et al., 
2011). Vectors contained an eGFP reporter transgene driven either directly from the 
HNRPA2B1 promoter (Antoniou et al., 2003; Zhang et al., 2007) or a CMV promoter 
with the core A2UCOE linked upstream of this element (Williams et al., 2005) (Figure 
4.1) . 
 
The A2UCOE and CMV vectors were designed in the Antoniou laboratory, with 
the A2UCOE-EGFP and A2UCOE-CMV vectors provided by Gillian Talbot and the 
UCOE-EGFP-WPRE construct by Pascal LeClere. 
 
The vectors employed are self-inactivating (SIN) due to a deletion of the U3 
region within the 3’ LTR. Therefore, only the internal promoter is active from the 




















Figure 4.1 Diagrammatic illustration of lentiviral vectors. All vectors employ an 
enhanced green fluorescent protein (eGFP) reporter gene. (A) CMV promoter construct 
(Follenzi et al., 2000) (B) A2UCOE driving expression from the HNRPA2B1 promoter 
(Zhang et al., 2007); (C) as (A) but with a 1.5kb core A2UCOE fragment linked 
upstream of the CMV promoter (Williams et al., 2005); (D) as (B) but with the WPRE 
inserted downstream of eGFP. WPRE, woodchuck hepatitis virus post-transcriptional 
regulatory element.  The vectors are self-inactivating (SIN) due to a deletion of the U3 





   U3    R    U5    SIN    R    U5 
   U3    R    U5    SIN    R    U5 
   U3    R    U5    SIN    R    U5 
   U3    R    U5    SIN    R    U5 
  
















CBX3  A2 
CBX3  A2 











Viral vector titer of EGFP-containing preparations was determined by transducing 
HEK293T cells cells with serial dilutions of virus and monitoring expression after 3 days 
FACS analysis. Titres ranged from between 5-10x10
8
 transducing units/ml.  
 
4.4.1 Vector studies performed in vitro 
 
Lentiviral vectors were used to transduce HEK293T cells cells at a MOI to 
achieve 30-40% eGFP positive cells by FACS analysis. 3 pools of cells were transduced 
with identical amounts of virus per construct. Transduced cells were collected and FACS 

















4.4.1.1 In vitro Results 
 
All vectors used in this study (Figure 4.1) were tested initially in vitro. Figure 
4.2 collates the images from the transduced wells and information obtained by FACS 
analysis, graphs with eGFP fluorescence and CV values. 
 
Upon analysis of Figure 4.2 it is important to note that the negative control 
sample shows a positive value for coefficient of variation (CV) due to a small number of 
cells being present in the positive quadrant in the histogram for eGFP expression. This is 
due to mis-placement of the gate arising from inexperience of FACS machine operation 
by the operator/student in training. One should have gated the negative population so that 
no cells were present in the positive quadrant and, only then, carry on with the FACS 
analysis. Nevertheless, this initial experiment is still informative as it gave an indication 
of relative vector performance.  
 
The results show a clear difference between populations transduced with 
A2UCOE-based vectors and the CMV promoter alone construct and negative control. 
(Note: cells were transduced so that populations exhibit 20-40% eGFP positivity to avoid 
multiple copy integration per cell. Photographs were taken with the same exposure: t = 
7s, f/4). This is a mere qualitative result but its evident that populations transduced with 
the A2UCOE-based vectors show an overall greater green fluorescence and are less 
prone to island clusters of EGFP positive cells (Figure 4.2A). 
 
FACS plots showing eGFP expression of each transduced cell population can be 
found in Figure 4.2B. Again quantitatively it is possible to say that both CMV-UCOE 
and UCOE-WPRE show a much higher and consistent expression, with cell populations 
expressing equally. The cell population transduced with the A2UCOE-eGFP vector 
shows a lower but more consistent pattern of expression than that obtained with the 
CMV-eGFP vector as evidenced by the lower CV value (191 for CMV vs 123 for 










The CV values represent the variation amongst positively transduced cells, or the 
difference between individual cells in a given cell pool; that is, how much does each 
gated cell differ from another in relative level of expression. Figure 4.2C shows sample 
variation when transduced with different vectors - both constructs containing the CMV 
promoter (CMV and CMV-UCOE) display 2 individual  peaks of cell populations 
whereas in wells transduced exclusively with the A2UCOE vectors (UCOE and UCOE-
WPRE) show a single peak.  
CV values alone also show the reproducibility in the UCOE and UCOE-WPRE  
vectors, with the CMV vectors presenting much higher variation (191.47 and 160.93) 
than the exclusive UCOE  constructs (123.47 and 137.06).  
 
These in vitro studies show that the addition of the WPRE has a positive effect on 
reporter gene expression. There is a clear shift to higher levels of expression when the 
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Figure 4.2 Expression analysis of lentiviral vectors in HEK293T cells. HEK293T 
cells were transduced with the different lentiviral vectors (Figure 4.1) at a multiplicity of 
infection to achieve 30-40% eGFP positive cells by flow cytometry analysis. (A) 
Fluorescence microscope images taken with exposure: t = 7s, f/4. (B) Flow cytometry 
plots of percentage eGFP positive cells. (C)  Flow cytometry analysis of tranduced cell 



















4.4.2 Vector studies performed in vivo  
 
The results obtained with the 4 vectors in vitro (Figure 4.2) were next expanded 
on by conducting a comparative study in vivo. 
 
4.4.2.1 Neonatal injections 
 
Wild-type neonate mice were injected intra-vascularly with 40 l of the viral 
suspension (1-2x10
8
) via the superficial temporal vein 6-12 h post- birth. The pups were 
anaesthetised by being kept on ice for a few minutes, as due to their small size and 
limited resistance the pups cannot withstand any other form of anaesthesia. The injection 
was performed under a stereo microscope taking care not to inflict damage to any vital 
organ/ tissue that would result in tissue malfunction/death.  
A small number of pups were rejected by their mums post-injection. 
 
Injected mice were sacrificed at 6 weeks post-injection. By then all mice showed 
normal tissue morphology and there were no visible signs of vector toxicity. IIndividual 
tissues were collected from the carcases for determination of vector copy number and 




















Figure 4.3 Fluorescence stereomicroscope images of liver samples from neonatally injected mice at 6 weeks post-injection. 
Wild-type mice were injected intra-vascularly via the superficial temporal vein with 40 l of viral vector suspension. Animals were 
sacrificed 6 weeks post-injection and freshly excised liver observed under a fluorescence stereomicroscope. Images are representative 













Figure 4.3 Fluorescence stereomicroscope images of liver samples from neonatally 
injected mice at 6 weeks post-injection. Wild-type mice were injected intra-vascularly 
via the superficial temporal vein with 40 l of viral vector suspension. Animals were 





















4.4.2.2 Post-mortem analysis (6 weeks after neonatal injection) 
 
Liver, spleen, heart and lung were collected from animal carcases. Individual 
tissues were placed in PBS solution and macerated using a sonicator to obtain a smooth 
homogenate, from which DNA could be extracted (see section 2. 2.5.1). 
Vector copy number was determined by quantitative PCR employing the TaqMan system 
(see section 2.2.3.4.2 Chapter 2). 
 
In order to determine eGFP protein levels, an ELISA approach was used and 


























4.4.2.3 eGFP expression per copy number 
 
The results for copy number estimation via qPCR of both liver and spleen, are 
shown in Tables 4.1 and 4.2. Vector presence was not detected in either heart or lung 
tissues in the qPCR runs performed and neither was eGFP protein found in these organs 
by ELISA analysis. 
Liver 
CMV UCOE CMV UCOE UCOE WPRE 
1.3 1.3 0.7 1.5 
0.7 1.2 0.6 0.8 
1.3 0.7 1.2 0.7 
2.0 - 1.5 1.2 
- - - 0.9 
Average 1.3 Average 1 Average 1 Average 1 
_______________________________________________________________________ 
Table 4.1 - Average LV copy number obtained by qPCR in liver tissues. Individual 
tissues were macerated and DNA extracted to determine vector copy number per cell 
using qPCR. Individual DNA samples were run in triplicate (n=3) and vector presence 
estimated by reference to an internal gene control (GAPDH) and a cell sample of known 
vector copy number value. 
 
Spleen 
CMV UCOE CMV UCOE UCOE WPRE 
0.7 0.6 0.6 0.3 
0.3 0.3 0.6 0.7 
0.3 0.6 0.5 0.7 
0.5 - 1.1 1 
- - - 0.6 
Average 0.4 Average 0.5 Average 0.7 Average 0.7 
_______________________________________________________________________ 
Table 4.2 - Average LV copy number obtained by qPCR in spleen tissues. Individual 
tissues were macerated and DNA extracted to determine vector copy number per cell 
using qPCR. Individual DNA samples were run in triplicate (n=3) and vector presence 
estimated by reference to an internal gene control (GAPDH) and a sample of known 





It is known that injection via the superficial temporal results in fluid travelling 
into the mouse liver before spreading throughout the rest of the body via blood stream. 
Therefore, it is no surprise that large amounts of vector were found in mouse liver. 
Similarly, because the spleen is mainly responsible for the deposition of red blood cells, 
we were expecting large numbers of positively transduced cells in this organ. 
 
Protein samples collected from mouse tissues were used to perform an eGFP 
ELISA to determine vector expression in individual organs. The results obtained for this 
experiment were normalized according to copy number and are shown in Figure 4.4. 
 
The CMV-eGFP construct showed relatively low levels of expression per LV 
copy number in both liver and spleen cells. Given that the viral vector preparations 
injected contained approximately similar amounts of viral particles in suspension, it is 
possible to say that this vector presents more difficulties in transducing murine cells than 
the construct in which the A2UCOE element is present. 
 
UCOE-eGFP and UCOE-CMV-eGFP vectors performed similarly, with relative 
expression per copy in the liver and higher expression in the spleen. The UCOE-CMV 
vector showed expression levels very similar to the other UCOE vectors in this study, 
suggesting that the CMV promoter can be influenced by the UCOE element.  
 
Finally, the A2UCOE construct containing the WPRE element (UCOE-WPRE) 
showed a surprisingly high eGFP expression per vector copy number in liver and a 
positive expression also in the spleen although lower than the other UCOE-containing 
constructs (Figure 4.4). One possible explanation to this result is that the transduced cells 
are still in the circulation (and somehow acquired advantage over untransduced cells in 
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Figure 4.4 Expression of lentiviral vector constructs in vivo. DNA was extracted from 
murine tissues after systemic administration of lentiviruses and vector copy number per 
cell determined by qPCR employing the TaqMan system (Tables 4.1 and 4.2). eGFP 
protein levels were determined by ELISA and values normalised with respect to vector 
copy number. (A) The table presents the final values obtained and the graph (B) shows 
the eGFP expression per vector copy number. Vector presence and expression were not 
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4.5.1 Incorporation of A2UCOE avoids vector silencing 
 
Given that the values for copy number for each vector were within the same range 
(Tables 4.1 and 4.2), the most probable cause for the lower values of expression per copy 
number with the CMV vector (Figure 4.4) is disturbance of the vector’s expression by 
insertion site position effects. Indeed, previous studies have reported that this promoter is 
highly prone to DNA-methylation mediated silencing (Strathdee et al., 2006: Zhang et 
al., 2007)  
 
All vectors driven by the A2UCOE element showed good eGFP expression in the 
2 tissue samples analysed (Figure 4.4). The expression values vary according to different 
vector design but, in this experiment, expression is confined to the UCOE vectors. This 
observation together with previous studies (Nair et al., 2011) showing promoter 
exclusivity suggest that the UCOE element is capable of rescuing the vector from 
eventual silencing caused by DNA methylation and insertion site position effects, 















4.5.2 The search for an ideal vector for in utero injections 
  
The ideal vector has to be capable of transducing effectively cells in the foetal 
liver since we are aiming to target HSC in this organ, before these cells migrate to the 
bone marrow compartment, which starts at approximately 14-16 days of gestation (refer 
to Introduction of both, Chapter 5 and 6). 
 
Naturally hepatocytes are also going to be targeted by the LV in addition to HSC 
in the foetal liver. However, recent studies have shown that LV toxicity is very low and 
it’s important to notice that all animals injected (n=3) presented normal tissue 

























4.5.1 Conclusion remarks 
 
 Our data suggest that the A2UCOE is capable of rescuing insertion site position 
effects commonly associated with the CMV promoter, as well as on its own and 
to provide stable, consistent and reproducible levels of gene expression required 
for a safe, controlled gene therapy approach. 
 
 A2UCOE driven LV construct containing both an eGFP reporter gene and the 
WPRE provided a highest degree of expression in comparison with the other 
vectors tested 
 
We therefore decided to use the UCOE-EGFP-WPRE vector for in utero HSC 















DEVELOPMENT OF IN UTERO GENE THERAPY APPROACHES 















 Determine the optimal time of in utero gene therapy vector delivery in mice, prior 
to the switch of haematopoiesis from the foetal liver to bone marrow 
 























5. 2. Introduction 
 
5.2.1 In utero gene therapy 
 
Somatic gene delivery in utero is an approach to gene therapy for genetic diseases 
based on the hypothesis that prenatal intervention may avoid the development of severe 
manifestations of early-onset disease with permanent correction by stable transduction of 
relevant foetal progenitor cell populations. 
 
In the investigation described in this Chapter, injections in utero aim to deliver 
LVs to the HSC population located in the foetal liver. This methodology takes advantage 
of the large scale migration of stem and progenitor cells to multiple organ compartments 
that occur during foetal development, with therapeutics providing treatment in time to 
prevent the development of severe disease manifestations. The approach is less likely to 
cause an immunological reaction due to foetal predisposition of immune tolerance to 
therapeutic transgenic proteins 
 
 
5.2.2 Murine haematopoiesis 
 
Delivery in utero aims to target the haematopoietic system at a specific site of 
haematopoiesis. Haematopoiesis is the process by which immature precursor cells 
develop into mature blood cells (Figure 5.1). 
 
Haematopoiesis in mice first occurs in the blood islands of the yolk sac and the 
aorta-gonad-mesonephros (AGM) region, 7 days post-conception (dpc) and lasts in these 
areas until 13 dpc. HSC activity is simultaneously detected in the placenta around 11 dpc. 
The next wave of haematopoiesis begins in the foetal liver at 12 dpc and in the spleen 
at15 dpc. HSC activity is subsequently detected in BM as early as 17.5 dpc, from where it 




and relocation of HSC are thought to be regulated by chemokines as well as adhesion 
molecules (Kikuchi & Kondo, 2006). 
 
In addition to the different sites of hematopoiesis, it is known that HSC acquire 
different properties and differentiation potentials during  ontogeny; RBC derived from 
haematopoiesis in the yolk sac are primitive nucleated erythrocytes containing embryonic 
haemoglobin, whereas erythrocytes derived from the foetal liver or BM are non-




Figure 5.1. Schematic illustration of murine haematopoiesis switching.  Mouse 
haematopoiesis starts in the yolk sac and shifts to the liver at gestational stage E14. A 
second switch in the site of haematopoiesis occurs again at E16-E17.5 with stem cells 








5.2.3 Luciferase reporter gene 
 
The aim of part of this project was to test A2UCOE-based vectors with different 
reporter gene systems, since each possesses distinct advantages. Luciferase was used as a 
reporter to assess in vivo transcriptional activity in mice injected in utero with LVs 
containing the luciferase gene driven directly by the HNRPA2B1 promoter of the 
A2UCOE.   
 
Luciferase emits light in the presence of a luciferin and ATP as substrate. Photon 
emission can be detected by a light sensitive apparatus such as a luminometer or 
modified optical microscopes. In this study imaging in vivo of treated mice employed the 
IVIS Imaging 50 Series (Xenogen) system, which measures photons from 
bioluminescence after intraperitoneal injection of luciferin. This system allows 
observation of biological processes in vivo, with the vector’s presence and expression 





















5.3 In utero injection of eGFP reporter gene vectors 
 
5.3.1 LV used in this study 
 
The initial in utero injections were conducted with the best candidate vector 
accessed previously using a neonatal delivery approach as described in Chapter 3. This 
SIN LV contains the A2UCOE driving expression of an eGFP reporter gene and a WPRE 




Figure 5.2 - Schematic illustration of the UCOE-eGFP-WPRE SIN LV. The vector 
contains the A2UCOE  element driving expression of an eGFP reporter gene. The WPRE 
element is known to increase vector potency and transgene expression by facilitating  
transcript nuclear export. 
 
 
5.3.2 Vector preparation 
 
UCOE-GFP-WPRE was prepared as previously described (section 2.2.3). Viral 
stocks were titred by serial dilution and concentrations determined by flow cytometry 
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5.3.3 In utero injections  
 
Note: In utero procedures were conducted by Dr Simon Waddington. 
Pregnant female MF1 mice at 14 and 16 days post-conception were used in this 
study. The procedure of intravascular injection into foetuses was similar to that 
previously described (Schachtner et al., 1999; Waddington et al., 2004; see section 
2.2.4.2, Chapter 2).  Briefly, under isoflurane anesthesia, each horn of the gravid uterus 
was exposed through a full-depth midline laparotomy (Figure 5.3). A 34-gauge needle 
was used to perform a transuterine injection of 20 l viral suspension into the vitelline 




Figure 5.3. Exposure of murine uteri prior to foetal injection. 
 
The laparotomy was closed in 2 stages, using interrupted stitches of 6-0 silk 








5.3.4 In utero time points of delivery, E14 and E16 
 
Initial in utero injections were a study to investigate targeting of the 
haematopoietic system.  Various reports have been published describing the site of 
haematopoietic switching to and from the foetal liver (Kikuchi & Kondo, 2006; Yoder, 
2007) but fail to time the migration of different HSC progenitors to and from foetal liver. 
An ideal timing of in utero injection should target not only the erythroid precursor cells 
but maximum numbers of HSC. We therefore decided to test 2 gestational time points, 






Figure 5.4 - Schematic illustration of in utero injections performed in pregnant 
mice. All in utero injections were performed during the time window of between E14 and 










5.3.5 Blood collection and analysis by flow cytometry  
 
 
Blood was collected from mice 90 days post injection with animals under 
isoflurane anesthesia. Blood was mixed with anticoagulant solution (0.109 M sodium 




Analysis of peripheral blood samples was conducted by staining with the 
appropriate antibodies for individual cell blood types, as shown in Table 5.1. 
 
Antibody Specificity 
Ter119 Monoclonal antibody Ter119 recognizing a component of glycophorin 
A and specifically marks late stages of the murine erythroid lineage 
(Kina et al., 2000) 
CD11b Monoclonal antibody CD11b recognizing mainly monocytes/ 
macrophages, granulocytes and microglia (Campanella et al., 2002) 
CD19 CD19 protein is expressed on follicular dendritic cells and B cells. It 
is present on B cells from earliest recognizable B-lineage cells during 
development to B-cell blasts but is lost on maturation to plasma cells  
(Tedder & Isaacs, 1989) 
_______________________________________________________________________ 




Collected blood was divided into 50 l aliquots for staining as described in section 
2.2.5.7, Chapter 2. Briefly, whole blood was used for Ter119 staining. Staining for 
CD11b the cell aliquot was lysed prior to any antibody incubation. After washing and 




increase murine specificity of the antibody). Samples were further incubated with control 
isotype antibody (coupled with PE, APC or FITC as appropriate) or specific antibody 
followed by another wash and fixation step in PBS solution containing 4% of 
formaldehyde. Individual stained samples were then analysed by flow cytometry against 





























5.3.6 Results obtained from cellular staining of peripheral blood 
collected from mice injected in utero with the UCOE-eGFP-WPRE 
vector, 90 days post injection 
 
The results obtained from the cellular staining of peripheral blood collected from 
mice injected at E14 are shown in Figures 5.5 to 5.9 
 
 Figure 5.5 shows the overall pattern obtained for each injected mouse 
compared to the uninjected controls. (The figure displays a representative 
mouse - mouse number1). 
 
 The graphs in Figures 5.6 to 5.9 depict the percentage of cells expressing 
positively for a given antibody - Ter119, Cd11b and CD19 (the former 
exclusively at E16) - and eGFP simultaneously, and compared with the 



















5.3.6.1 Cellular staining of peripheral blood collected from mice injected 














Figure 5.5 - Staining of peripheral blood cells collected from a representative mouse 
injected in utero at E16. A) The plots compare blood staining with different conjugated 
antibodies (FL2) against expression of eGFP (FL1). B) Upper panels represents the 
average staining pattern of an un-injected mouse, with the gate set with regards to the 
first panel (yellow) (injected, unstained) and variation from this staining pattern is shown 
in the remaining plots. (C) Lower panels Ter119 antibody detects mature erythrocytes, 
CD19 detects B cells and CD11b the monocyte population. FL1= eGFP ; FL2= APC or 
PE. As the results are similar for each stained peripheral blood sample, one representative 
profile is presented. Individual results for each mouse can be found in Figures 5.6 - 5.9. 
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5.3.6.2 Cellular staining of peripheral blood collected from mice injected 
in utero at E14 at 90 days post injection 
 
5.3.6.2 .1 Cellular staining with Ter119 
 
As can be seen in Figure 5.6, the percentage of cells with simultaneous Ter119 
staining and eGFP expression is significantly higher than the (unstained) population 
expressing only eGFP, in some cases reaching values close to 10-fold higher (mouse 1, 5, 
6, 7 & 8). The graph compares two populations of cells; the population expressing only 
eGFP (unstained) and the population expressing eGFP and fluorescing positively for the 



























Figure 5.6 - Staining of peripheral blood cells collected from mice injected in utero 
at E14 with Ter119 to highlight the erythroid population. Mice were injected in 
utero at E14 with 20 l of UCOE-eGFP-WPRE vector and subsequently bled at 90 
days post injection. Control sample (blood from uninjected mice unstained) was used to 
gate the flow cytometry and used as a standard for the analysis of blood samples of 
injected mice, stained (red) and unstained (blue). The graph shows the variation of 
stained and unstained cell populations.  Each pair of stained and unstained histogram bars 











5.3.6.2.2 Cellular staining with CD11b 
 
CD11b staining of cells from E14 injected fetuses is shown n Figure 5.7 The 
results show that the monocyte population in the blood sample is positively stained, in 
some cases up to 4-fold higher (mouse 1, 2, 6 & 7). However, mouse number 3 is an 




Figure 5.7 - Staining of peripheral blood cells collected from mice injected in utero 
at E14 with CD11b to highlight monocytes. Mice were injected in utero at E14 with 
20 l of UCOE-eGFP-WPRE vector and blood samples collected 90 days post injection. 
A control blood sample from uninjected mice that was unstained for  CD11b was used to 
appropriately gate the flow cytometry analysis and was used as a standard for the analysis 
of blood samples of injected mice, stained (green) and unstained (blue). The graph shows 
the variation of stained and unstained cell populations.  
 




5.3.6.3 Staining of peripheral blood cells collected from mice injected in 
utero at E16 at 90 days post injection   
 
5.3.6.3 .1 Staining of cells for Ter119  
 
 As before the number of cells positively staining for Ter119 and simultaneously 
expressing eGFP is about 10-fold higher than the population expressing exclusively 
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Figure 5.8 - Staining of peripheral blood cells collected from mice injected in utero 
at E16 for Ter119 to highlight the erythroid population. Mice were injected in utero at 
E16 with 20 l of UCOE-eGFP-WPRE vector and bled 90 days post injection. A control 
blood sample from uninjected mice that was unstained for Ter119 was used to 
appropriately gate the flow cytometry analysis and used as a standard for the analysis of 
blood samples of injected mice, stained (red) and unstained (blue). Each pair of 










5.3.6.3.2 Cellular staining for CD19 and CD11b  
 
The number of cells positively staining for CD19 and simultaneously expressing 
eGFP is overall 1-fold higher than the population expressing exclusively eGFP (Figure 
5.9). In contrast, the number of cells staining for CD11b and expressing eGFP is overall 




Figure 5.9 - Staining of peripheral blood cells collected from mice injected in utero 
at E16 with CD19 and CD11b to highlight B-cells and monocytes respectively.  
A control blood sample from uninjected mice that was unstained for Ter119 was used to 
appropriately gate the flow cytometry analysis and used as a standard for the analysis of 
blood samples of injected mice, stained with CD19 (yellow) and CD11b (green) and 
unstained (blue). Each triplet of histogram bars shows the result of stained and unstained 
cell populations from an individual mouse injected in utero with 20 l of UCOE-eGFP-
WPRE vector. Blood samples were collected 90 days post-natally. 
 





Animals were sacrificed by heart puncture so that the maximum amount of 
circulating blood was obtained.  Liver, spleen, heart and lung tissues were collected from 
animal carcases. Individual tissues were submerged in PBS solution and macerated using 
a sonicator to obtain a smooth homogenate, without particulate suspension, from which 
DNA could be extracted. 
 
Bone marrow cells were isolated from femurs and tibiae as described in section 
2.2.4.7, Chapter 2. Collected cells were used for proviral copy number estimation and 
stained for flow cytometry analysis.  
 
5.3.7.1 Liver morphology 
 
All mice showed normal tissue morphology. Livers collected post mortem were 
analysed by fluorescence microscopy to detect any eGFP positive cells. Figure 5.10 
shows representative images taken from the control mouse and injected test animals 1, 2 
and 3.     
 
 
The results show that injections performed in utero at gestational day E14 hit a 
higher percentage of precursor cells and therefore account for a higher number of eGFP 










   
          
  
_______________________________________________________________________ 
Figure 5.10 - Representative pictures of livers expressing eGFP under fluorescence 
microscopy. Mice 1, 2 and 3 were used as representative samples since all livers showed 
a similar morphological pattern of expression. All tissues showed normal morphology in 






















5.3.7. 2 Determination of proviral copy number   
 
Mouse liver, spleen, heart and lung tissues were collected for viral vector copy 
number analysis using qPCR. Vector was detected in liver and spleen tissues as well in 
BM cells. The qPCR reaction was unable to detect vector presence in both lung and heart 
tissues. Copy number calculated and the results are shown in Table 5.2, below. Vector 
presence was not detected in either heart or lung tissues in the qPCR analyses performed. 
 
 
Mouse Liver Spleen BM Lung Heart 
control Undetected Undetected Undetected Undetected Undetected 
1 2.582 0.528 0.895 Undetected Undetected 
2 2.145 0.125 1.32 Undetected Undetected 
3 2.761 0.236 0.481 Undetected Undetected 
4 2.021 0.514 0.624 Undetected Undetected 
5 1.527 0.951 0.472 Undetected Undetected 
6 2.158 0.751 1.593 Undetected Undetected 
7 1.925 0.467 1.593 Undetected Undetected 
8 2.352 0.524 0.587 Undetected Undetected 
9 2.470 0.825 1.020 Undetected Undetected 
 
Table 5.2. LV Copy number estimation in tissues of mice injected in utero at E14 
with the UCOE-eGFP-WPRE vector. In the liver the number of LV copies per cell 
averaged 2.215 in the total injected population. In both spleen and BM the values 
obtained for proviral copy number are lower (average of 0.546 and 0.953, respectively 











Mouse Liver Spleen BM Lung Heart 
control Undetected Undetected Undetected Undetected Undetected 
1 2.945 0.852 0.524 Undetected Undetected 
2 2.594 0.423 0.210 Undetected Undetected 
3 1.894 1.085 0.631 Undetected Undetected 
4 2.396 0.892 0.127 Undetected Undetected 
5 2.127 0.954 0.784 Undetected Undetected 
6 1.545 1.237 1.214 Undetected Undetected 
7 2.395 1.295 0.958 Undetected Undetected 
______________________________________________________________________ 
Table 5.3. LV Copy number estimation in tissues of mice injected in utero at E16 
with the UCOE-eGFP-WPRE vector.  In the liver the number of LV copies per cell 
averaged 2.270 in the total injected population. In both spleen and BM the values 
obtained for proviral copy number were lower (average of 0.962 and 0.635, respectively 
for the whole population analysed).  Vector presence was not detected in either lungs or 
heart. 
 
These results clearly show that the injections were successful and the vector is 
present in mice tissues (liver and spleen) and BM cells. They prove that an in utero 
injection delivers vector onto these tissues, and, importantly for this project, efficiently 









5.4 Comparing different reporter genes in utero: the UCOE-Luciferase-
WPRE vector 
 
The accurate, quantitative monitoring of expression of a given vector with an 
eGFP promoter is limited to isolated single cell populations such as peripheral blood and 
post mortem analysis. Following recent results obtained by collaborators we decided to 
incorporate in this study a vector that allows monitoring of its expression in vivo in which 
the eGFP reporter was replaced by a luciferase gene.  
 
The 2.5kb A2UCOE (Antoniou et al., 2003) was obtained from the 
A2UCOE‐eGFP vector by digestion with EcoRI and SalI. Digestion of the plasmid SFFV 
with a multiple cloning site (SFFV‐MCS‐WPRE) with EcoRI and XhoI allowed removal 
of the SFFV promoter and creation of UCOE‐MCS‐WPRE. The 1.6kb luciferase cDNA 
was then amplified by PCR from SFFV‐Luc‐WPRE using primers that created SbfI 
restriction sites at both the 5’ and 3’ ends of the PCR product. Digestion of the plasmid 
UCOE‐MCS‐WPRE with SbfI allowed the ligation of luciferase and creation of the 
UCOE‐Luc‐WPRE construct (Figure 5.11; construct kindly provided by Dr. Nathalie 




Figure 5.11 - Schematic illustration of the UCOE-Luciferase-WPRE SIN LV 
construct. The lentiviral vector construct contains a 2.5kb ubiquitous chromatin opening 
element (UCOE) from the human CBX3-HNRPA2B1 locus acting as a promoter element 
driving expression a luciferase transgene (vector courtesy of Dr. Nathalie Ward, ICH, 
UCL).  
 
   
U3    R    U5 
   
SIN    R    U5 
   
LUCIFERASE WPRE UCOE 




5.4.1 UCOE-Luc-WPRE titer estimation 
 
Preparations of the UCOE‐Luc‐WPRE LV were tested for titre by qPCR (section 
2.2.3.4.2, Chapter 2). This assay showed that vector stocks could be produced efficiently 
at an equivalent to 1.32 x 10
9
 TU/mL.  
 
 
5.4.2 In utero injections of UCOE-Luc-WPRE 
 
The UCOE‐Luc‐WPRE LV was tested in vivo by in utero injection into foetal 
mice as described previously in this chapter for UCOE-eGFP-WPRE and in section 
2.2.4.2 Chapter 2. Mice were injected with 20μL Optimen as negative controls. 
 
5.4.3 Expression of Luciferase in vivo 
 
Analysis of luciferase expression can be monitored over time using consecutive 
bioluminescent imaging. Quantification of in vivo luciferase expression was assessed 
using the IVIS Imaging 50 Series (Xenogen) system for bioluminescence detection after 
intraperitoneal injection of luciferin. Imaging was carried out for all animals at 30 and 
360 days post-injection. Representative images from both time points are shown in 











5.4.3.1 Results 30 days after in utero injection at E14 with the UCOE-




Figure 5.12 - Images of luciferase bioluminescence 30 days post in utero injection 
with UCOE-Luc-WPRE vector. Murine foetuses were injected at E14 and 
bioluminescence measurements taken at 30 days post-natally. Bioluminescence indicates 
the presence of actively expressed vector. A & D are male and B & C are female animals. 












Figure 5.13 - Images of luciferase bioluminescence 360 days 
post in utero injection with the UCOE-Luc-WPRE vector. 
Mice A,B,C & D are those presented in Figure 5.12. Mice E & 
F were not subjected to bioluminescence measurements at day 
150 post-injection.  Bioluminescence indicates the presence of 
actively expressed vector. Note: the images presented have different 
color bars as the IVIS Imaging 50 Series (Xenogen) system automatically 
compares animals in a given shot and establishes aperture in accordance to 
expression. Image-brightness is therefore not comparable. 
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Figure 5.13 - Images of luciferase bioluminescence 360 days post in utero injection 
with the UCOE-Luc-WPRE vector. Mice A,B,C & D are those presented in Figure 
5.12. Mice E & F were not subjected to bioluminescence measurements at day 150 post-
injection.  Bioluminescence indicates the presence of actively expressed vector. Note: the 
images presented have different color bars as the IVIS Imaging 50 Series (Xenogen) system automatically 
compares animals in a given shot and establishes aperture in accordance to expression. Image-brightness is 





















Luciferase protein activity per mouse 360 days after in utero injection is show in Table 
5.4 
 























Table 5.4 - Luciferase activity values per mouse 360 days after in utero injection at 
E14. Luciferase values can be correlated with images in Figure 5.13.  
All injected test mice had expression clearly well above background. In utero 
injection of the UCOE-Luc-WPRE vector in mice mediates expression in the central part 
of the body, most likely in the liver. No expression was observed in joints or BM. 
However, it is unknown if any expression was detectable in BM as the IVIS Imaging 50 
system adjusts its analysis to the highest expressing areas and ignores/neutralises lower 
traces of expression.  
 
 
5.4.4 Post-mortem analysis 360 days after in utero injection 
 
Mice were sacrificed at 360 days post-injection and liver, spleen, heart and lung 
tissues together with BM cells were taken for analysis. Tissue samples were analysed for 
luciferase expression using the Luciferase Assay System (Promega) and a Bradford 
protein assay (BioRad) to give relative luciferase units (RLU) per μg protein. The number 
of integrated proviral copies was also assessed using quantitative real‐time PCR (qPCR) 





5.4.5 Determination of integrated proviral copy number - luciferase 
injections 
 
Liver, spleen, heart and lung tissues were taken from mice for determination of 
average viral vector copy number per cell using qPCR. Table 5.5 shows the copy number 
for all tissues analyzed. Vector presence was not detected in either heart or lung in the 
qPCR analyses performed. 
 
 
Mouse  gender Liver Spleen BM Lung Heart 
A male 3.3645 1.532 2.0150 Undetected Undetected  
B female 6.4815 1.384 0.0221 Undetected  Undetected  
C female 1.1582 0.128 1.9738 Undetected  Undetected  
D male 2.5696 0.743 3.4909 Undetected  Undetected  
E female 3.2704 0.341 0.8224 Undetected  Undetected  
F female 3.4739 0.524 1.6445 Undetected  Undetected  
control male 0.0911 Undetected  Undetected  Undetected  Undetected  
 
_______________________________________________________________________ 
Table 5.5 - LV average copy number per cell in tissues of mice following in utero 





5.4.6 Quantification of luciferase activity in tissues of mice injected in 





Luciferase reporter gene expression was determined as relative luciferase units 
(RLU)/μg total tissue protein and the results summarised in Table 5.6. 
 
 
Tissue/organ compartment Average RUL/ g protein 






BM 4.1 x 10
3 *
 




Table 5.6 - Average relative luciferase units (RLU) per g total tissue protein. The 
table shows the averaged values obtained for the whole set of tissues collected. 
Luciferase activity was not detected in either heart or lung tissues.*Note: the average RLU 
value for BM included mouse B, which gave proviral copy number of 0.0221. If this sample is excluded the 
























Figure 5.14 - Quantification of relative luciferase units (RLU) per g total protein in 
individual tissues collected from mice injected in utero with the UCOE-Luc-WPRE 
vector. Liver, spleen, heart and lung tissues were collected from mice 360 days post-
injection. Luciferase expression analysis using the Luciferase Assay System in 

















Individual variation can be accessed by comparison of luciferase RLU units with 
values obtained for proviral copy number (Table 5.5) 
 
 






































Figure 5.15. Luciferase protein expression per LV copy number in individual tissues 
collected from mice injected in utero with UCOE-Luc-WPRE. Mouse liver, spleen, 
heart and lung tissues were collected from injected mice 360 days post-injection. The 
values obtained for luciferase expression (Figure 5.14) were plotted against the values 
obtained for proviral copy number (Table 5.4) to give luciferase RLU/ng values per 
vector copy. 
 
These results clearly show the presence of the Luciferase vector in mice tissues 
(liver and spleen) and vector engraftment into the BM tissues. Again, these positive 









5.5.1 Injections with UCOE-eGFP-WPRE in utero  
 
5.5.1.1 Liver morphology 
 
The pictures obtained by fluorescence microscopy of mouse livers after in utero 
injection of UCOE-eGFP-WPRE (Figure 5.10) differ significantly from those obtained 
by the administration of the very same vector to mouse neonates, where a homogeneous 
background for this vector was observed. (Figure 4.3, Chapter 4).  
 
After in utero delivery, the UCOE-eGFP-WPRE vector expresses as isolated 
islands of what appear as colonies of transduced cells. 
 
The titre of both vector preparations was similar so it is possible to say that the 
discrepancy between these two routes of delivery comes from the techniques used 
(neonatal versus in utero injections).  
 










Figure 5.16 - Differences in UCOE-eGFP-WPRE vector expression patterns in liver 





Differences in the cellular status of the liver between foetal and post-natal stages 
of development may contribute to the observed difference in UCOE-eGFP-WPRE vector 
expression patterns. The foetal liver is a mixture of both hepatocytes and haematopoietic 
stem and progenitor cells. Therefore, the more efficient transduction of hepatocytes over 
haematopoietic cells would give a distinct island, colony appearance, especially if this 
resulted from the expansion of a single transduced cell. 
 
 
5.5.1.2 Staining of peripheral blood 
 
Both the E14 and E16 time points of in utero vector delivery showed that a large 
percentage of cells in the circulation stain for Ter119, with a yet greater proportion of  
cells (10-fold higher) simultaneously staining for Ter119 and expressing the eGFP 
reporter gene compared to eGFP alone (unstained). This result suggests that the great 
majority of mature red cells in the circulation are derived from HSC transduced whilst 
still in the foetal liver. Both time points showed positive results but at E14 the marking 
seems more evident with some mice showing dual Ter119 staining and eGFP expressing 
over 90% of the cell population (mice 7 and 8). 
 
For Cd11b, the staining pattern differed significantly between the two time points 
of vector delivery. While at E14 the difference between the stained and unstained 
populations was markedly different, at E16 the populations showed similar values.  It is 
possible that monocyte precursors have started their migration to the BM by 16
th
 dpc and 
are therefore no longer present when the E16 injection took place. It is worth noting that 
switching of the site of hematopoiesis is not an immediate process but a gradual 
migration of cells and at a given point of murine gestation it is possible to find HSC and 
progenitors in more than one location. 
 
Positive results shown by Cd19 staining following injection at E16 confirm the 




progenitor cell populations resulting in vector presence in more than one circulating cell 
type.  
 
The values obtained for proviral copy number in different organ compartments 
can be found in Tables 5.2 and 5.3. The organ showing higher values of copy number in 
both E14 and E16 time points is the liver (averaged of 2.215 and 2.27, respectively). 
These values correlate well with the bioluminescence images shown in Figure 5.10, 
where liver tissues show evident expression of the eGFP reporter gene. In both spleen 
and BM the values obtained for proviral copy number are relatively lower. In spleen the 
average was 0.546 and 0.962 at E14 and E16 respectively and in BM average copy 
number was 0.953 and 0.635 respectively at E14 and E16. While vector detection in 
spleen confirms vector presence in the circulation, vector presence in the BM shows 
positive engraftment of the BM cells with the vector upon in utero injection, with a 
higher engraftment at E14. These results validate the hypothesis in this study. 


















5.5.2 Injections with UCOE-Luc-WPRE in utero 
 
5.5.2.1 Bioluminescence xenograph images 
 
We decided to use a luciferase reporter gene LV as this allows in vivo 
documentation of vector expression in living animals. Animals were injected in utero 
with the UCOE-Luc-WPRE construct at E14 and vector expression analysed in vivo at 
both 150 and 360 days after injection (Figures 5.12 and 5.13). Both images show 
consistent expression in vivo and, more importantly, they show vector persistence 1 year 
after injection.  
 
5.5.2.2 Proviral copy number 
 
With regards to copy number the values obtained in the liver are not entirely a 
surprise, given the luciferase activity that is detected in the central part of each animal 
(Figures 5.12 and 5.13). The copy number values obtained in splenocytes are minimal 
and therefore cannot account for the bioluminescence visible in Figures 5.12 and 5.13.  
LV copy number values found in BM cells at 360 days post-injection are highly positive 
and validate the hypothesis behind these experiments; that is, vector delivery transduces 
HSC in foetal liver, which at a later gestational stage migrate to BM niches. Vector 
presence after such an extended (12 month) period of time also indicates that transduction 
is stable and not lost upon cellular division.  
 
Interestingly, mouse B shows a high value of transduction in the liver and spleen 
but a low value in BM suggesting that vector transduction of HSC in the foetal liver has 








5.5.2.3 Luciferase assay 
 
Luciferase activity results in post-mortem tissues obtained from mice injected in 
utero with the UCOE-Luc-WPRE vector are very encouraging. As predicted by the in 
vivo images (Figures 5.12 and 5.13), luciferase expression in the liver is significantly 
higher than in any other organ compartments analysed.  
 
Bone marrow cells transduced with UCOE-Luc-WPRE are clearly present as 
evidenced by the positive values obtained with the luciferase assay with this tissue.  
 
Although luciferase activity in spleen cells is lower than in other organs, it is 
nevertheless indicative of transduced cells in the mouse blood circulation. Note that even 
though the bioluminescence image (Figure 5.12 and 5.13) suggests transduction of 
central body organs, tissues like heart and lung show neither presence nor expression 
from this vector. This result suggests that transduction of cells and tissues by in utero 
vector delivery via the route employed here, is confined to specific organs, and nearby 
tissues. 
 
It is also interesting to note the lower RLU value in spleen cells in mouse A compared to 
other mice. For example, mouse B (RLU 1.2 x 10
4
)  luciferase expression is 11 times 
higher than that obtained in mouse A (RLU 1 x 10
3
), even though the amount of vector 
injected was the same in both animals.  
 
The evident lower level of transduction in mice can be explained by faulty 
injections of the vector; note that these injections are a difficult procedure on relatively 








5.5.2.3 Luciferase expression units per copy number 
 
 Since the samples analysed are homogenates from the same tissue, and to account 
for individual variations, we plotted the values obtained for luciferase expression (Figure 
5.14) against the values obtained for proviral copy number (Table 5.5) to obtain RLU 
values per vector copy (Figure 5.15). 
Liver expression is constant in all animal samples analysed (blue bars), with the 
results presented not showing evident individual differences. The sample from mouse C 
shows lower vector expression in liver tissues. With the exception of mouse A, 
transduced cells in the spleen show expression values ranging from 5000-15000. These 
values indicate that although a relatively low percentage of cells in spleen are transduced 
(refer to the proviral copy number values, Table 5.4) their individual expression is high. 
Further integrational studies to determine possible vector integration sites and nearby 
transcription sequences may be informative with regards to the upregulation of the 
transgene in this case.  
 
Expression per copy number in BM cells is represented by the green bars in 
Figure 5.15. With the clear exception of mouse B, BM cells show a lower expression per 
copy number within the range of tissues analysed. Nevertheless, these results are very 
encouraging as this degree of LV marking demonstrates the feasibility of an in utero 
delivery approach for targeting HSC to bring about early correction of disease.  Mouse B 
shows an atypical high level of luciferase expression per LV copy number. Again, this 
sample would benefit from further vector integration analysis to access trasngene 
insertion sites and more importantly, if the pools analyses derive from different 









5.5.3 Conclusion Remarks 
 
 The use of eGFP vectors in utero has shown that both at E14 and E16 time points 
vector expression does not suffer significant changes relative to the amount of 
HSC and erythroid precursors transduced. 
 
 On the contrary, cellular staining of the myeloid population indicates that at the 
E16 time point the population of transduced cells is significantly lower than at 
E14. 
 
 The use of luciferase vectors allowed monitoring of vector presence and 
expression in vivo. We observed clear vector expression from the liver, and this 
visual result was later confirmed by both qPCR and luciferase enzyme assays. 
 
 Both sets of experiments clearly document vector presence and expression in BM, 
proving that the starting experimental hypothesis was correct; that is, HSC can be 












DEVELOPMENT OF IN UTERO GENE THERAPY APPROACHES 


















 Inject wild type (MF1) mice in utero with an LV containing an HBB expression 
cassette 
 
 Analyse peripheral blood 150 days post-injection 
 
 Sacrifice mice 250 days post-injection. Analyse peripheral blood, bone marrow 






















6.2.1 Previous studies with HBB-based LV - GLOBE  
 
 
Previous studies with GLOBE LV performed in adult animals via an ex vivo bone 
marrow (BM) transplantation procedure have shown transcription levels of HBB 
sufficient to rescue severe β-thalassaemia intermedia and major phenotypes in mouse 
models of this disease (Miccio et al., 2008). In addition, studies have shown that 
successful transduction of GLOBE into CD34
+
 cells from patients is capable of 
correcting the globin chain imbalance and restoring erythropoiesis upon differentiation 
(Roselli et al., 2010). 
 
The success obtained with GLOBE in vivo led us to hypothesise that the 
administration of this or a similar vector by in utero injection via the vitelline placental 
vessel, would successfully transduce the HSC population located in the liver during foetal 
development, which are known to then migrate into BM niches around the time of birth 
(see Figure 5.1, Chapter 5). 
The presence of the HBB transgene in BM, even if at a relatively low level, would 
theoretically mimic the positive results obtained previously by an ex vivo procedure 
(Miccio et al., 2008) and should therefore greatly reduce phenotypic effects of 
haemoglobin imbalance in the newborn. 
 
 
6.2.2 Transcription termination 
 
The percentage of human RNA polymerases capable of initiating and successfully 
completing gene transcription has been estimated to be in the order of 1% (Banerjee et 
al., 2009). RNA polymerase II transcription complex activity is thought to be affected by 
chromatin modifying factors and intrinsic properties of the template and transcript that 




Recent studies suggest that transcriptional termination is linked to mRNA 
processing and may be required for optimal gene expression in human cells (West & 
Proudfoot, 2009) Consequently, transcription termination is now thought to be required 
for efficient mRNA processing, export, and therefore, for protein production.  
Termination is important to pause RNA polymerase II (Pol II) and allow cleavage 
of the pre-mRNA with a functional polyadenylation [p(A)] signal at the p(A) addition 
site. However, the termination signal, located downstream of the p(A) signal, may also be 
required for efficient polyadenylation (Dye & Proudfoot, 2001). A failure in efficient 
termination by Pol II leads to inefficient pre-mRNA cleavage and polyadenylation, 
resulting in the formation of uncapped transcripts and consequently, low gene expression 
(West & Proudfoot, 2009). 
Several models for polyadenylation associated transcription termination have been 
proposed:  
 
 the allosteric model, or anti-terminator model, posits that p(A) signals cause a 
change in the complement of anti-termination factors associated with Pol II, 
making it more susceptible to termination (Logan et al., 1987)   
 
 the torpedo model suggests that a 5′ to 3′ exonuclease attacks the transcript at the 
p(A) cleavage point and degrades the nascent transcript in pursuit of the RNA 
polymerase, leading to termination (Connelly et al., 1988) 
 
 and more recently the combined allosteric/torpedo model (Luo W, et al., 2006), 
which includes a role for the phosphorylation state of the Pol II C-terminal 










6.2.3 HBB transcription terminator 
 
The process of cleavage and polyadenylation of HBB transcripts has been shown 
to occur efficiently only following RNA self-cleaving activity located in the 3' flanking 
region 600-1200bp downstream of the p(A) site. These events are dependent on 
transcriptional termination by Pol II in this region (designated as “ term”). Recent 
studies performed with plasmid vectors suggest that the inclusion of the term region 
downstream of the p(A) site increased mRNA and protein production 4-fold (West & 
Proudfoot, 2009). The authors report that the addition of the term region into a globin 
expression system increased the overall efficiency of pre-mRNA cleavage, 
polyadenylation and transcription termination.  
 
Based on these studies we sought to augment the function of the HBB cassette 
within the GLOBE vector by incorporation of the term region at a position 3’ of HBB 




















6.3 LVs used in this study  
 
6.3.1 GLOBE2  
 
GLOBE2 was generated by Dr Sha Sha, a former member of the Gene Expression 
and Therapy Group, as follows; a 850bp term region genomic fragment with 850bp 
from the HBB polyadenylation site, was excised from a pBluescript plasmid vector 
with HpaI and EcoRV restriction enzymes and inserted into the original GLOBE at the 




Figure 6.1 - Schematic illustration of GLOBE2 lentiviral vector. GLOBE2 is as the 
original GLOBE vector (Miccio et al., 2008) but with an 850bp genomic fragment 
spanning the HBB transcription termination region ( term) inserted at a HpaI site 
upstream of the LV cppt element. 
 
Results obtained in vitro by transduction of murine erythroleukemia (MEL) cells 
and in vivo by ex vivo BM transplantation of HSC in mice using a eGFP reporter gene 
variant of GLOBE2, showed overall expression greater than 4-fold higher compared to a 
vector lacking term (Kao, V and Antoniou, M, unpublished results).  
 Based on these observations we decided to proceed with experiments in utero 





6.3.2 Vector preparation 
 
GLOBE2 vector was prepared as described in section 2.2.3, Chapter 2. Viral 
stocks were serial diluted, used to transduce cultures of known cell density, and incubated 
for 3 days after which DNA was extracted. Extracted DNA was used to determine viral 
stock titre by qPCR analysis by comparison with a sample of known vector copy number. 




 TU/mL. This titre value is 
relatively lower than that obtained with the equivalent eGFP-reporter construct and those 
routinely obtained with GLOBE. In all likelihood this is due to the larger size of 





















6.4 Animal  experiments 
 
6.4.1 In utero injections 
 
Injections in utero were performed as previously described (section 2.2.4.2, 
Chapter 2) and following the methodologies applied in experiments with eGFP and 
luciferase reporter vectors (sections 5.3.3 and 5.4.2, Chapter 5; section 2.2.4.2, Chapter 
2). Based on the results obtained in utero with eGFP and luciferase reporter vectors, the 
whole set of injections in this study employing GLOBE2 were performed at embryonic 
day 14 (E14). 
Unborn mice were injected with equal amounts of transgene vector and Optimen 




6.4.2 Animal procedures 
 
Blood was collected from live animals 120 days after in utero injection. As 
described in section 2.2.4.3, Chapter 2. Mice were sacrificed by cardiac puncture so that 
the maximum amount of circulating blood was obtained, 250 days after in utero injection, 
as described in section 2.2.4.4, Chapter 2. Blood samples were used for DNA extraction 
for proviral copy number determination (section 6.5.1.1), haemoglobin-ELISA assay for 
quantification vector expression (section 6.5.1.2) and the 250 day sample was used to 
estimate HBB expression levels in blood (section 6.5.1.3) 
 
Bone marrow cells were isolated from femurs and tibiae.  Liver and spleen tissues 
were collected from carcases. Collected cells were used for proviral copy estimation 
(section 6.5.2.1) and expression analysis (section 6.5.2.2).  DNA removed from tissues 





6.5 Expression analysis  
 
 
6.5.1 Analysis of peripheral blood 
 
6.5.1.1 Determination of proviral copy number  
 
DNA was extracted from peripheral blood and used for vector copy number 
estimation (section 2.2.5.1.1, Chapter 2). Proviral estimation was determined using qPCR 
and vector presence and concentration in samples was estimated by comparison with an 
endogenous control and a sample of known copy number (section 2.2.5.2, Chapter 2). 
 
At the time of sacrifice, 2 mice not subjected to the injection procedure were 
added to the experimental set, namely mouse numbers 9 and 10. (Note: the control mice 





















Table 6.1. GLOBE2 LV copy number values in peripheral blood at 120 and 250 
days post-in utero injection. Values were obtained by analysis of DNA by qPCR. The 
results show that GLOBE2 sequences are present in the mouse circulation. Copy number 
values averaged at 1.347 (120 days) and 0.761 (250 days) viral copies per cell. Mice 
injected with GLOBE2: 1, 3, 4, 5 and 7.  
1
Mice not subjected to the injection procedure. *The copy number estimation was repeated and this value 
was consistent (n=2). The amplification cycle in this reaction was very high at 35-38 cycles (reaction with 
40 cycles). Amplification at this stage of the reaction cannot be considered copy number amplification but 
residual traces of vector in the sample. ** The samples were run in duplicate and the PCR was repeated but 
a positive value (albeit at a very low level) was obtained for amplification of control mouse 1; analysis of 
the results obtained in the qPCR reaction show that this sample amplified DNA with the vector detection 
primers (labelled at LTR primers in section 2.2.3.4.2, Chapter 2) at the 35th cycle, when the whole reaction 





Gender LV copy number 
120 days post injection 
LV copy number 
250 days post injection 
1 male 1.405 0.229 
2 control 1 male 0.108* 0.003** 
3 male 0.432 1.109 
4 male 0.376 1.354 
5 male 1.613 0.161 
6 control 2 male Undetected Undetected 
7 female 2.910 0.952 














Figure 6.2 - Determination of GLOBE2 vector copy number in peripheral blood of 
mice at 120 and 250 days post-in utero injection (n=2). DNA extracted from peripheral 
blood collected from mice injected in utero with the GLOBE2 was analysed for vector 
copy number (VCN). Graphical representation of data shown in Table 6.1. Results 








Determination of GLOBE2 vector copy number in peripheral blood 120 and  
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6.5.1.2 Determination of HBB chain levels in haemoglobin in peripheral 
blood  
 
Determination of GLOBE2-derived HBB chain levels 250 days post-injection was 
performed by Haemoglobin ELISA. The technique takes advantage of structural 
differences between mouse and human, detecting the later (see section 2.2.5.5, Chapter 
2). HBB chain presence was estimated by comparison with a standard normal human 




Gender HBB chain levels 
120 days post injection 
(ng/ml) 
 
HBB chain levels 250 days 
post injection (ng/ml) 
 






3 male 0.155 0.104 
4 male 0.079 0.042 












9 un-injected 1 male - 0.069 
10 un-injected 1 male - 0.093 
_______________________________________________________________________ 
Table 6.2 - GLOBE2-derived HBB chain levels in peripheral blood collected at 120 
and 250 days after in utero injection (n=2). Blood samples were diluted and used to 
determine HBB chain levels in peripheral blood using the Human Hemoglobin ELISA 








 Hbb chain levels 



































































Figure 6.3 - HBB chain levels in peripheral blood of mice collected at 120 and 250 
days after in utero injection. HBB chain levels obtained (ng/ml) for both time points 
were plotted against the haemoglobin value obtained with a human control sample 
(0.107ng/ml). Comparison of both assay values (120 and 250 days) by Student’s t-test 
returned a P-value of 0.0517 (P-value≥0.05), indicating no differences between the 2 








The value obtained with mouse number 2 (control 1) raised questions regarding the 
specificity of the assay. However, there is some consistency between the values of 
control 2 and 3 (0.082 and 0.09) and the negative (un-injected) samples also scored 
values below the human positive control level. In addition, the P-value obtained by the 
comparison of both set of results (120 and 250 days) in a Student’s t-test shows 
consistency in the set of results.  
We decided to include this set of results from a merely qualitative point of view, 




The graph presented in Figure 6.3 although informative hides individual variance 
and does not account for the amount of vector in peripheral blood (amount of vector that 
gives rise to HBB chains in circulation). Therefore, the results obtained from HBB chain 
analysis together with the values obtained for GLOBE2 proviral copy number were used 
to calculate HBB chain levels per copy number to obtain a more quantitative presentation 
of the results (Figure 6.4). 
 
Analysis of the graph in Figure 6.4 shows that HBB chain levels at 120 days post-
injecting are constant and ranged from 0.2-0.4ng/ml per vector copy. At 250 days post-
injection a greater variation of expression was observed with mouse number 5 showing 
the highest values of HBB chains per copy.  Overall, the results show that over time HBB 
chain values in the peripheral circulation decreased in mouse numbers 3 and 4 but in 














Haemoglobin levels per copy number  
















































































Figure 6.4 - HBB chain levels in peripheral blood per GLOBE2 copy number. HBB 
chain levels obtained from both time points (120 and 250 days post-in utero injection) 














6.5.1.3 Quantification of HBB mRNA levels in peripheral blood  
 
RNA extraction from peripheral blood was performed as described in section 
2.2.5.1.2, Chapter 2. For consistency, the same cell sample was used for simultaneous 
DNA and RNA extraction (respectively for copy number estimation and HBB mRNA 
quantification).  
 
Figure 6.5 shows a qualitative analysis of the RNA samples by agarose gel 
electrophoresis. The result shows the presence of intact 28S and 18S ribosomal RNA 




Figure 6.5 - Analysis of RNA extracted from peripheral blood, 250 days post-in 
utero injection by agarose gel electrophoresis.  
 
6.5.1.3.1 Reverse Transcriptase (RT) qPCR 
 
Total RNA was converted into complementary DNA (cDNA) by means of a 
reverse transcriptase reaction using the Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT) kit (Invitrogen; see section 2.2.5.3.2, Chapter 2). 
 
RNA collected from peripheral blood 






Quantification of HBB expression levels from GLOBE2 per mouse was achieved 
through SYBR® Green qPCR. Figure 6.6 shows HBB gene expression per vector copy 
in relation to endogenously expressed GAPDH. 
The results obtained were analysed using the 2
Ct
 methodology (Winer et al., 1999, 
Termo Scientific Tech notes, Josh Haimes & Melissa Kelley, 2010; Applied Biosystems 
Guide to perform relative Quantitation of Gene Expression Using Real-Time 
Quantitative PCR, 2008) using untransduced controls as calibrators to determine HBB 













Difference of expression 
(compared to GAPDH) per vector copy number 




















































Figure 6.6 – Difference of \HBB expression HBB transgene expression compared to 
GAPDH per vector copy number in peripheral blood (n=2). Total RNA extracted 
from blood collected 250 days post-in utero injection was analysed to determine HBB 
transgene expression. RNA samples were equalized with regards to their concentration 
using a Nano-Drop 1000D detection system and reverse transcribed into cDNA using the 
M-MLV RT kit. cDNA sample quantification was determined by qPCR and plotted 
against peripheral blood copy number values (section 6.6.3.1) to determine expression 
per vector copy. Mean fold difference values were obtained by dividing by half taking 
into account GAPDH endogenous gene copy number of 2 per cell versus integration of 










6.5.2 Bone Marrow 
 
6.5.2.1 Determination of proviral copy number from DNA extracted 
from bone marrow cells 
 
Mice number gender Estimated vector copy number 
(BM, 250 days post injection) 
 
























9 un-injected mouse1 male 
Undetected 
10 un-injected mouse1 male 
Undetected 
_______________________________________________________________________ 
Table 6.3 - GLOBE2 vector copy number in BM cells analyzed 250 days after in 
utero injection (n=2). Vector copy number determined by qPCR ranged between 0.03-
0.89 (average 0.371) per bone marrow (BM) cell. 
1











Figure 6.7 - Determination of GLOBE2 vector copy number in bone marrow cells 
250 days post-in utero injection (n=2). DNA extracted from bone marrow cells from 
mice injected in utero with the GLOBE2 was analysed for vector copy number (VCN) 
per cell by qPCR. 
 
With the exception of mouse number 3 (0.892), all mice injected with vector showed 
copy number values in BM lower than 0.5 copies per cell, but still, all at higher values 










6.5.2.2 Quantification of HBB mRNA levels in bone marrow cells 
 
The same cell sample was used for simultaneous DNA and RNA extraction 
(respectively for vector copy number estimation and HBB mRNA quantification). Figure 
6.8 confirms the integrity of the RNA extracted. The samples were resolved by agarose 
gel electrophoresis and show the presence of the 28S and 18S ribosomal RNA bands in 




Figure 6.8 - RNA extracted from bone marrow cells at 250 days post in utero 
injection. The picture shows analysis of the RNA samples by agarose gel 
electrophoresis, which shows intact 28S and 18S ribosomal RNA bands. 
 
Spectrophotometric analysis indicated a high level of purity (A260/280nm≥1.7). Total 
RNA was converted into complementary DNA (cDNA) by means of a reverse 
transcriptase reaction using the Moloney Murine Leukemia Virus Reverse Transcriptase 






Quantification of GLOBE2 HBB expression levels per mouse was achieved 
through SYBR® Green qPCR.  Figures 6.9 show HBB expression per GLOBE2 vector 
copy in relation to endogenously expressed GAPDH.  
Results obtained were analysed using the 2
Ct
 methodology (Winer et al., 1999) and 
Termo Scientific Tech notes (Josh Haimes & Melissa Kelley, 2010), using untransduced 















(compared to GAPDH) per vector copy number



















































Figure 6.9 - HBB mRNA levels per GLOBE2 vector copy number in bone marrow 
(n=2). RNA was isolated from bone marrow (BM) cells at 250 days post-in utero 
injection and analysed to determine HBB transgene expression. RNA samples were 
equalised with regards to their concentration using a NanoDrop 1000D detection system 
and reverse transcribed into cDNA. HBB mRNA quantification was determined by a 
qPCR and plotted against vector copy number (see section 6.6.3.2) to determine mRNA 










6.5.3 Analysis of liver and spleen tissues 
 
6.5.3.1 Determination of proviral copy number from DNA extracted 
from liver and spleen at 250days post-injection 
 
Mice number gender Vector copy number 
Liver 
(250 days post injection) 
 
Vector copy number 
Spleen 
( 250 days post injection) 
 
































Table 6.4 - GLOBE2 vector copy number in liver and spleen tissues at 250 days post 
injection. Total genomic DNA from liver and spleen was analysed for GLOBE2 LV 
copy number by qPCR. Liver average copy number is 2.51; spleen average copy number 
is 0.225. 
1








6.6.1 Analysis of GLOBE2 vector copy number in peripheral blood  
 
Analysis of GLOBE2 vector copy number values obtained by DNA analysis and 
comparison with a control cell sample with a known single copy integration event, 
revealed that mouse numbers 1 and 5 showed values close to 1 copy per cell, whilst 
mouse number 7 showed values close to 3 integration events per cell. Mouse numbers 3 
and 4 contained less that 1 copy per 2 cells in peripheral blood with values of 0.4327 and 
0.3762 respectively. The initial vector copy number values at 120 days post-injection 
(Table 6.1, Figure 6.2) are encouraging and confirmed GLOBE2 vector presence in the 
circulation. However, at this point it was still unclear whether this vector resulted from 
progenitor cells in the circulation upon injection or newly derived blood constituents 
from HSCs in BM.  
The analysis of vector copy number values in peripheral blood at 250 days post-in 
utero injection (Table 6.1, Figure 6.2) show that mouse numbers 3 and 4 have the 
highest amount of vector in the bloodstream with 1.909 and 1.354 vector copies per cell 
respectively. Mouse number 7 showed a vector copy number of 0.952/cell whereas 
mouse numbers 1 and 5 showed the lowest level of vector marking at 0.229 and 0.161 per 
cell respectively.  
 
The comparison of the 120 day and 250 day vector copy number estimations 
shows that mice with higher copy number values at 120 days post-injection decreased in 
their vector copy number in the circulation over time. In contrast, mouse numbers 5 and 
6, which showed relatively low viral copies per cell in the peripheral blood at 120days, 





Based on these results it is possible that the vector copy values obtained initially 
for peripheral copy number at 120 days post-injection may be arising from transduced 
progenitor cells rather than HSC. 
 
 
6.6.2 HBB chain levels in blood 
 
Determination of GLOBE2 vector derived HBB chain levels at 120 days post-
injection was performed by Haemoglobin ELISA (Table 6.2, Figure 6.3). 
 
Upon careful consideration, we decided to analyse the results obtained in this set 
of experiments excluding mouse number 2, as the value obtained for this sample differs 
significantly from the values obtained with the other mice analysed, the other controls 
(mice 6 and 8) and the values obtained for the negative controls. With this in mind, the 
values obtained correlate with the values obtained for vector copy number; mouse 
numbers 1, 5 and 7 showed highest values of HBB chain levels, as can be predicted from 
the values obtained for vector copy number (1.4055, 1.6138 and 2.9104 respectively). 
Mouse number 4 showed a HBB chain value very similar to control mice (6 and 8), as 
can be expected by the value obtained for proviral copy number estimation in peripheral 
blood (0.3762).  
 
The surprising result in this assay is for mouse number 3, which shows steady 
HBB chain levels (0.155ng/ml) above the human control sample value (0.107ng/ml) but 
with a proviral copy number in blood of only 0.4327 viral copies per cell. This implies 
that accumulation of HBB chains in the circulation increases whilst vector copy number 
is gradually decreasing. The discrepancy between vector copy number and HBB chain 
levels in this mouse may be accounted for by preferential expansion of a clone or clones 





The specificity of the human HBB chain assay was once again called into 
question upon analysis of the blood samples collected at 250 days post-injection as 
control mice injected with solely Optimen medium (mice 2, 6 and 8) scored surprisingly 
high values (Figure 6.3).  
 
We nevertheless decided to include this set of results in this study because, even 
though the control samples showed positive values, these are generally lower than the 
values obtained with samples from animals injected with GLOBE2. In addition, when 
analysed purely qualitatively these data provide evidence for the presence of HBB chains 
in the circulation of the vector injected animals. In an attempt to clarify this issue upon 
sacrifice and second collection of samples we also isolated RNA samples for the 
determination transgene expression levels though qPCR methodology. 
 
In order to account for individual differences in the samples due to variation in 
GLOBE2 vector copy number, we plotted the values obtained for HBB chains against the 
values found for proviral copy number in circulation (Figure 6.4). (Note: in this figure 
we omitted the positive values obtained for mouse 2). 
Overall, the results show that over time HBB chain values in the peripheral 
circulation decreased in mouse numbers 3 and 4 but in mice 1, 5 and 7 surpassed the 
value obtained at 120 days post-injection. The variation between the results obtained at 
both time points can be accounted for by the degree of GLOBE2 vector presence in the 
BM of the injected animals; that is, BM engraftment of transduced HSCs will cause 
differentiated erythroid cells to produce HBB chains, whereas transduction of only 
committed progenitor cells, the transgene will not be present in BM HSCs and vector 










6.6.3 HBB mRNA levels in peripheral blood at 250 days post-injection 
 
With the exception of mouse 5 (see below), injected mice showed consistent HBB 
transgene mRNA values in peripheral blood (approximately 1-fold higher than the 
GAPDH control) whilst control mice 2, 6, 8, 9 and 10 did not produce a detectable qPCR 
product (Figure 6.6).   
 
6.6.4 Peripheral blood - comparison of results obtained 
 
There is generally a good correlation between transgene mRNA levels per vector 
copy number (Figure 6.6) with the values obtained for HBB chain presence in peripheral 
blood cells determined by haemoglobin ELISA. Overall both studies show 
complementary results with the transgene mRNA analysis validating the HBB chain 
levels in the blood cells analysed. For mouse number 5, both experimental sets of results 
showed high expression for the vector when corrected for copy number values obtained 
in peripheral blood. 
The surprising finding in this comparison is mouse number 1, which showed a 
positive level of HBB chains per vector copy number but no transgene mRNA 
expression.  
 
Based on results obtained previously with LVs containing HBB expression 
cassettes, including within human clinical trials (Cavazzana-Calvo et al., 2010), it would 
be interesting to determine the sites of vector integration in mouse 5 to determine if the 
high expression seen in this case is due to clonal expansion of a specific cell population 
caused by host genome elements near the site of insertion causing upregulation. 
However, a study with the original GLOBE vector clearly showed that this integrates 
preferably within transcriptionally active genes, with no bias towards integration in 
proximity of oncogenes, as reported to occur with both lentiviral and retroviral vectors 
(Roselli et al., 2010). It is thus important to notice that this mouse on sacrifice showed no 




6.6.5 Analysis of GLOBE2 vector copy number in bone marrow  
 
The existence of positive engraftment of cells harbouring GLOBE2 in BM 
validates the initial hypothesis formulated in this study and shows that it is possible to 
transduce HSCs whilst present in the foetal liver at a pre-migration stage into BM niches. 
 
Results obtained by analysis of DNA extracted from BM cells (Figure 6.7) show 
that, although at a relatively low copy number and with less than 1 copy per cell in the 
BM compartment, GLOBE2 vector is present.  
 
At 250 days post-injection it is possible to see a clear correlation between BM 
engraftment (copy number values obtained in BM cells) and the viral copies present in 
the mouse bloodstream (copy number in peripheral blood, Figure 6.2). These results 
clearly suggest that the vector copy number found in the circulation is highly dependent 
on progenitors arising from transduced cells in the BM. 
 
 
6.6.6 HBB mRNA expression levels in BM at 250 days post-injection 
 
Results obtained from quantification of HBB transgene expression in BM cells 
(Figure 6.9) show that with the exception for mouse number 1 all other injected mice 
gave a positive result compared to the GAPDH normalised gene.  
 
Given that the values obtained for copy number estimation in peripheral blood 
were much higher than the values obtained in BM cells at 250 days post-injection 
(Figures 6.2 and 6.7), it is possible to conclude that transduced cells in BM are 
expressing higher levels of transgene than those in the circulation. This may be accounted 
for by the presence of larger numbers of HBB mRNA positive erythroid progenitor cells 







6.6.7 Analysis of copy number in non-haematopoietic mouse tissues at 
250 days post-injection 
 
As expected the liver and spleen in GLOBE2 injected mice showed vector 
presence. Vector copy number is higher in the liver due to LV delivery in utero is 




























6.6.8 Overall analysis 
 
In this study, we investigated the possibility of an intrauterine gene therapy 
approach for correction of the haemoglobinopathies in wild type mice. In an overall 
analysis of the results, it is possible to conclude that in utero injection with GLOBE2 
(Figure 6.1) is capable of transducing the HSC population in the foetal liver resulting in 
subsequent engraftment in BM until, at least, 250 days post-injection. This engraftment is 
responsible for the observed prolonged transgene presence and expression at both an 

























6.6.9 Conclusion remarks 
 
 The results show positive engraftment of BM cells containing the GLOBE2 
vector following in utero injection 
 
 The results validate the initial hypothesis formulated in this study and show that it 
is possible to transduce HSC while in the foetal liver, before migration into the 
BM niches 
 
 Vector presence in peripheral blood and BM up to at least 250 days after injection 
suggests targeting of HSCs in foetal liver 
 
 
 HBB transgene expression levels determined by mRNA and HBB chain analysis 
suggest that levels capable of rescue of the -thalassaemia phenotype are possible 
and pave the way for a therapeutic experiment in mouse models of -thalassaemia 


















































The last decade has seen great advances in the field of gene therapy with the first 
successful outcomes in clinical trials (Cartier et al., 2009; The use of gammaretroviral 
vectors has provided long-term correction for severe combined immune deficiency 
(SCID) following ex vivo delivery to HSC in conditions such as SCID-X1 (Cavazzana-
Calvo et al., 2000; Gaspar et al., 2004) and SCID-ADA (Aiuti et al., 2009). AAV vectors 
have been employed with success in targeting the retinal pigment epithelium in Leber's 
Congenital Amaurosis (Bainbridge et al., 2008; Maguire et al., 2008; Ali et al., 2012). 
More recently outcomes from the use of lentiviral vectors in clinical trials to treat 
inherited monogenic diseases have been reported. Using ex vivo delivery to HSC a 
successful outcome was achieved in patients with X-linked adrenoleukodystrophy 
(Cartier et al., 2009) and a partial success in one case of -thalassaemia (Cavazzana-
Calvo et al., 2010).  
 
Despite these successes, problems regarding insertional mutagenesis resulting 
from viral vector integration remain and the search for an optimal delivery vector is far 
from its end.  
In 2003 the follow up from the X-linked SCID human trial in Paris reported that 
one of the patients had developed a monoclonal lymphoproliferative disease and since 
then, four additional patients have developed similar forms of leukaemia (Hacein-Bey-
Abina et al., 2003). Analysis of T-cell clones from patients revealed integration near the 
LMO2 proto-oncogene in four out of the five cases, leading to aberrantly high 
transcription (Hacein-Bey-Abina et al., 2003a).  
More recently, there has been reports of the apparent successful treatment of an 
18-year old patient with transfusion dependent HbE/ -thalassaemia via BM re-
implantation of genetically modified HSC with an LV containing a functional HBB 
(Cavazzana-Calvo el al., 2010). Results showed 10-20% of reconstituted HSCs but it was 
not until further analysis confirmed that 50% of genetically modified cells and 
consequent increased levels of HBB seen in this patient, were a result of clonal dominant 
expansion of a single myeloid progenitor harbouring an LV integration within HMGA2, a 





proto-oncogene. This integration event resulted in an exons 1-3 truncated HMGA2 
peptide being produced and abolition of the miRNA-mediated control of this gene 
normally present in the terminal exon 5. Once again a therapeutic success is associated 
with a (fortuitous) insertional mutagenesis event.  
 
 
As things stand, despite key milestones in the field of gene therapy being 
achieved, there is a wide window for improvement in LV design still to be developed, 
mainly with regards to safe integration, increased transduction efficiency and transgene 
expression levels. This project addresses the major issues associated with gene therapy 
lentiviral cassettes targeting the haemoglobinopathies and aims to develop a therapeutic 
globin vector capable of overcoming silencing and to achieve sustained, long term, tissue 




















7.1 Comparative study accessing the ability of both ubiquitous and 
tissue specific elements to express from within an ID-LV context 
 
In order to address problems associated with integration mutagenesis ID-LV 
vectors have been developed (Esposito and Craigie, 1998; Gerton et al., 1998; Leavitt et 
al., 1996; Masuda et al., 1998). Whilst retaining attractive properties of LVs, such as the 
ability to transduce both dividing and quiescent cells, ID-LV are delivered with a mutant 
integrase protein, which specifically prevents proviral integration resulting in the 
generation of increased levels of 1-LTR and 2‐LTR circular episomes in transduced cells. 
  
When compared to regular integrating LVs, ID-LVs have significantly lower risk 
of causing insertional mutagenesis together with lower risk of generating replication 
competent retroviruses. So far, success from within an ID-LV context has solely been 
reported with transgene expression from ubiquitous promoter/gene combinations (Yanez-
Munoz et al., 2006; Apolonia et al., 2009) using vectors with a mutation in the catalytic 
motif of the integrase protein (DD35E, residue D64) that impairs integration (Leavitt et 
al., 1996).  
 
The first question in this study (Chapter 3) was whether expression from within 
ID-LV can be achieved only with ubiquitous regulatory elements or whether this can be 
extended to tissue specific control. 
 
Tissue-specific promoters are usually relatively weak when compared with 
ubiquitous promoters but their function is almost invariably augmented by enhancer or 
LCR elements to boost expression in a cell-specific manner. Vectors containing such 
tissue specific regulatory elements augmenting transcription offer many significant 
advantages over non-specific vectors and are able to limit immune responses against the 
therapeutic product due to abrogation of ectopic expression in antigen presenting cells 
(Weeratna et al., 2001). Furthermore, they have less potential to promote insertional 





oncogenesis and most importantly limit ectopic expression that may have toxic 
consequences for other organs.  
 
Tissue-specific elements from the human HBB LCR have been successfully 
included in the development of LVs for the treatment of the haemoglobinopathies (see 
section 1.4.1) with LCR sites HS2 and HS3 included in our therapeutic GLOBE vector 
(Figure 1.18). 
 
In Chapter 3 we document the comparison of both ubiquitous expressing and 
tissue specific elements in an ID-LV using the same integrase mutation as previously 
described (D64; Yanez-Munoz et al., 2006). All vectors expressing from either 
ubiquitous (SFFV) or tissue specific (HBB and muscle DES / CK-M specific) regulatory 
elements were produced without major complication and expressed from both IP an ID 
configurations. Thus, we demonstrate that utility of ID-LV can be extended to provide 
tissue-specific as well as varying degrees of ubiquitous therapeutic gene expression 
depending on the control elements used. 
 
 As initially expected, the expression for ID-LV constructs decreased significantly 
following successive rounds of cell division and reached values close to zero in some 
vector configurations. Nevertheless, this study demonstrates that tissue specific as well as 
ubiquitous promoters can express from an ID-LV context, albeit at low intensity levels. 
 
Our results also demonstrate that the concentration of initial viral DNA (3 days 
post transduction) is similar for all integrating and non-integrating vectors analysed, so it 
is possible to conclude that the studied integrase defective vectors do not have an impact 
on reverse transcription. However, the sustainability of the vector in mitotic cell 
populations is dependent on initial MOI. Because transduction at high copy number can 
be impracticable as large scale production of virus is expensive and laborious, the 
approach is limited to transient expression. Also, the transduction of large amounts of a 
given vector aiming for initial high copy number values may lead to over expression of 





the transgene, protein accumulation and toxicity. Nevertheless, since maintenance and 
sustained expression from ID-LV can occur in non-dividing cell populations (Yanez-
Munoz et al., 2006), it is possible that long-term tissue specific expression can also be 
obtained with this system in post-mitotic tissues.       
 
 
7.1.1 Applications of ID-LVs 
 
As in previous studies we found that ID-LVs are capable to deliver viral DNA to 
target cells, but regardless of the tropism of the driven vectors, expression from these 
vectors is transient due to vector loss through successive rounds of mitosis. Although 
limiting, there are several applications of such vectors. An example would be the 
development of cascade effects for cellular protein expression. For example, the 
expression of HoxB4 has been shown to increase self-renewal and promote expansion of 
HSCs (Antonchuk et al., 2002). However, permanent production of HoxB4 protein is 
associated with toxicity (Zhang et al., 2007b; Krosl et al., 1998). The use of ID-LVs in 
such a project would be of great use to provide temporary expression of the protein, 
avoiding effects of protein accumulation caused by LV integration. 
 
A development of replicating ID-LV would be of great use in the field. This 
would simultaneously reduce the risk of insertional mutagenesis and maintain transgene 
expression in both, dividing and non-dividing cells. Previous studies have shown that it is 
possible to incorporate the simian virus 40 (SV40) OriT into ID-LVs allowing the 
maintenance of the episomal DNA in dividing cells, without reversion to an integrative 
phenotype. Replication and expression from this vector was sustained for 56 days in cells 
expressing the SV40 Large T-antigen. However, under the selective conditions of T-
antigen, stable expression was not seen (Lu et al., 2004; Vargas, Jr. et al., 2008). 
Nonetheless, it is important to notice that these vectors still carry a risk of mutagenesis 
due to the presence of the SV40 Large T-antigen. An alternative system that can 
potentially confer replication status on ID-LV is the incorporation of a scaffold/matrix 





attachment region (S/MAR) as has been achieved in plasmid vectors (Hagedorn et al., 
2011). However, to the best of our knowledge, success incorporating an S/MAR in an ID-
LV has not been reported.  
 
More recently, ID-LVs have also been shown to be efficient immunogens with 
long-lasting immune responses (Karwacz et al., 2009; Negri et al., 2007). In fact, these 
vectors make use of the infectivity properties of regular LV vectors efficiently 
stimulating cell-mediated and humoral immunity. 
 
Finally, some groups have recently reported the use of ID-LVs to deliver specific 
DNA sequences without genome integration, but using a different strategy for stable 
expression in dividing cells.  The first obvious development that comes to mind is the use 
of Rep protein from AAV. Rep protein can site-specifically integrate DNA substrates into 
the human genome, including circular DNA (Kotin et al., 1990). Therefore, it would be 
interesting to study the combination of this protein with the delivery of the target DNA 
mediated by ID-LVs.  
 
DNA delivered by ID-LVs has been used as a template for homologous 
recombination. Examples include the phage ΦC31 integrase (Calos et al., 2005), and the 
Sleeping Beauty transposase (Staunstrup et al., 2009; Vink et al., 2009). 
 
To the best of our knowledge, the work presented here is the first of its kind to compare a 













7.2 Integration proficient LV, the challenge 
 
The study of ID-LVs, although informative, failed to provide a positive direction 
for this study. We therefore decided to focus this project in the improvement of current 
integrating LVs for the haemoglobinopathies. 
 
Current gene therapy approaches in the search of an optimal vector as a 
therapeutic agent for the haemoglobinopathies highlights the need for a design of safer 
vectors along with a reduction in vector copy number in target cells, ideally limited to 1-2 
copies per cell. However, the need of delivery of fewer vector copies brings the need for 
high-expressing vectors. Sustained therapeutic levels of protein expression with a low 
vector copy number can only be attained by the optimisation of transgene cassettes that 
display a low probability of silencing at most integration sites and efficient post-
transcriptional processing.  
 
The HBB-based GLOBE vector has shown successful transduction of HSC and 
correction of the thalassaemia phenotype in mice (Miccio et al., 2008). Furthermore, 
GLOBE restores globin chain imbalance following transduction of CD34+ cells from 
thalassaemic patients (Roselli et al., 2010). Analysis of integration sites revealed that 
GLOBE integrates preferentially, as expected, within transcriptionally active genes, with 
no bias towards integration in proximity of oncogenes. More importantly, despite 
integration within or near active genes, GLOBE did not give rise to increased host gene 
expression suggesting a low insertional mutagenesis potential (Roselli et al., 2010). 
Modifications of of GLOBE made by the host lab have led to improvements with regards 
to vector expression levels mediated by inclusion of the term element (GLOBE2, 
Figure 6.1). This design is based on studies conducted with an HBB-eGFP- term 
cassette in LVs, which in vivo showed overall expression over 4-fold higher compared to  
to the same vector without term (Kao V el al., unpublished results). 
 
 





7.2.1 Vector test studies: injection in neonatal mice with different 
reporter gene cassettes.  
 
Neonatal injections offer a good model system within which to evaluate 
therapeutic gene therapy. We were inclined to use a UCOE-driven construct since this 
system has been proven to provide reproducible and sustained expression in vivo 
following ex vivo manipulation of HSC in mice (Zhang et al., 2007 & 2010). 
Nevertheless, we decided to conduct a comparison of different vector designs to 
determine which would be most suitable to take forward with in utero delivery 
experiments. 
 
In Chapter 4 we document the expression obtained from the eGFP reporter gene 
in tissues of neonate mice injected via the temporal vein. As expected, expression at a 
high level was found in the liver (Figure 4.6) and spleen with none being detected in 
either lung or heart tissues. Expression in the spleen shows that vector is present in the 
peripheral blood system. 
 
In this initial study we considered a couple of promoter /enhancer combinations to 
be tested: 
Firstly, the CMV promoter is frequently used in an LV context (Follenzi et al., 
2000) and it is known by its strong promoter capability. In this set of experiments we 
were not able to monitor expression initially following injections but until sacrifice. 
However, it would be interesting to compare the initial expression of the CMV vector and 
then at periodic intervals post delivery. CMV is known to function as a strong promoter 
in certain tissues, stronger than the A2UCOE. However, the results obtained here showed 
CMV to express at lower levels than the A2UCOE, even though initial vector titre at the 
time of delivery was similar. 
 
Secondly, the A2UCOE element was chosen to be incorporated in this study as it
 
is not prone to transcriptional silencing (in
 
contrast with strong viral promoters such as 





SFFV and especially CMV) (Zhang et al., 2007). UCOEs are able to fully negate the 
process of PEV and confer stable, high level transcription on a transgene in both stably 
transfected cell lines (Antoniou et al., 2003; Williams et al., 2005.) and from lentiviral-
transduced cells (Zhang et al., 2007 & 2010; Brendel et al., 2011). . In addition, the 
A2UCOE has been shown to lack classical enhancer function, thereby reducing the risk 
of activating a nearby promoter, which is highly significant for improving the safety 
profile of integrating vectors.  
 
We expected that a vector containing a WPRE sequence would, in theory, provide 
higher vector production and levels of expression per vector copy, but that comparison 
with and without this element needed to be performed by conducting in vivo studies in 
our neonatal model system. Results with both A2UCOE driven vectors +/-WPRE were 
consistent in the sense that they provided stable expression of the construct. It is visible 
by the pictures shown in Figure 5.10 that both the A2UCOE-eGFP and A2UCOE-EGFP-
WPRE show expression in most cells in the sample. Cells expressing A2UCOE-eGFP are 
less bright but expression from this vector is consistent in all cells in the sample shown. 
This is an important measure with regards to therapeutics in gene therapy. The ideal gene 
therapy vector transduces efficiently and expresses in all transfected cells, avoids 
variegation of expression, but is a concise and reproducible vector.  
 
According to our data the vector that best suited the requirements of an ‘ideal in 
utero vector’ was the UCOE-eGFP-WPRE and was thus the vector used for further in 
utero marking experiments (Chapter 5). 
 
These experiments prove the feasibility of the neonatal technique to deliver LV 
into the mouse circulation. Neonatal tests checked the feasibility of the vector design for 









7.2.2 Novel therapeutic options: in utero gene therapy 
 
The second project objective aimed to investigate whether a sustained and 
reproducible level of expression can also be obtained when an LV expressing human 
HBB is delivered in utero into wild-type mice and ultimately, if sufficient expression is 
obtained to attempt rescue of a knock-out model of -thalassaemia by this approach.  
 
In the last two Chapters in this study, we covered in utero delivery (Chapters 5) 
and accessed whether this approach is feasible to be applied as a therapeutic approach for 
the haemoglobinopathies (Chapter 6). 
 
 The in utero procedure for therapeutic gene delivery has been developed by others 
previously (Dejneka et al., 2004: Rucker et al., 2004: Waddington et al., 2004) and 
therapeutic progress in animal models using this technique has been reported in a broad 
spectrum of genetic disorders. The approach provides the correction of the disease 
phenotype in time to prevent manifestations of disease and, most importantly, the vector 
delivery is thought to occur during a period of low immunogenicity and therefore the 
technique prevents a severe immunological reaction that may to occur if the transgene is 
delivered later in the patient’s life in some cases. However, the technique is still 
relatively new as its possible complications and limiting factors must be accessed before 
being used for clinical trials. 
 
 
 In utero studies performed so far have focused on liver transduction (Waddington et 
al., 2004) and vector systemic delivery (van der Wegen el al., 2006) and to our 
knowledge, the technique has not been used in marking studies attempting to target 
HSCs. Unlike effective fetal treatment of metabolic diseases, where liver cells could be 
targeted during most of the duration of pregnancy, treatment of hematopoietic disorders 
may have a much narrower window for effective HSC targeting. With this in mind, our 
study started with marking experiments to evaluate the ideal timing of in utero delivery 





in mice that would account for the higher percentage of engrafted HSCs. We embarked 
on an experiment to compare different in utero delivery time points and check the 
protein/vector copy number value obtained in various organ compartments (Chapter 5).  
 
As described previously, the A2UCOE-GFP-WPRE vector was used as an eGFP 
reporter gene marker in this phase of the in utero study. Injections in utero with this 
vector proved the feasibility of the experiment and showed positive results (Chapter 5). 
The vector showed sustained and reproducible expression of eGFP injected in utero into 
wild-type mice at both time points (E14, E16) analysed. However, staining with different 
antibodies both at E14 and E16 time points showed different marking profiles, with the 
E14 seeing a higher population of myeloid cells expressing the vector in peripheral 
blood. These results clearly show that the time of delivery of the vector is an important 
variable to take in account in an in utero delivery approach when the final objective is to 
target the hematopoietic progenitors located in the fetal liver.  
 
Results obtained with the A2UCOE-eGFP-WPRE vector were confirmed by 
injection of a twin vector expressing luciferase, which allows vector expression to be 
monitored in vivo throughout the whole experimental time period, which lasted for up to 
360 days (Figure 5.13). High expression of luciferase was observed in liver in vivo 
throughout the duration of the experiment. Post-mortem vector and protein expression 
analysis showed not only the feasibility of the in utero delivery system for BM 
engraftment but also long-term vector expression (up to 360 days with a luciferase 
reporter gene). 
 
These reporter gene marking studies served as a precursor to our therapeutic study 
using a vector capable of expressing HBB to rescue a thalassaemia phenotype. However, 
it should be noted that this approach can also in principle be applied to other therapeutic 
studies, which aim to target HSCs. For instance, this approach can be used to target 
chromosome associated Myelodysplastic Syndrome (MDS), a group of diseases 
characterised by abnormal bone marrow cell production, which leads to symptoms of 





anaemia, infection, excessive bleeding and bruising, and genetic defects such as Fanconi 
Anaemia resulting from mutation of one of a number of proteins responsible for DNA 





























7.2.3 In utero studies performed with a therapeutic HBB-based LV in 
WT mice 
 
 Following the promising reporter gene marking experiments described in Chapter 
5, we continued our line of investigation by performing in utero injections with a 
therapeutic vector containing an HBB expression cassette. Due to problems in breeding 
and expanding the th3 thalassaemic mouse colony as used in previous studies (Miccio et 
al., 2008), we proceeded with initial experiments employing MF1 (wild type) mouse 
strain recipients. 
 
Chapter 6 described the results from the delivery in utero of a HBB vector 
(GLOBE2) into wild type mice and showed sustained expression. Mice were analyzed at 
5 and 8 months of age for HBB gene expression. As expected GLOBE2 vector was 
detected not only in peripheral blood and BM but also in liver and spleen.  
 
 To test in vivo different globin vectors and access their performance with regards 
to expression levels per copy number we used an improved, new version, GLOBE2, 
which is a development of the prototypical GLOBE vector, which has been shown to 
successfully rescue the thalassaemia phenotype in mice (Miccio et al., 2008) and human 
patient cells (Roselli et al., 2010). GLOBE2 was built based on results obtained with an 
HBB-eGFP LV showing that inclusion of the HBB transcription termination region (West 
and Proudfoot, 2009) results in up to a 4-fold increase in protein production both in cell 
lines in vitro and in vivo following ex vivo manipulation of HSC (Kao V et al., 
unpublished results).  
 
The results obtained clearly show persistent GLOBE2 vector presence in 
peripheral blood and BM at both 150 and 250 days post-partum implying successful 
transduction of HSC in fetal liver following in utero injection. The results validate the 
initial hypothesis formulated in this study and show that it is possible to transduce HSC 
while in the fetal liver, before migration to the BM. 





Expression levels obtained by mRNA analysis may be of a level capable of 
rescuing the thalassaemia phenotype and pave the way for a therapeutic experiment onto 
a thalassaemia mouse model system such as th3 using the GLOBE2 vector. By the 
combination of the elements tested and others, the achievement of expression levels 
sufficient for therapeutic correction of the thalassaemia major phenotype can be 
anticipated. 
 
 The only report to date targeting in utero gene therapy for the 
haemoglobinopathies was performed with a TNS9-derived vector (Figure 1.13), which 
contains HBA under control of an extended HBB promoter, HBB proximal enhancers, and 
genomic fragments of the human HBB locus control region HS2, HS3 and HS4 (Xan et 
al., 2007). In this study the authors claim that this LV can be an effective vehicle for 
delivering the HBA gene in cases of -thalassaemia. 
Intrauterine injection performed at E14.5 in 3 mice resulted in expression of HBA 
at birth and reached a peak of up to 20% in some mice at 3-4 months but the level of 
expression declined to 5% at approximately the 7th month. Very few erythroid colonies 
cultured from the bone marrow after decline of expression contained the transgene. The 
authors claim that the decline may be due to the loss of the transgene as a result of the 
inadequate transduction of HSC (Xan et al., 2007).  
 
In our study, at 250 days (approximately 8 months) we observed variation of HBB 
transgene expression in the recipient mice obtained. This variation of expression is 
expected since in vivo delivery can be highly variable and, more importantly, the 
expression will be highly dependent on the vector integration sites. In our recipients 
injected in utero with the GLOBE2 vector, 3 showed a decrease in HBB levels per vector 
copy number, while 2 animals showed increased levels of HBB in peripheral blood 
during the course of the experiment (Figure 6.4). However, the degree of cell marking 
with GLOBE2 that we observe suggests transduction of HSCs, which is supported by the 
proviral copy number (average 0.371; Figure 6.7) and expression (Figure 6.9) found in 
BM upon sacrifice. 










It was part of the workplan of this study to conduct in utero injections as 
described here in a severe -thalassaemia intermedia mouse model system, th3
+
 
(C57Bl/6 Hbb(th3/+)) with the GLOBE2 vector. As homozygous th3/th3 mice die 
prenatally or perinatally, survival of these animals following in utero injection of 
GLOBE2 would be a clear indication of successful therapy. 
 
Unfortunately, major difficulties in breeding the C57Bl/6 Hbb(th3/+) mice and time 

























7.3 Final Conclusions 
 
At present, it seems likely that future gene therapy vectors for the 
haemoglobinopathies will employ numerous methods to improve the efficacy and safety 
of gene therapy treatment used to replace blood transfusions. These may include the use 
of integration deficient vectors to decrease the risk of insertional mutagenesis and vector 
delivery at earlier developmental stages to avoid age onset malfunctions.  
 
In this thesis we report a new therapeutic approach for the haemoglobinopathies. 
We describe the efficient transduction of HSC progenitors in fetal liver by in utero 
injection at 14-16dpc. Transduction of HSC is followed by successful BM engraftment 
and transgene levels in the systemic circulation. 
 
Further studies are necessary to assess the feasibility of the in utero procedure in a 
human context, especially experiments in a murine model of thalassaemia followed by 
studies in larger animals such as sheep and primates. We envisage the development of 
new vector designs, capable of exploiting transduction of BM cells. These experiments 


















7.4 Future work 
 
Leading on from the work presented here are several lines of research that would be 
interesting to pursue: 
 
1. Addition of more globin LCR HS sites to the HBB cassette in the LV namely HSI 
and HSIV, in order to try and obtain higher levels of expression per vector copy. 
 
2. For further experiments, higher MOls should be used and since the volume 
administered in the in utero procedure cannot be increased and therefore it 
becomes essential to generate the HBB vector preparations at a higher titer.  
 
3. Corrective gene therapy treatment would benefit from increased efficiency of 
transduction of HSC. It would therefore be very interesting to attempt to increase 
vector transduction of HSC by pseudotyping LVs with other envelope 
glycoproteins, such as feline leukemia virus (FeLV) RD114 and FeLV-C94 
proteins. These FeLV envelope proteins have been shown to give rise to good 
human HSC transduction, and be less toxic to cells than VSV-G (Hanawa et al., 
2005). 
 
4. It would be interesting to perform HBB transgene codon optimisation to attempt 
an improvement in protein production.  
 
5. Finally, injection of larger animal models in which the fetal circulation can be 
accessed earlier and more readily and which is more similar to the human 
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